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ABSTRACT 
 
Introduction: The cure rates for children with cancer have improved with the use of high-
intensity chemotherapy, aggressive surgical techniques, radiotherapy, and bone marrow 
transplantation. These treatment modalities render them more susceptible to 
immunosuppression and increase their susceptibility to infectious complications, which is a 
leading cause of death in this group of patients. Children diagnosed with cancer additionally 
are immunocompromised due to underlying malnutrition, HIV-infection, and Mycobacterium 
tuberculosis infection, which could further compound the increased susceptibility to 
infectious complications. 
  
Objectives: The aim of this research program was to investigate the infectious related 
morbidity and mortality in predominantly black-African children treated for cancer at one of 
the largest hospitals in the Southern Hemisphere (Johannesburg, South Africa) and in a setting 
with a high prevalence of HIV-infection and tuberculosis. 
 
Methods: The events studied were all febrile episodes in children who received cancer 
treatment. The standard care for these patients included a detailed history and physical 
examination, blood investigations (full blood count with a differential and a blood culture for 
suspected sepsis). In addition, patients enrolled into the study had anthropometric measures 
undertaken on admission, a tuberculin skin test by the Mantoux method and blood was drawn 
to undertake the T.-SPOT.TB test. For each septic episode, a detailed history and physical 
examination was performed, blood was obtained for culture, full blood count and differential, 
CRP and PCT, a nasopharyngeal aspirate was performed for the identification of respiratory 
viruses, and empiric antibiotic treatment was initiated.  
 
Results: We documented a high incidence (per 100 child years) of suspected septic episodes 
(102.9), microbiologically confirmed sepsis (69.4), respiratory virus associated (61), and 
27.4% of all microbiologically confirmed septic episodes had respiratory viral and 
bacterial/fungal co-infections. In addition, a high proportion of septic episodes were 
polymicrobial in aetiology (40.6%). We also documented an incidence of 4.7 per 100 child 
vi 
 
years of tuberculosis in our study cohort. All of these were higher in the cohort with 
haematological malignancies than in those with solid tumours. Indwelling catheters, high-
dose corticosteroids, high-risk haematological malignancies, metastatic solid tumours, high-
intensity treatment, the presence of pneumonia, and tuberculosis increased the risk of sepsis 
and death in our patients. In HIV-infected patients with Non-Hodgkin’s lymphoma, advanced 
disease, and severe immunosuppression due to the HIV-infection and chemotherapy, 
increased the risk of sepsis in this group of patients. The incidence risk ratio for pneumonia 
was 6.5, for tuberculosis 10.8, for invasive fungal infections 4.1, and for Herpes stomatitis 3.1 
compared with the HIV-uninfected cohort. 
 
Conclusion: Infectious complications following treatment in the Black South African child 
with cancer is a major burden, which contributes significantly to morbidity and mortality in 
this group of children. We need to pay greater attention to nutritional therapy (as the majority 
of patients were malnourished), aseptic techniques, monitoring of patients who are at risk for 
sepsis, and the judicious use of antibiotic therapy, paying heed to the principals of anti-
microbial stewardship. Additionally there needs to be an increased vigilance for tuberculosis 
and pneumonia in children treated for cancer. Patients with haematological malignancies and 
HIV-infected children should be treated with Isoniazid prophylaxis for the course of the 
cancer therapy. Isolation facilities would help control the spread of infections in the unit. 
Increasing the awareness of childhood cancer will result in children being diagnosed with less 
advanced and aggressive cancer, which will ultimately decrease the infectious complications 
associated with intensive chemotherapy advanced surgery and extended-field radiotherapy for 
advanced disease. Early identification of HIV-infection, antiretroviral therapy and screening 
for malignant diseases in HIV-infected children may allow for earlier identification of AIDS-
related malignancies. 
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1. INTRODUCTION 
 
  The survival of children with cancer in high-income countries (HIC) has improved with the 
use of aggressive chemotherapy, surgery, radiotherapy, and bone marrow transplantation (Pui 
et al., 2011, Winther et al., 2015). As a result of multi-modal therapy, these children are more 
susceptible to infections, which are a leading cause of death in this population (Adamski et 
al., 2008). Many host and disease factors increase the infectious complications in children 
undergoing treatment for cancer. Chemotherapy-induced bone marrow suppression, depress-
ion of the immune system due to disease or treatment, mucosal barrier injury, intravascular 
devices, the type of cancer, chemotherapeutic proto-cols, surgery, radiotherapy and the 
duration of hospital stay have been recognized as risks factors for infections (Lehrnbecher et 
al., 1997).  
 
  In South Africa we have additional challenges of poverty, which contributes to low levels of 
parental education, unemployment, poor access to health care facilities, malnutrition, epi-
demics of tuberculosis and HIV/AIDS and delayed presentation with advanced disease 
(Poyiadjis et al., 2011) which requires more aggressive treatment regimens. 
 
  A high incidence of sepsis has been demonstrated in paediatric patients receiving chemo-
therapy; approximately 12.8% in children aged one to nine years and 17.4% in children aged 
ten to nineteen years, making febrile neutropenia (FN) a serious and worrying complication in 
paediatric cancer treatment (Yadav et al., 2014). In high-income countries (HIC), 16.4 per 
1000 adult patients with cancer experience an episode of severe sepsis annually. Up to 8.5% 
of adult oncology deaths are due to severe sepsis (Williams et al., 2004b). There is a paucity 
of data regarding mortality and morbidity from infectious toxicity in children treated for 
cancer. 
 
  There are few studies on febrile illnesses in children from low-middle income countries 
(LMIC) (Gavidia et al., 2012), however, FN is a major cause of hospitalization in this patient 
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group. In El Salvador, it has been documented, that treatment related complications were 
responsible for approximately 50% of deaths in children with acute lymphoblastic leukaemia 
(ALL) and acute myeloid leukaemia (AML) (Gupta et al., 2012b). Infections were the most 
common cause of treatment related mortality, with 12.3% of episodes of FN resulting in death 
(Gupta et al., 2011a). Similarly sepsis (53.3%) and bleeding (15.7%) were common causes of 
mortality in a cohort of Indian children treated for ALL (Yadav et al., 2011). Infectious 
complications in paediatric ALL makes it a particularly challenging disease to treat in LMIC 
(Gupta et al., 2009). Children who present with high-risk FN i.e. relapse of ALL, hypo-
tension, an absolute neutrophil count (ANC) < 100 cells/µL, an absolute monocyte count 
(AMC) < 100 cells/µL, blood urea nitrogen ≥ 18 mg/dL, CRP ≥ 90 mg/L, and positive blood 
cultures, have a risk of death due to severe sepsis (Santolaya et al., 2007).  
 
There is conflicting evidence about the susceptibility of children with solid tumours (ST) to 
chemotherapy-induced FN. Blood stream infections (BSI) and their aetiology in children with 
ST are under-reported.  
 
  The incidence of sepsis in oncology patients has increased globally over the past three 
decades, with up to 30% of deaths attributed to sepsis (Thirumala et al., 2010). This is perhaps 
due to the availability of intensive chemotherapeutic protocols, invasive procedures, immune-
suppressive drugs, trans-plantation, and the increasing incidence of antimicrobial resistance. 
Severe underlying disorders are frequently (55% of 192 980) reported in patients with sepsis, 
with one in six having an underlying malignant disease (Angus et al., 2001) . 
 
  Health-care associated bacterial infections may be responsible for 25 000 deaths in African 
children annually, and its overall incidence in LMICs is double that in HICs (Allegranzi et al., 
2011, Aiken et al., 2014). A recent South African study reported the crude infection mortality 
in children was 20%. High antimicrobial resistance rates, hospital-acquired sepsis, HIV 
infection, fungaemia, and Gram-negative bacteraemia significantly contributed to mortality 
(Dramowski et al., 2015).  
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  A South African study investigated infections in children treated for cancer at Chris Hani 
Baragwanath Academic Hospital in 2001, prior to the onset of the HIV epidemic. This study 
documented a 14.3% incidence of bacteraemia (70% Gram-positive bacteria, 20% Gram-
negative bacteria, and 10% fungal organisms). Fungi, Gram-negative bacteria (GNB) and 
Hickman lines were associated with a high mortality. Sixty-four percent of the fungal infect-
ions occurred in patients with Hickman lines, 42% of which were due to Candida parapsilosis 
(van de Wetering et al., 2001). 
 
  Since this study, there have been many changes in the Paediatric Oncology Unit at Chris 
Hani Baragwanath Academic Hospital. Patient numbers have more than doubled (Poyiadjis et 
al., 2011), Hickman lines were discontinued in favour of Porto-catheters, many treatment 
protocols for haematological malignancies (HM) and ST were intensified, the number of 
patients with HIV-related cancer has increased and there have been structural changes to the 
unit. The existing facilities were renovated and new ward and outpatient clinic were added on. 
The unit now has two in-patient wards and an outpatient clinic. 
 
  As fever and neutropenia frequently complicate paediatric oncology treatment and causes 
potentially life-threatening infections, the successful management of FN is based on careful 
monitoring and the prompt use of empiric broad-spectrum antimicrobials. It is imperative to 
document the pathogens isolated from patients with sepsis, their antimicrobial susceptibility 
patterns, and the clinical course of febrile neutropenia to optimize empiric treatment 
(Agyeman et al., 2014) . 
 
  The objective of the research reported in this thesis was to investigate the infectious related 
morbidity and mortality in predominantly black-African children treated for cancer at one of 
the largest hospital in the Southern Hemisphere, in Johannesburg, South Africa.  
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2. REVIEW OF THE LITERATURE 
2.1. SURVIVAL IN CHILDREN WITH CANCER 
2.1.1. CHILDHOOD CANCER SURVIVAL IN HIGH-INCOME COUNTRIES 
 
  Between 1975 and 2009, the survival rates for all childhood cancers in the United States 
increased. The Surveillance, Epidemiology, and End Results programme, National Cancer 
Institute reported on survival data for paediatric childhood cancer for the periods between 
1975 to 1979 and 2003 to 2009. Leukaemia survival improved from 48% to 84%, lymphoma 
from 72% to 91%, brain tumours (BT) from 59% to 75%, neuroblastoma (NBL) from 54% to 
79%, retinoblastoma (RBL) from 92% to 99%, Wilm’s tumour from 75% to 90%, bone 
tumours from 49% to 73%, and rhabdomyosarcoma (RMS) from 49% to 64% (Howlander, 
2013). Some childhood cancers e.g. NHL and leukaemia are now considered curable. By 
contrast, the survival rates for children with certain ST, e.g. those with disseminated disease 
and most brain tumours have not improved significantly, with the exception of gonadal 
cancer, NBL and bone cancer (Pui et al., 2011). Studies from Europe confirm this improved 
survival in children with cancer (Lacour et al., 2014, Winther et al., 2015). However, the 
gains achieved by treatment intensification, individualised treatment and bone-marrow 
transplantation are lost by infection-related mortality and morbidity (O'Connor et al., 2014) 
 
2.1.2. CHILDHOOD CANCER SURVIVAL IN LOW AND MIDDLE INCOME COUNTRIES 
 
  In 2010, 5.7 billion (83%) of the world’s population of 6.9 billion people lived in LMICs. 
These countries have younger median ages and higher proportions of children in their 
populations than HICs. Overall, 27% of the population of middle-income countries (MIC) and 
40% of the population of low-income countries (LIC) are younger than 15 years, compared 
with 17% of the population of HICs. GLOBOCAN estimated that about 148 000 cancers in 
children aged zero to fourteen years occurred in LMICs with a total population of 5.5 billion. 
In HICs, 28 000 cancers occurred in the same age group with a population of 1.2 billion 
(Ferlay et al., 2010).  
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  The economies of most LMICs are characterised by poverty, too few health-care providers, 
weak health systems, poor access to education, and healthcare, and limited access to modern 
laboratory equipment. LMICs also have younger people, therefore have larger numbers of 
children with cancer than HICs (Magrath et al., 2013). 
 
  The cure-rates of cancer in children from HICs are significantly higher than in LMICs 
(Gupta et al., 2011a). This may be due to many factors, including delayed presentation with 
advanced disease, tumour biology and treatment toxicity in LMICs (Howard and Wilimas, 
2005). Infection-related mortality contributes to overall survival in childhood cancer (Gupta et 
al., 2009). 
 
  Survival data of childhood cancer in LMICs is scanty. Data from India for the period 1990-
2001, described the 5-year survival of 49.4% for Hodgkin’s lymphoma, Wilm’s tumour, RBL, 
NHL, Osteogenic sarcoma, ALL, and astrocytoma (Swaminathan et al., 2008). The overall 
survival rate for the period January 1995 to December 2004 in the Ivory Coast was 9.4% (Yao 
et al., 2013) and 54% in Zambia (Slone et al., 2014). 
 
2.1.3. SOUTH AFRICAN CHILDHOOD CANCER SURVIVAL 
 
  In South Africa, the overall survival for children with cancer for the period 1987 to 2011 was 
52.1%. Lymphoma and WT had the highest survival rates at 63.9% and 62.6%, respectively. 
Brain tumours had the lowest survival rate at 46.4%. A comparison between ethnic groups 
showed white children had the highest survival (62.8%); 53.8% in children of mixed racial 
origin and 48.5% in black African children (Stones et al., 2014). 
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2.1.4. RACIAL AND SOCIOECONOMIC STATUS AND ITS IMPACT ON SURVIVAL OF CHILDHOOD 
CANCER 
 
  Despite advancements in the treatment of childhood leukaemia, socio-economic status may 
potentially affect disease prognosis. Children from low socio-economic sectors in the United 
States of America suffer two-fold higher death rates from ALL (Petridou et al., 2015). 
Treatment abandonment is a risk factor for poorer outcome in children treated for ALL. Rates 
of treatment abandonment is significantly lower in HICs than in LMICs (Gupta et al., 2013). 
Patients who live in the lowest socio-economic neighbourhoods at diagnosis had a 39% 
increased risk of death relative to those from higher socioeconomic neighbourhoods (Abrahao 
et al., 2015). Racial/ethnic differences in childhood cancer survival may be attributable to 
disease biology and host pharmacogenetics but are probably also linked to socioeconomic and 
cultural factors, including differences in access to health care, inadequate education, advanced 
disease stage at presentation, adherence to therapy and disbelief in modern medicine (Bhatia, 
2011). However, some studies identified race/ ethnicity as an independent predicting factor 
(Viana et al., 2001, Bhatia, 2004). 
 
  There are also racial differences in the survival outcomes in children with ALL. Survival 
from ALL remains lower among non-White children in the US. Five-year survival is 85.0% 
for White, 81.4% for Asian, 79.0% for Hispanic and 74.4% for Black children (Abrahao et al., 
2015). 
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2.2. THE SPECTRUM OF INFECTIONS IN CHILDREN TREATED FOR CANCER 
2.2.1. PREDISPOSITION TO INFECTIONS IN CHILDREN TREATED FOR CANCER 
 
  Patients who have cancer have a greater tendency to acquire infections than the general 
population. The critically ill cancer patient is at a high risk for infections and its resulting 
complications. Multiple factors are responsible for this heightened risk of infection. In 
addition to cancer treatments, mal-nutrition at diagnosis and during treatment, disruption of 
mucosal and integumentary barriers, neutropenia, cell-mediated and humoral immune 
dysfunction, presence of indwelling vascular catheters, local tumour effects, and prolonged 
duration of hospital stay contribute to the increased risk of infection. In this population, 
organisms with low virulence can cause significant morbidity and mortality. Bacteria, viruses, 
fungi, and protozoa can cause infection in the critically ill patient with cancer (Thirumala et 
al., 2010). 
 
  Various mechanisms are responsible for the risk of infections related to cancer treatment. 
Cortico-steroids, used for the treatment of ALL, NHL and BT, results in altered phagocytosis 
and defective cell-mediated immune responses which subsequently increases the suscep-
tibility to fungal, viral and bacterial infections. Neutropenia, a major side effect of chemo-
therapy, contributes to immune-suppression and systemic bacterial and fungal infections. 
Methotrexate and purine analogues (the mainstay of treatment for ALL), decreases the 
number of T-cells and predisposes the individual to infections by Pneumocystis jirovecii, 
Mycobacterium species and viral infections. HM induces immunosuppression by the direct 
impairment of immune cells, including the number and functioning of T- and B-lymphocyte 
cells. Abnormalities of the innate and acquired immune system have also been recognized 
early in the course of ST (Lehrnbecher et al., 1997).  
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2.2.2. BACTERIAL INFECTIONS 
 
  Bacteria are the most common cause of microbiologically documented infections in the child 
with cancer (Hakim et al., 2010). Factors identified to increase the risk of invasive bacterial 
infection in children with febrile neutropenia (FN) include intensity of chemotherapy, stage of 
disease, mucositis, intravascular devices, depression of the immune function, prolonged 
neutropenia (> 7 days), profound neutropenia i.e. ANC < 100 cells/µL, immunosuppressive 
treatment, malnutrition, aggressive surgery, and wide-field radiotherapy. A study from the 
United Kingdom reported that infection-related mortality in children with cancer was 2.4%, 
accounting for 75 (64%) of 117 treatment related deaths. Sixty-eight percent of cases were 
associated with bacterial infection (64% GNB) and 20% with fungal infections (O'Connor et 
al., 2014). Studies from Italy, United States of America, and Germany have reported 50-79% 
of febrile illnesses in children are culture-negative) (Lehrnbecher et al., 2004, Castagnola et 
al., 2007, Hakim et al., 2010) 
 
2.2.2.1. BACTERIAL INFECTIONS COMPLICATING CHILDHOOD CANCER TREATMENT 
IN LOW AND MIDDLE INCOME SETTINGS 
 
  Very few studies in LMICs have documented the incidence, microbiological aetiology, risk 
factors, and outcome of sepsis in children treated for cancer. In a prospective study from El 
Salvador, of 106 episodes of FN among 85 patients, 22% had a microbiologically confirmed 
sepsis and 12% of these resulted in death. Sixty-one percent of the bacteria were GPB, 48% 
GNB, including 48% being polymicrobial. Pneumonia was the only predictor of mortality 
(Gupta et al., 2011a). Infection is the commonest cause of treatment-related mortality in 
paediatric oncology patients treated in El Salvador (Gupta et al., 2012b). Studies from India 
have documented a predominance of Gram-negative bacteraemia (55.7%) in high-risk FN 
episodes (Ghosh et al., 2012). Gram-negative bacteraemia (46.7%) was twice as common as 
Gram-positive bacteraemia (23.3%) in children treated for ALL in India (Bakhshi et al., 
2008). Data from Africa is limited, although it is proposed that sepsis-related mortality in 
African children treated for cancer may be higher than reported in HICs (Depasse et al., 2013, 
O'Connor et al., 2014). 
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2.2.2.2. INFECTIONS IN CHILDREN WITH SOLID TUMOURS  
 
  Kocak et al reported on a study to determine whether there were differences in patterns of 
infections and outcome of episodes of FN in paediatric patients with HM and ST. There was a 
diagnosis of fever of unknown origin in 73% and 74% of episodes in patients with HM and 
ST, respectively. Bacteraemia occurred in 18% with HM and 16% with ST. GPB were the 
most common in both groups. The median duration of fever was two days in both groups. The 
depth of neutropenia was similar, with 75% of HM and 70% of ST patients presenting with 
profound neutropenia. The median duration of neutropenia was nine days in patients with HM 
and six days in ST patients, while the median duration of antibiotic treatment was nine days 
and seven-and-a half days in the respective groups. There were no deaths in either group 
(Kocak et al., 2002).  
 
2.2.2.3. CHANGING EPIDEMIOLOGY OF BACTERIAL ISOLATES 
 
  Gram-negative bacteria were the dominant pathogens associated with FN in the 1960s, 
which was followed by the gradual emergence of GPB. This may have been due to the 
increased use of indwelling catheters and the evolution of new chemotherapeutic strategies 
(Aslan et al., 2012). In the last decade, Gram-negative pathogens in sepsis among cancer 
cases has increased, including the emergence of multi-drug resistant species (Menzo et al., 
2015). In LMICs, Gram-negative bacteraemia may be more frequent, (Bothra et al., 2013) as 
the predominance of Gram-positive pathogens in HICs` is likely due to increased use of 
indwelling catheters, antimicrobial prophylaxis, and antacids which change the pH of the 
gastric contents . 
 
  Multi-drug-resistant Gram-negative bacterial species are causing an increasing number of 
infections in FN patients. Klebsiella species and Escherichia coli strains with acquired 
extended-spectrum β-lactamase (ESBL) genes frequently show a broad range of β-lactam 
antibiotic resistance. These ESBL producers are often only susceptible to Carbapenems, but 
the use of these antimicrobials may induce the selection of bacteria with broader resistance 
patterns. Infection with multi-drug resistant GNB is associated with increased morbidity and 
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mortality (Trecarichi and Tumbarello, 2014). The majority of documented studies on the 
prevalence, risk factors, and outcomes of multi-drug resistant bacteria are from the adult 
population. In children with cancer, factors associated with multi-drug resistant Gram-
negative bacteraemia are high-intensity chemotherapy and hospital-acquired bacteraemia 
(Haeusler et al., 2013).  
 
2.2.3. RESPIRATORY VIRAL INFECTIONS IN CHILDREN 
 
  Approximately 150 million episodes of acute lower respiratory tract infection (LRTI) occur 
each year among children globally (Rudan et al., 2013). In children under two years of age, 
respiratory viruses cause most of these infections. Mixed viral-bacterial and virus-virus co-
infections occur in 15-30% of cases (Nascimento-Carvalho et al., 2008), and in 25%-45% of 
patients, respiratory viruses can be detected in the absence of respiratory symptoms (Berkley 
et al., 2010). Bacterial co-infection with respiratory viruses increases morbidity and mortality 
(Dawood et al., 2014), but the impact and clinical implications of co-infection with multiple 
respiratory viruses is unclear. 
 
  The incidence of paediatric acute LRTI is highest in LMICs. In sub-Saharan Africa alone, 
more than 35 million episodes occur each year, resulting in 500 000 deaths (Rudan et al., 
2013). More than 90% of acute LRTI deaths occur in LICs (Black, 2003, Williams et al., 
2004a). 
 
  Real-time multiplex polymerase chain reaction (RT-PCR) is automated, less laborious, and 
less expensive than conventional methods. Hence, it may be more suitable for LMICs (Jartti 
et al., 2013). Recent studies using RT-PCR postulated a substantial role for respiratory viruses 
in paediatric LRTI episodes in LMICs (Berkley et al., 2010, Pretorius et al., 2012). An 
infection from respiratory viruses in healthy children is often self-limited; however, such 
infections can cause significant morbidity and mortality in the immunocompromised children. 
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2.2.3.1. RESPIRATORY VIRAL INFECTIONS IN HIV-INFECTED CHILDREN 
 
  Immunocompromised children, irrespective of the cause of immunodeficiency, are at 
increased risk to develop viral infections, have more severe disease and a poorer outcome than 
immunocompetent children. In a study carried out in Soweto, South Africa, Madhi et al 
showed that HIV-infected children are at increased risk of respiratory virus associated severe 
LRTI (Madhi et al., 2000a). In another study, Madhi et al also found that HIV-infected 
children are more likely to develop RSV and influenza-associated pneumonia and have a 
greater fatality ratio than HIV-uninfected children (Madhi et al., 2004). Another South 
African study (8723 children < 5 years of age, hospitalized with LRTI, 12% HIV-infected and 
64% less than 12 months of age) reported the prevalence of respiratory virus identification to 
be 78%, including 37% for human Rhinovirus (HRV), 26% for Respiratory Syncytial Virus 
(RSV), 7% for influenza virus and 5% for human Metapneumovirus (HPMV) (Cohen et al., 
2015). 
 
2.2.3.2. RESPIRATORY VIRAL INFECTIONS IN PAEDIATRIC ONCOLOGY PATIENTS 
 
  Bacterial and fungal infections have been the focus of research in cancer patients, as 
infections caused by these pathogens are treatable. Recent advances in viral diagnostics have 
produced sensitive and accurate methods for detecting viruses, with quick results and these 
tests are able to screen for multiple species and subtypes (Debiaggi et al., 2012, Jartti et al., 
2013).  
 
  In the USA and Europe, in children with cancer, respiratory viruses were detected in 40-75% 
of paediatric oncology patients presenting with febrile illnesses, making respiratory viruses an 
important cause of febrile illnesses in such children (Christensen et al., 2005, Koskenvuo et 
al., 2008, Lindblom et al., 2010, Torres et al., 2012b, Srinivasan et al., 2013, Benites et al., 
2014). This may have the potential to individualise infection treatment, and to tailor the 
extensive use of antibiotics in immune-compromised children with FN. These studies, 
however, did not include a control group. Hence, the significance of identification of some of 
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the respiratory viruses is uncertain as they have also been identified in asymptomatic healthy 
children, (e.g. HRV, human Bocavirus) and need further investigation in immunocompetent 
and immunocompromised children. 
 
  In both HICs and LMICs, respiratory diseases are responsible for a high proportion of 
morbidity and mortality in childhood. It is estimated that 25% to 33% of deaths in children 
one to 59 months of age are caused by acute respiratory infections (ARI) and their 
complications. Respiratory infections are also the most common syndrome associated with 
febrile illnesses in children < 5 years age, including in children treated with anti-neoplastic 
drugs (Koskenvuo et al., 2008). Many protocols are designed for the management of FN in 
children with cancer. However, there are still doubts regarding the true incidence and the role 
of respiratory viruses in ARIs in these patients (Christensen et al., 2005, Koskenvuo et al., 
2008, El Saleeby et al., 2008b). In addition to only a few studies being published on this 
subject, there is also a paucity of data on more recently discovered viruses such as human 
Coronaviruses (HCoV), human Polyomaviruses (HPyV), human Bocavirus (HBoV) and 
HMPV in immunocompromised paediatric patients (Gerna et al., 2006). Furthermore, there is 
a paucity of data on the role of multiple respiratory viruses in children with cancer, which 
could increase the risk of severe illness (Nair et al., 2010).  
 
  Respiratory virus associated infections have been documented in children undergoing 
treatment for HM and ST (Christensen et al., 2005). This may explain the poor responses to 
antibiotics in certain children, and the high proportion of febrile episodes for which 
aetiological agents are not identified on blood culture in children with cancer, and are deemed 
fever of unknown origin. However, certain fungi e.g. Aspergillus are not identified on blood 
culture. 
 
  Severe RSV infection is more likely in children with cancer who are receiving 
immunosuppressive chemotherapy. The greater the severity of immunodeficiency, the higher 
the risk is of RSV infection, of progression to LRTI and of RSV-related mortality (Chemaly 
et al., 2014). HRV was the most commonly identified virus in paediatric patients with cancer 
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and acute LRTI and fever (Hirsch et al., 2013) and in adult patients (Ohrmalm et al., 2012). 
The significance of identifying HRV in the pathogenesis of an illness is however unclear, 
since HRV is also frequently identified from the healthy population (Jacobs et al., 2013) In 
paediatric leukaemia and HSCT patients, symptomatic para-influenza virus infections have 
been reported to range from 2 to 7%, one-third of which manifest as LRTI (Chemaly et al., 
2012). HMPV was detected in 55 immunocompromised children in Seattle, USA, between 
2006 and 2010, 44% of whom had a HM, 16% were undergoing  haemopoietic stem cell 
transplantation , and 16% had a ST. Twenty-three percent of these required intensive care 
support (ICU) support, including 5% with HMPV-associated pneumonia (Chu et al., 2014). 
Disseminated HBoV infection in the immunocompromised patients has also been described in 
a few reports, although in some cases co-pathogens are also present and the clinical relevance 
of HBoV detection is unclear (Campbell et al., 2015). 
 
  Haematological malignancies are considered a major risk factor for severe influenza virus 
infection (O'Riordan et al., 2010). Prolonged duration of clinical symptoms, a high rate of 
concurrent bacteraemia and considerable chemotherapy delay has been reported (Feldman et 
al., 1977). These early studies remain concordant with findings 30 years later (Tasian et al., 
2008). The clinical patterns of HPyV infection has not been clearly described in 
immunocompetent or immunodeficient groups of patients (Debiaggi et al., 2012) . Infections 
with WUPyV and KIPyV in children with cancer occurred in older children (Mourez et al., 
2009). Severe adenovirus (ADV) infections have been reported in immunocompromised 
patients, such as transplant patients, those with inherited and acquired immunodeficiency 
states, and patients undergoing chemotherapy (Steiner et al., 2008). 
 
  More than one virus has been detected in some FN episodes in children treated for cancer 
(Koskenvuo et al., 2008, Suryadevara et al., 2012b, Srinivasan et al., 2013, Benites et al., 
2014). HRV is the most common respiratory virus detected, either as a sole virus or in 
combination with other viruses (Suryadevara et al., 2012a, Hirsch et al., 2013, Srinivasan et 
al., 2013, Benites et al., 2014). There are conflicting opinions on the significance of the 
presence of HRV in children with a respiratory illness. Children with viral infections 
complicating FN have a more benign illness and favourable outcome if a single virus was the 
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only positive finding for a febrile infection (Torres et al., 2012a, Suryadevara et al., 2012b, 
Srinivasan et al., 2013). Another study described fatal viral associated infections in children 
with cancer (Mendoza Sanchez et al., 2006). 
 
  Two studies have evaluated the association of chemotherapy intensity on the epidemiology 
of respiratory virus infections in children treated for AML and ALL. The frequency and 
severity of ARI was increased in children treated with more intensive chemotherapy 
regimens, with fatal outcomes from respiratory viruses, 14% in children treated for AML 
(Sung et al., 2009) and 31% during the induction phase therapy in ALL cases (Salzer et al., 
2009). 
 
  The degree of bone marrow suppression is associated with respiratory viral infections in 
children treated for cancer. Prolonged and profound neutropenia and lymphopenia increase 
the predisposition to respiratory viral infections in children with cancer (Koskenvuo et al., 
2008, Srinivasan et al., 2013, Choi et al., 2013). Some studies have only documented an 
association with neutropenia and respiratory virus infections in children treated for cancer 
(Benites et al., 2014) and others have only documented lymphopenia as a risk factor for 
respiratory virus infections (El Saleeby et al., 2008b). 
 
  An important consequence of respiratory virus infections is the delay in the chemotherapy 
protocol. Chemotherapy protocols, especially in the paediatric population are designed in a 
metronomic fashion with multi-modal drug combinations and delays in the schedule may lead 
to drug resistance and relapse of disease with adverse outcomes. Forty to 50% of oncology 
patients experienced a median delay of 7 days in scheduled chemotherapy due to respiratory 
virus infections (Mendoza Sanchez et al., 2006).  
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2.2.3.3. RESPIRATORY VIRAL AND BACTERIAL CO-INFECTION IN CHILDREN WITH 
CANCER 
 
  Many microorganisms, both commensals and pathogens, colonize the upper respiratory tract. 
Respiratory viral infections can increase the bacterial load by changing the physical barriers 
and the immune system.  
 
  Studies have detected a high bacterial load in approximately 40% of lower respiratory tract 
samples from paediatric RSV infections (Hishiki et al., 2011), which can lead to secondary 
complications such as pneumonia (Madhi et al., 2004, Madhi et al., 2006). Usually the 
bacteria co-detected with respiratory viruses are opportunistic pathogens, such as 
Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and Moraxella 
catarrhalis (Honkinen et al., 2012). 
 
  Viral-bacterial co-infections are a common and clinically significant problem. An immune-
compromised state is a risk factor for mortality in children with a variety of respiratory viral 
pathogens, including RSV, influenza virus, and ADV (Spaeder et al., 2013). Patients with 
bacterial-viral co-infections often have more severe disease and delayed responses to 
antibiotics than those with a sole bacterial infection (Koskenvuo et al., 2007) or sole 
respiratory virus infection (Torres et al., 2012b). The role of respiratory viruses as sole 
infecting pathogens or as co-infections with bacteria and or fungi as a cause of overall FN 
episodes in children with cancer has not been well investigated and characterized compared to 
bacterial infections in children with cancer. 
 
  Co-infections with bacteria or fungi complicate respiratory virus infections in paediatric 
oncology patients (El-Mahallawy et al., 2005, El Saleeby et al., 2008b). Fifteen percent of 
paediatric oncology cases with influenza virus had simultaneously diagnosed bacteraemia. 
Concomitant pathogens included Pseudomonas aeruginosa, Enterobacter cloacae, 
Enterococcus faecalis, and Coagulase-negative Staphylococcus (CONS) (Tasian et al., 2008). 
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Patients with bacterial-viral co-infections had more severe illnesses and slower response to 
antibiotics than those with a sole bacterial infection (Koskenvuo et al., 2007).  
 
  The increased susceptibility to bacterial co-infection in individuals with respiratory viral 
infections has been reported for RSV and influenza virus. This includes many of the fatalities 
of the 1918–1919 influenza pandemic which were caused by secondary bacterial pneumonia 
(Klugman and Madhi, 2007). Respiratory viral infections assist bacterial adhesion by altering 
physical and immune system barriers. Respiratory viruses increase the ability of bacteria to 
infect or adhere to mucosal surfaces by alterations in the host cell membranes. Respiratory 
viruses can also damage the lung epithelia thereby increasing bacterial trans-location. 
Exudates on mucosal surfaces resulting from respiratory virus infections may also increase 
bacterial growth. The neuraminidase protein from the influenza virus plays an active role in 
thinning the mucus and exposing receptors on epithelial cells, leading to increased bacterial 
translocation and infectivity (Peltola et al., 2005). The host immune defence against bacteria 
can be affected by respiratory virus infections through the inhibition of nonspecific 
phagocytosis, or by exacerbating the effect of bacterial toxins. Influenza virus infection can 
inhibit neutrophilia, which allows an increase in bacterial infection (Bordon et al., 2013). 
Respiratory viruses may also increase the expression of host receptors used by bacteria to 
enter cells, particularly platelet-activating receptor, a key factor for Streptococcus 
pneumoniae infection (Grigg, 2012). Bacterial co-infection occurs during the dampening of 
the immune response. Interleukin-10 is the cytokine involved in the resolution of the immune 
response, but it can lead to an increase in bacterial infections (van der Sluijs et al., 2004). A 
general down regulation of pathogen sensing may also occur following a respiratory virus 
infection, leading to an increased incidence of bacterial infection (Tregoning and Schwarze, 
2010, Chorazy et al., 2013). 
 
  Examples of co-infecting bacterial and viral pathogens are common in the literature, but 
reports tend to be virus-specific. For example, most deaths associated with influenza 
pandemics are associated with secondary bacterial infection including Streptococcus 
pneumonia and Haemophilus influenzae. 
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  The importance of viral and bacterial co-operation in cases of pneumonia is growing 
(Honkinen et al., 2012). Pavia et al. conducted a study among patients hospitalized with 
community-acquired pneumonia and demonstrated that HRV-pneumococcal co-infection was 
independently associated with severe pneumonia (Pavia, 2013). Johannson et al. demonstrated 
that HRV-bacterial or HCoV-bacterial co-infections were independently associated with 
severe pneumonia (Johansson et al., 2010). Another study of children with community-
acquired pneumonia suggested that mixed viral-bacterial co-detections were associated with 
treatment failure (Honkinen et al., 2012). 
 
  Respiratory virus infections in children receiving anticancer chemotherapy were also 
investigated for in a paediatric oncology unit in the Western Cape, South Africa. Evidence of 
a viral and bacterial infection was found in 31 (30%) and 24 (24%) episodes, respectively. 
Within these, a combined viral and bacterial infection was demonstrated in six (6%) episodes. 
Thirty-five viral isolates were identified in 31 febrile episodes. Infectious agents were more 
likely to be of bacterial (30%) than viral (15.5%) origin (Bouw et al., 2007).  
 
2.2.4. FUNGAL INFECTIONS 
 
  Fungi are an important cause of infections in patients with prolonged neutropenia. 
Neutropenic patients who remain febrile despite a course of broad-spectrum antimicrobial 
therapy are prone to fungal disease. Candida and Aspergillus species. are the most common 
fungi responsible for invasive fungal infections (IFI) in children. They are associated with a 
high mortality and morbidity rate. In infants and children, invasive candidiasis is five times 
more frequent than invasive Aspergillus. Candida species represents the third most common 
agent found in healthcare-associated BSI in children. Invasive aspergillosis is more often 
associated with HM than ST. Candida albicans is the main Candida species associated with 
invasive candidiasis in children (Brissaud et al., 2012). 
 
  The incidence of IFIs has increased in paediatric cancer patients over the last decade, and is 
a major cause of morbidity and mortality. This may be due to the use of aggressive cancer 
18 
 
protocols, aggressive surgery, and radiotherapy with its consequent immunosuppression and 
increase in the number of bacterial infections and the subsequent use of broad spectrum 
antibacterial agents (Castagnola et al., 2011). Prolonged and profound neutropenia (Nesher 
and Rolston, 2014), severe mucositis, the use of broad-spectrum antibiotics and high-dose 
corticosteroids, and invasive procedures contribute to this increase in the incidence of IFIs in 
the child with cancer (Groll et al., 2014). In the child with febrile neutropenia, Candida and 
Aspergillosis are the most common fungal pathogens causing IFIs (Pappas et al., 2009, Segal 
et al., 2011). Invasive candidiasis has a case fatality ratio approximating 10% (Zaoutis, 2010) 
while Aspergillosis has a fatality ratio between 30% and 50% (Steinbach, 2010). HM, 
especially AML and chemotherapy- induced bone marrow suppression is a well-recognized 
risk factor for IFIs (Villarroel et al., 2010).  
 
  The identification of fungal pathogens is extremely challenging in the paediatric population. 
Fungal culture from a sterile site remains the gold standard of identification but fungal 
cultures lack sensitivity. Invasive procedures for histological diagnosis may be life 
threatening in the child with neutropenic sepsis, thrombocytopenia, and septic shock. Imaging 
studies lack specificity (Roberts et al., 2012). Galactomannan antigen detection has a low 
sensitivity in children (Zou et al., 2012) and ß D-glucan studies have many false positive 
results in the child previously treated with cell-wall inhibitor antibiotics, as it the first-line 
empiric antibiotics in febrile children with cancer (Lamoth et al., 2012). In LMICs, imaging 
studies may not be easily and timeously available, galactomannan testing is not routinely 
available, and ß D–glucan studies have a slow turn-around time, which limits the usefulness 
of these tests for the diagnosis of IFIs.  
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2.2.5. POLYMICROBIAL AND MIXED BLOODSTREAM INFECTIONS IN PATIENTS WITH 
CANCER 
 
  Polymicrobial infections are responsible for approximately 15% of infections in immune-
compromised patients with cancer. There is limited information regarding the spectrum and 
microbiology of these infections, even in severely neutropenic cancer patients (Rolston et al., 
2007). Polymicrobial infections in children with cancer are poorly documented (Hung et al., 
2003). Blood stream infections (BSI) are a growing worldwide concern because of their 
potential for severe consequences. Most BSIs are monomicrobial, but according to the largest 
series reported, polymicrobial BSIs account for 6%–34% of BSIs (Sutter et al., 2008). 
Polymicrobial BSIs are usually associated with a higher morbidity and more severe prognosis 
than monomicrobial BSIs. Microorganisms causing polymicrobial BSIs are usually 
combinations of GPB and GNB or Candida species. However, infections with mixed bacterial 
and Candida species is a neglected entity of uncertain clinical significance (Bouza et al., 
2013). 
 
2.2.6. PNEUMONIA IN CHILDREN WITH CANCER 
 
  Pneumonia is a common clinical syndrome in children with cancer and a strong predictor of 
mortality (Ghosh et al., 2012, Bakhshi et al., 2008). Bacterial pathogens are the most common 
cause of ARIs complicating cancer chemotherapy. Staphylococcus aureus, Streptococcus 
pyogenes, Streptococcus pneumoniae, and Enterococcus faecalis are the most common GPB, 
whereas Escherischia coli, Pseudomonas aeruginosa, and Klebsiella species are the most 
common GNB associated with pneumonia in children with cancer. Mycobacterium 
tuberculosis (MTB) is also a cause of pneumonia in the immunocompromised patient. Factors 
associated with high mortality are bacteraemia, refractory neutropenia, and a delay in 
appropriate antibiotic treatment. Despite appropriate treatment, more than 50% of patients die 
of progressive infection or haemorrhage (Thirumala et al., 2010). Common respiratory viruses 
causing acute respiratory tract infections include influenza, parainfluenza virus (PIV), RSV, 
cytomegalovirus, and herpes simplex virus. RSV accounts for 30% to 49% of all respiratory 
viruses in patients who are immunocompromised and have HM. In cancer patients, RSV 
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usually presents as an upper respiratory tract infection (URTI) that can progress to fatal 
pneumonia (Shachor-Meyouhas et al., 2013). Patients who have prolonged and profound 
myelosuppression, and lymphopenia, and exposure to high-dose corticosteroids, are at the 
highest risk for progressing from pneumonia to death. The single most important predictor of 
mortality in influenza-associated pneumonia is absolute lymphopenia. Invasive pulmonary 
aspergillosis can occur in patients who are neutropenic and is commonly fatal with a mortality 
rate as high as 60%. Pneumocystis jirovecii pneumonia (PCP) is less common among patients 
who have cancer compared with patients who have HIV infection. The incidence among 
patients with HM is higher than those with ST. Corticosteroids are a major risk factor for 
PCP. Other predisposing factors include intensity of chemotherapy and a low CD4+ 
lymphocyte count.  
 
  Acute respiratory failure often requires admission to the ICU in patients with cancer and is 
associated with high mortality. In recent years, several studies have reported an increase in 
survival rates in cancer patients requiring mechanical ventilation for acute respiratory failure. 
Investigators have attributed these higher survival rates to recent advances in oncology and 
critical care management of these patients.  
 
2.2.7. TUBERCULOSIS 
 
  Young children and immunocompromised children of all ages, are at high risk of acquiring 
tuberculosis (TB) and progressing to infection and of developing more severe forms of the 
disease including disseminated disease (Zar and Pai, 2011). It is estimated that children make 
up 10% to 15% of the global burden of TB (Marais et al., 2006b). The relationship between 
latent TB and active TB depends on the balance between the immune system and 
Mycobacterium tuberculosis. A latent state or active TB will ensue, depending on the balance 
between the microbe and the immune system. Various individual or environmental factors 
favour the development of active disease such as HIV status or immunodeficient conditions 
(Zumla et al., 2013). 
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2.2.7.1. HIV DISEASE AND TUBERCULOSIS IN CHILDREN 
 
  Tuberculosis rates are at extremely high levels in countries with a high burden of HIV 
infection. TB remains one of the most frequent causes of morbidity and the primary cause of 
death in HIV-infected adults in sub-Saharan Africa, with southern Africa at the epicentre of 
the dual epidemic. The high TB incidence rates among HIV-infected children may be 
explained by an increased Mycobacterium tuberculosis exposure and or an increased 
vulnerability to develop active TB following exposure (Marais et al., 2011). 
 
  Immunocompromised children are a highly susceptible group for TB infection. HIV-infected 
infants have a 20-fold increase in TB incidence compared to HIV-uninfected infants. The risk 
of TB is four times higher in children with CD4+ percentage < 15% than among those with 
CD4+ percentage > 15% (Marais et al., 2011). 
 
2.2.7.2. CANCER AND TUBERCULOSIS 
 
  Since 1970, the American Thoracic Society and Centre for Disease Control and Prevention 
have recognized that cancer increases the risk of TB especially in those patients with ALL and 
HL (Cliffton and Irani, 1970). The incidence of TB is high in patients with HM because of 
defects in the T-cell component of the immune system, which is caused by both the 
underlying disease and its treatment. The relative risk of TB disease in adult patients with HM 
is two to 40 times that of the general population. Neutropenia, impaired humoral and cellular 
immunity are frequent complications in patients with HM. Neutrophils produce a number of 
mycobactericidal cytokines and chemokines. In adults with cancer, the risk of latent TB 
infection has been shown to be inversely proportional to the baseline ANC (Martineau et al., 
2007). 
 
  It is unclear about the timing of TB reactivation in patients with HM. Re-activation could 
result from impaired immunity caused by the underlying malignant process or by the 
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chemotherapy-induced immunosuppression or by re-infection. Progression to active TB in 
immunocompromised individuals might contribute to the high burden of TB in cancer 
patients. The risk of developing TB can vary depending on the type of cancer. In adult 
patients, chronic lymphocytic leukaemia (Silva et al., 2005) and AML (Chen et al., 2011) 
have been reported as risk factors for re-activation of latent TB. There are underlying 
immunological deficiencies which facilitate the emergence of infections in patients with HM 
(Pagano et al., 2012). Alteration in the Th1 cell response of the HM itself or high doses of 
corticosteroids leads to an impaired immune response, which may promote the progression 
from latent TB to active TB (Al-Anazi et al., 2007). 
 
  There are reports of TB in children undergoing chemotherapy from both high burden 
(Karakas et al., 2003) and low burden countries (Lancioni et al., 2009, Klossek et al., 2004). 
In a study from South Africa, the incidence of TB in children treated for cancer was 9117 per 
100 000 years, which was 22 fold greater than the incidence in the general population of 
children (Stefan et al., 2008b). 
 
2.2.7.2.1. THE DIAGNOSIS OF TUBERCULOSIS 
 
  It is imperative to diagnose TB in patients with cancer and to ensure early treatment is 
initiated to eliminate the Mycobacterium tuberculosis before a deterioration in the immune 
system increases the risk of active TB (Anibarro and Pena, 2014). TB is difficult to diagnose 
in children because the clinical presentation and radiological signs may be non-specific. 
Young children rarely present with cavitatory lung disease, hence TB in children is often 
pauci-bacillary. The diagnostic gold standard for active TB relies on the detection of TB by 
culture methods. Sputum-smear microscopy is positive in < 10-15% of children with TB, and 
culture yields are low (30-40%), but may be higher in children with advanced disease (Marais 
et al., 2006c) Diagnosis is even more difficult in children with HIV-infection with its resultant 
malnutrition and anergy, further impeding the interpretation of the TST tests (Zar and Pai, 
2011). Additionally, acute pneumonia is a common disease in children from LMIC which 
adds to the challenges of diagnosing TB (Singh and Aneja, 2011).  
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  At present, tests used to diagnose latent TB include the tuberculin skin test (TST) and two 
interferon γ release assays (IGRA) assays (Quantiferon- TB Gold-in-Tube (QFT) and T-
SPOT.TB (T-SPOT)(Pai et al., 2014). The IGRA tests are based on the detection of 
interferon-γ released from sensitized lymphocytes against specific antigens of TB.  
 
2.2.7.2.2. THE TUBERCULIN SKIN TEST 
 
  The TST is a standard method used to determine whether a person is infected with MTB. 
The TST measures the delayed type of hypersensitivity response to the purified protein 
derivative (PPD) also known as tuberculin. The Mantoux technique is the preferred method of 
PPD administration. The test is performed by injecting 0.1 ml of PPD intradermally on the 
volar aspect of the forearm. The skin test is read between 48 and 72 hours after 
administration. The reaction is measured in millimetres of induration i.e. the hard, palpable, 
and raised area of swelling. The diameter of the induration is measured perpendicular to the 
long axis of the forearm. A positive Mantoux response is defined as ≥ ten mm (≥ five mm in 
an HIV-infected child or severely malnourished child). A positive TST does not indicate 
disease, but, infection with MTB. 
 
  A negative TST does not exclude TB infection or disease, and may be due to disseminated 
(miliary) TB and/or TB meningitis, HIV-infection (or other viral infections such as measles), 
immune-suppressive drugs e.g. corticosteroid therapy, severe malnutrition and recent TB 
exposure (2-3 month delay in conversion) (Moore 2009). 
 
2.2.7.2.3. THE T-SPOT.TB TEST 
 
  The killing and clearance of invading pathogens are mediated by T-effector cells. These cells 
have a short life and die-off when the pathogen is cleared. Hence, their continuing presence 
indicates the cellular immune response is currently encountering a pathogen somewhere in the 
body. Measurement of effector T-cells in a sample therefore diagnoses an on-going infection. 
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This is the basis of the T-SPOT.TB test. The T-SPOT.TB
®
 technology is designed to detect 
and quantify effector T cells (Lalvani et al., 2001). 
 
  T-cells release interferon γ together with a number of other cytokines, which detects and 
destroys infecting organisms. T-cells recognize specific epitopes on the infecting organism, 
which initiates the release of cytokines. The T-SPOT.TB test uses very specific antigens 
(ESAT-6 and CFP 10) to stimulate the effector T-cells. 
 
  The Centres for Disease Control recommend the use of IGRA tests in children, but there is 
little evidence to support this (Mazurek et al., 2010). In the immunocompromised, very 
young, HIV-infected or malnourished child, IGRA may have a role in diagnosis. However, as 
with the TST, a positive test does not equate with active TB disease (Zar and Pai, 2011). 
IGRA sensitivity, like with the TST test, is diminished by HIV infection and low CD4+ 
lymphocyte counts have been associated with higher rates of indeterminate IGRA results 
(Lalvani and Pareek, 2015). 
 
  A study in adult patients with cancer concluded that neither IGRA nor TST can conclusively 
rule out active TB in the immunocompromised patient (Jung et al., 2012). The diagnosis of 
TB in children with cancer is particularly challenging. A South African study assessed the use 
of the TST and two IGRA tests for the detection of MTB infection in children with cancer 
before initiating chemotherapy treatment. TST and IGRA results were discordant, with fewer 
positive results than expected. The TST and IGRA tests performed sub-optimally in this 
group of children, and therefore none of them could be used in isolation to exclude MTB 
infection (Stefan et al., 2010) The sensitivity of the tests for detecting latent TB infection in 
patients with underlying immunodeficiency is lower than that in patients with conserved 
immunity (Redelman-Sidi and Sepkowitz, 2013). Very few studies have evaluated the value 
of IGRAs in patients with cancer. Piana et al compared TST and T-SPOT.TB test in 138 adult 
Italian patients with HM who had been in contact with a smear-positive TB patient. Of these 
patients, 17% were positive for the TST compared to  44% who were positive to the T-
SPOT.TB test (Piana et al., 2006). Richeldi et al found a similar result in 95 Italian patients 
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with HM. The percentage of positive results for IGRAs was higher than that for the TST 
(26% for QFT, 18% for T-SPOT.TB compared to 10% for the TST). However, the authors 
cautioned that IGRA does not have greater sensitivity than the TST for detecting latent TB 
infection in this group of patients (Richeldi et al., 2009). 
 
  A recent study by Moon SM et al compared the TST and QFT in 244 South Korean patients 
before HSCT. Most of the patients were vaccinated with BCG. The percentage of positive 
results was not significantly different (10% for the TST with a cut-off of 10 mm against 16% 
for the QFT) (Moon et al., 2013).  
 
  Immunosuppressed patients have a higher prevalence of indeterminate results with both the 
T-SPOT.TB test and QFT. In a recent report of 18 children with cancer or primary 
immunodeficiencies who had been exposed to an adult with smear-positive TB, the T-
SPOT.TB test had fewer indeterminate results than the QFT (Carvalho et al., 2013). In 
another study with 34 South African children with cancer, indeterminate results were found in 
four patients (11%) with the T-SPOT.TB technique, as against 15% when using the QFT. 
Indeterminate results were more frequent in children with HM than in those affected by other 
types of malignancy (Stefan et al., 2010). 
 
2.2.8. MALNUTRITION 
 
  It is estimated that approximately 826 million people in the world are undernourished. In 
2013, fifty-one million under-five year olds were wasted and 17 million were severely wasted. 
Approximately two thirds of these children lived in Asia and almost one third in Africa 
(Unicef, 2015). 
  In 2008, 8.8 million children under the age of five years died globally, 93% occurred in 
Africa and Asia. Malnutrition is directly or indirectly responsible for 54% of deaths in 
children under five, and contributes to every second death (53%) associated with infectious 
diseases among children under five years in these countries (WHO, 2013). 
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  The HIV pandemic contributes to childhood malnutrition. De Maayer et al documented 
clinical outcomes of severe malnutrition in a high TB and HIV setting in Johannesburg, South 
Africa. Fifty-one percent of 113 severely malnourished children were HIV-infected. The 
overall case death rate was 11.5%. HIV-infected children were six times more likely to die 
than HIV-uninfected children (De Maayer and Saloojee, 2011). 
 
2.2.8.1. THE INTERACTION BETWEEN MALNUTRITION AND INFECTION 
 
  Malnutrition is the most common cause of immunodeficiency worldwide and increases the 
vulnerability of the host to infections (Enwonwu et al., 2006).The immune system first 
executes the innate and then the acquired host defence functions, in response to infections. 
Both processes consume anabolic energy, and the mediators of inflammation increase the 
catabolic response. Hence, the nutritional status of the host determines the outcome of the 
infective process (Schaible and Kaufmann, 2007). 
 
  Protein energy malnutrition causes atrophy of lymphoid tissues, particularly T-lymphocyte 
areas, and causes the thymus to involute, which results in the arrest of lymphocyte 
development, reduced numbers of circulating mature CD4+ helper cells and impairment of 
antibody production to T-dependent antigens. The lymphocytes are reduced in number and 
activity (Beisel, 1996). Malnutrition also reduces complement formation, which results in a 
decrease in phagocytosis of infecting pathogens. Patients with malnutrition have phagocytes 
with reduced bactericidal and candidicidal effects (Rytter et al., 2014). The gut mucosa is 
atrophied and permeable in malnourished children (Prendergast and Kelly, 2012).Cell-
mediated immunity is impaired in malnourished children, which in turn increases the 
susceptibility to intracellular pathogens, reactivation of viral infections and susceptibility to 
developing opportunistic infections (Schaible and Kaufmann, 2007). 
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2.2.8.2. CHILDHOOD CANCER AND MALNUTRITION 
 
  Children with cancer are vulnerable to malnutrition, because they have increased substrate 
needs due to the disease and its treatment (Bauer et al., 2011). At the same time, children have 
increased requirements of nutrients to achieve appropriate growth and neurodevelopment 
(Han-Markey, 2000). Malnutrition in children with cancer is mainly due to a decreased intake 
and reduced absorption of nutrients caused by gastrointestinal side effects of cancer therapy, 
primary effects of the cancer itself, and changes in metabolism. Malnutrition contributes to 
impaired immune function, delayed wound healing and altered drug metabolism which 
impacts negatively on the disease outcome (Tisdale, 1997). A decreased tolerance, altered 
metabolism of chemotherapy and an increase in infection rates in malnourished individuals 
has been described (Gomez-Almaguer et al., 1998, Zimmermann et al., 2013). Underweight 
children are less likely to complete their treatment and are at high risk for relapses and 
mortality as compared to normally grown children (Khan et al., 2006). 
 
  Body mass index (BMI) and changes in BMI during treatment may influence treatment 
outcomes of paediatric patients with ALL. Being underweight at diagnosis is a risk factor for 
relapse, and a decrease in BMI early during treatment is associated with decreased survival 
(den Hoed et al., 2015). Information regarding the clinical relevance of weight loss during 
treatment for childhood cancer is lacking, but in adults, weight loss >5 % or a decrease ≥ 1.0 
in BMI Z-score, in the first three months after diagnosis was considered relevant (Brinksma et 
al., 2012).  
 
  Malnutrition is a significant prognostic factor for survival of children with cancer, especially 
those with ST and metastatic disease (Rickard et al 1986), NBL (Viana et al 1994), ALL and 
AML (Lobato-Mendizabal et al 2003) and RMS (Burke et al., 2013). The Children's 
Oncology Group investigated the effect of malnutrition on event-free survival and found that 
only those children with sustained malnutrition were at significantly greater risk for relapse or 
death and development of treatment related mortality (Orgel et al., 2014). 
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  A study set in Malawi to investigate the relationship between malnutrition and neutropenia 
in children treated for Burkitt’s lymphoma demonstrated that malnutrition in children at 
diagnosis was associated with increased chemotherapy-induced profound neutropenia. Acute 
malnutrition at diagnosis as assessed by arm muscle area (AMA) was associated with a higher 
rate of neutropenia, prolonged neutropenia, febrile neutropenia, delays in treatment and death 
during treatment. Four (4.9%) of the Burkitt’s lymphoma cases died of treatment related 
causes, including three due to Gram-negative septicaemia. All patients with profound 
neutropenia (12, 14.8%), prolonged neutropenia (7, 8.6%), and treatment related deaths (4, 
4.9%) were malnourished at diagnosis (Israels et al., 2009). 
 
2.2.8.3. RISK FACTORS FOR MALNUTRITION IN CHILDREN WITH CANCER  
 
  Malnutrition is associated with the type, stage, and metastatic status of the tumour (Rickard 
et al 1996). Patients who present at diagnosis with malnutrition often have advanced disease 
and or unfavourable biology (Barron et al 2007). Lack of family and health care support may 
lead to nutritional deprivation (Bauer et al 2011). Dysphagia, pain, early satiety, anorexia, 
nausea, vomiting, diarrhoea, oral and intestinal mucositis, anal fissures and alterations in 
smell and taste (van Bokhorst-de van der Schueren et al 2005) contribute to malnutrition in 
children with cancer.  
 
2.2.8.4. MALNUTRITION IN CHILDREN WITH CANCER IN LOW MIDDLE INCOME 
COUNTRIES 
 
  Eighty five percent of the world’s children live in LMICs. Infectious diseases, malnutrition, 
lack of health care facilities (Sala et al., 2004, Sala et al., 2005) and late presentation with 
advanced disease adversely affect these children. The prevalence of malnutrition in children 
diagnosed with cancer in developing countries is 50% (Sala et al., 2004). Malnutrition also 
correlates with low socio-economic status (Viana et al 2001). Malnutrition, poor housing 
conditions, low income, difficulties with communication and transportation, lack of health 
and laboratory services, contribute to a greater risk of recurrence in children with ALL 
(Lobato-Mendizabal et al 1991). 
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  Malnutrition at diagnosis is positively associated with treatment abandonment, one of the 
major reasons for a decreased survival outcome, in the developing world (Sala et al., 2012, 
Antillon et al., 2013). Malnutrition and low socio-economic status results in advanced disease 
at diagnosis, variability in drug metabolism (Murry et al 1998) and a high rate of 
abandonment of treatment (Barr et al 2000). 
 
  The prevalence of malnutrition in children diagnosed with WT in South Africa was recorded 
at 31% (Wessels et al., 1999). In Malawi, children with cancer and underlying acute 
malnutrition at diagnosis, had a higher rate of neutropenia, prolonged neutropenia, profound 
neutropenia, febrile neutropenia, delays in treatment and death during treatment than those 
who were not malnourished (Israels et al., 2008). In a study from Guatemala, more than 50% 
of the patients had some degree of malnutrition at diagnosis, reflecting both a possible delay 
in diagnosis and the general condition of the population (Sala et al., 2008). Malnutrition was 
documented in 52% of children with ALL (kumar et al., 2000) and 56.8% of all cancers (Jain 
et al., 2003) in newly diagnosed cancer cases among Indian children. In Bangladesh, 53% of 
children are malnourished at diagnosis. These children had two to three times more 
microbiologically documented and clinically proven infections, required a longer duration of 
induction and prolonged hospital stay (Hafiz and Mannan, 2008). In the children with severe 
mal-nutrition, after 6 months of treatment, the hazard of death was 2.4 fold the hazard of those 
who were well nourished or moderately malnourished (Sala et al., 2012, Antillon et al., 2013). 
Malnourished children more often abandoned therapy and their event free survival was 
inferior to that of other children (Sala et al., 2012). 
 
2.2.8.5. DIAGNOSIS OF MALNUTRITION 
 
  Body composition is assessed is using weight and height or length, from which the BMI 
(weight/height 
2
) is calculated. WHO Anthro and WHO Anthro-plus calculators calculate 
weight-for-height (WFH), weight-for-age (WFA), height-for-age (HFA), and their Z-scores. 
BMI-for-age defines underweight as < 15th centile and severe malnutrition as < 5
th
 centile. 
The classification of the World Health Organization defines malnutrition as WFA ≤ -2SD; 
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stunting as HFA ≤ -2SD and wasting as WFA ≤ -2SD (de Onis and Blossner, 2003) . A loss in 
body weight of ≥ 5% constitutes acute mal-nutrition and a HFA value < 5th percentile may 
reflect chronic undernourishment in children (Smith et al., 1991).  
 
  Weight may be an inaccurate measure in children with large tumour volumes, which may 
weigh more than 10% of their body weight (Sala et al., 2004). Measurement of nutritional 
status at diagnosis of childhood cancer relies almost exclusively on weight-related indices. 
Studies have compared the use of arm anthropometry with weight. There is strong evidence 
that malnutrition is common at the time of diagnosis in children with cancer, and arm 
anthropometry should replace the use of weight-related indices to identify malnutrition in 
children (Oguz et al., 1999). Mid-upper arm circumference (MUAC) provides an estimate of 
fat-free mass, which is very similar to lean body mass, while triceps skinfold thickness 
(TSFT) yields an estimate of fat mass (Barr et al., 2011, Webber et al., 2013).  
 
  There are different ways of evaluating nutritional status. Arm anthropometry is independent 
of tumour mass in children (Oguz et al., 1999). The most essential information in evaluating 
nutritional status is the lean body mass. MUAC and TSFT are also useful, both of which are 
used to determine the AMA. The lean body mass is calculated by measuring the MUAC and 
TSFT (i.e. muscle + fat) and triceps skin fold (i.e. fat only). AMA is then calculated from the 
MUAC and the TSFT, using the following equation: AMA = (MUAC mm – πTSFT mm) 
²/4(MUAC mm) (Frisancho, 1981).  
 
  Biochemical markers such as plasma protein, pre-albumin, retinol-binding protein, albumin, 
and transferrin are not particularly useful in children with cancer and in critically ill children. 
Infection, fever, and fluid shifts change these variables, as they are acute phase reactants 
(Brennan et al 1998). 
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2.3. IMMUNOLOGY 
 
  Children with cancer have disruptions in the host defence which interfere with the responses 
to infections and preventing establishment of long-term immunity (Lehrnbecher et al., 1997). 
 
  Cancer patients display varying degrees of immunosuppression at the time of presentation, 
prior to initiation of therapy. This has been described with ALL and other conditions 
associated with pancytopenia at the time of presentation. Prolonged and intensive 
chemotherapy administered with or without corticosteroids and radiotherapy, adds to the 
immunosuppression. Patients with HL have impaired lymphocyte proliferation to a variety of 
antigens, and patients with Burkitt’s lymphoma have variable levels of lymphocyte depletion, 
which relate to the stage of disease. Even patients with ST e.g. sarcomas, a disease not 
normally associated with immunosuppression, occasionally show reduced peripheral blood T-
cell populations at the time of presentation (Mackall, 2000). 
 
  Chemotherapy affects leukemic cells and normal T- and B- cells, and reduces 
immunoglobulin levels. Immune abnormalities may persist for months after the end of 
therapy. The degree of immune suppression may be related to the intensity of treatment and 
the time to complete recovery may be longer for the T- than for the B-cell compartment 
(Eyrich et al., 2009). 
 
2.3.1. INTEGUMENTARY BARRIERS 
 
  The systemic effects of the chemotherapy and the local effects of radiation on the oral 
mucosa cause mucositis. Chemotherapy and local radiotherapy damage the oral and 
gastrointestinal mucosa. Pro-inflammatory cytokines are released; these cause increased 
mucosal permeability and translocation of commensal bacteria and fungi, which colonizes the 
mucosal surfaces. This results in localized or systemic infection. Thereafter, cell repair and 
tissue healing occur (Bow, 2013). 
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  Younger patients are at higher risk of chemotherapy-induced oral mucositis, because their 
epithelium has a higher mitotic rate. The most common complication of mucositis, especially 
with neutropenia, is an increased predisposition to bacteraemia, septicaemia, and fungaemia. 
Streptococcus mitis and Streptococcus oralis are the most frequently isolated bacteria. 
Mucositis can also be the starting point for fungal infection, by Candida albicans, as well as 
other types of Candida species and Aspergillus (Sonis, 2004, Villa and Sonis, 2015). 
 
  The skin and mucosal surfaces are the primary host defence and protects against invasion by 
endogenous and acquired microorganisms. Specialized cells of the skin, respiratory tract, 
gastrointestinal tract and genitourinary tract protect the body from invading microbial agents 
(Lehrnbecher et al., 1997). The integrity of the integumentary barrier may be disrupted by 
invasion of local tumour, radiotherapy, surgery, and or chemotherapy. Many procedures, for 
example finger prick testing, venepuncture, bone marrow aspiration and insertion of venous 
catheters, can also disrupt the integument and provide a nidus for colonization and 
dissemination of pathogens (Dhainaut et al., 2005). 
 
2.3.2. NEUTROPHILS  
 
  Neutrophils are the first cells recruited to the site of an infection and contribute to the acute 
inflammatory response. Studies in adults cancer patients showed that serious bacterial 
infections occur with an absolute neutrophil count of < 500 cells/µL (Bodey et al., 1966). This 
was later confirmed in paediatric studies (Pizzo et al., 1982). Neutropenia may be secondary 
to the underlying cancer e.g. ALL or a result of chemotherapy or radiotherapy. Studies have 
shown that neutrophils from patients with leukaemia have sub-optimal chemo-attractive 
responsiveness, bactericidal activity, and superoxide production. In patients with AML, 
neutrophils have abnormal adhesiveness, migration, phagocytic function, and killing activity 
of Staphylococcus aureus and Candida albicans. Chemotherapy and radiotherapy also alter 
neutrophil function resulting in the depression of superoxide regeneration, phagocytosis and 
depressed microbicidal activity (Lehrnbecher et al., 1997). 
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  The incidence of infections in a neutropenic patient is 11 to 38 % (Lehrnbecher et al., 1997, 
Akova et al., 2005). The depth and duration of neutropenia is important. The likelihood of 
developing a microbiologically documented bacterial infection is almost 100% when a patient 
remains neutropenic for three or more weeks without antibiotic treatment (Dhainaut et al., 
2005). 
 
  Severe neutropenia is defined by an ANC of < 500 cells/µL and profound neutropenia by an 
ANC < 100 cells/µL. The incidence of infection was reported to be 14% if the neutrophil 
count fell below 500-1000 cells/µL and 24-60% if the ANC fell to < 100 cells/µL. The longer 
the duration of neutro-penia, and the more rapid the of decline in white cell count, the greater 
the incidence of infection. If the granulocytopenia was prolonged for > five weeks, then the 
incidence of infection was 100% (Lehrnbecher et al., 1997). Individuals who remain 
neutropenic develop secondary fungal or recurrent bacterial infections frequently associated 
with reduced antibiotic susceptibility. These infections may be refractory to standard therapy 
and are associated with a poorer prognosis (Bodey et al., 1966, Donowitz et al., 2001, Akova 
et al., 2005, Sepkowitz, 2005).  
 
  The median time to the first neutropenic fever corresponding to the time of the neutrophil 
nadir occurs at the end of the second week, typically between days ten and 14, from the first 
day of cytotoxic therapy. This is related to the time of the maximum cytotoxic effect of 
chemotherapeutic agents on the intestinal mucosa and the time of maximal oral and 
gastrointestinal mucositis. Neutropenia is an indirect marker for mucositis (Pizzo, 1993). 
 
  The rate of decrease circulating neutrophils is also important, as patients with a rapidly 
decreasing ANC after therapy for ALL are at greater risk for infectious complications than are 
patients with chronic neutropenia such as aplastic anaemia (Koh, 2012).  
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2.3.2.1. GRANULOCYTE COLONY STIMULATING FACTORS  
 
  Granulocyte colony stimulating factors (G-CSF) is administered immediately after a course 
of myelotoxic chemotherapy to decrease the depth and duration of neutropenia and the 
associated risk of infection. Early trials documented that the use of G-CSF in patients 
receiving myelotoxic chemotherapy can reduce the incidence of febrile neutropenia. Patients 
who received G-CSF had a shorter duration of neutropenia, faster recovery from fever and a 
shorter duration of antibiotic use (Mhaskar et al., 2014). The American Society of Oncology 
guidelines recommend the use of G-CSF for primary prophylaxis if the expected rate of fever 
and neutropenia is greater than 40% (Bennett et al., 1996). 
 
2.3.3. LYMPHOCYTES 
 
  Red blood cells, leukocytes, and platelets are short-lived, and are replaced continuously. 
Post-chemotherapy, these cells are replaced within 14-21 days. T-cells are comprised of short 
and long-lived cells, which are not capable of rapid mitotic division; hence, the restoration of 
T-cells after chemotherapy is a slow process.  
 
  Therapy-induced T-cell immunosuppression predisposes the patient to potentially fatal 
opportunistic complications. Patients with ALL are predisposed to infections with 
Pneumocystis jirovecii and other opportunistic infections. Leukaemias originate and spread in 
the primary and secondary lymphoid organs, therefore, these patients present with depleted 
lymphoid populations. Chemotherapy protocols are intensive and prolonged, which further 
adds to the depletion of lymphocytes. Cytotoxic chemotherapy and radiotherapy for ALL 
(MacLennan and Kay, 1978) and ST (Yovino et al., 2013) depletes T-cells, with CD4+ cells 
being more affected than CD8+ cells. Opportunistic infections occur in patients with CD4+ 
counts < 200 cells/µL. The abnormalities in T-cell function, which are seen post 
chemotherapy, are due to a combination of T-cell depletion and intrinsic functional defects 
(Lehrnbecher et al., 1997, Mackall, 2000). 
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  Transient lymphopenia is a risk factor for nosocomial infections. Profound lymphopenia is 
an independent predictor of RSV-related LRTI in children with cancer (El Saleeby et al., 
2008a). Prolonged lymphopenia is also a risk factor for nosocomial sepsis, multi-organ failure 
and death (Gurevich et al., 1995).Abnormalities of lymphocytes affect both the humoral and 
cellular components of the immune system. Patients with defects in the humoral system are 
susceptible to infections by encapsulated bacteria such as Streptococcus pneumoniae, 
Haemophilus influenzae, and Neisseria meningitides. Patients with NHL and HL have defects 
in their cellular immunity. 
 
  Cycle length of chemotherapy is determined by the time necessary to achieve safe values for 
neutrophils and platelets. Adequate time for lymphocyte reconstitution may not occur and 
could result in clinical complications related to immune incompetence. Mackall et al. studied 
ten children and young adults who were treated for cancer. The time between cycles was 
adequate for granulocytic, monocytic and platelet recovery but lymphocytes did not recover 
before the administration of successive cycles, which led to severe B-cell and T-cell depletion 
in these patients and all developed severe opportunistic infections (Mackall et al., 1994).  
 
2.3.4. GLUCOCORTICOIDS 
 
  Glucocorticoids are an integral component of the treatment for HM and brain tumours. 
Gluco-corticoids increase the risk of infections by inducing functional changes in cellular 
metabolism, vascular permeability and wound healing. They depress phagocytic function, 
suppress intracellular microbicidal activity, inhibit granulocyte adherence, block granulocyte 
aggregation and suppress the release of chemotactic factors which results in a decrease in the 
accumulation of phagocytes at the site of inflammation (Lehrnbecher et al., 1997). 
Corticosteroid exposure is an important risk factor for infection outcomes in children treated 
for cancer and, more specifically, is independently associated with both sepsis and infection-
related mortality (Dix et al., 2012) . 
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2.4. INDWELLING CATHETERS 
 
  Long-term venous access devices have facilitated the administration of chemotherapy 
antibiotics, blood products, fluids, feeds and collection of blood samples and these have 
improved the quality of life for patients with cancer. However, the use of indwelling catheters 
can lead to bloodstream infections, referred to as catheter-associated bloodstream infection 
(CABSI) (Tomlinson et al., 2011). 
 
  CABSI infections are related to the extra-luminal colonisation of the catheter, which 
originates from the skin, and from haematogenous seeding of the catheter tip, or intraluminal 
colonisation of the hub and lumen of the central venous catheter. Haematogenous seeding 
with organisms originating from the gastrointestinal tract is seen in patients who are 
neutropenic and those with mucositis.  
 
  Patients with cancer with indwelling catheters are at particular risk for CABSI. Signs and 
symptoms of these infections may be altered in patients with cancer due to neutropenia or 
steroid administration (Boersma et al., 2008). CABSI in neutropenic patients may be 
unaccompanied by inflammation at the catheter site. Central venous catheter-related 
infections are common, 0.5–2.8 per 1000 catheter days in children. They are associated with 
increased mortality, increased length of hospital stay, treatment interruptions, and increased 
complications in adults (Chesshyre et al., 2015) and in children with cancer (Celebi et al., 
2013). 
 
  Coagulase-negative Staphylococcus aureus, GNB, and Candida albicans are most common 
infections associated with indwelling catheters. Non-MTB infections are also associated with 
indwelling catheters (Marschall et al., 2014). Septic thrombi and infective endocarditis are 
life-threatening complications of indwelling catheters. Prolonged neutropenia contributes to 
the number of CABSI infections. 
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2.5. MARKERS OF SEPSIS 
 
  Despite modern algorithms for resuscitation and new antimicrobials, sepsis-related 
morbidity and mortality remain high. Bacterial infections are life threatening for neutropenic 
patients; therefore, early diagnosis of these severe infections is imperative for management of 
patients with sepsis. Infections account for 70% of fatal complications in ALL (Crokaert, 
2000). Careful clinical examination with attention to vital signs, a high index of suspicion and 
knowledge of the local bacterial isolates, including bacterial sensitivity are vital to early 
diagnosis and management, especially in LMIC settings. In neutropenic patients, bacteraemia 
can occur without major clinical findings, except for a high fever, but can rapidly lead to 
septic shock with multi-organ failure and death (Laws, Schneider et al 2000). Children who 
present with high-risk FN i.e. relapse of ALL, hypotension,, ANC < 100 cells/µL, AMC 
<.100 cells/µL, blood urea nitrogen ≥ 18 mg/dL, CRP ≥ 90 mg/L, and positive cultures, have 
a risk of death due to severe sepsis (Santolaya et al., 2007).  
 
  The most precise way to diagnose bacterial infections is by culture but there are often delays 
in results. The identification of early markers of bacterial infections could guide treatments, 
reduce the misuse of antibiotics and possibly improve long-term outcomes of patients treated 
for sepsis (Velicer et al., 2004). In HICs, C-reactive protein (CRP) and procalcitonin (PCT) 
have been investigated in both the adult and paediatric populations among immunocompetent 
and immunocompromised individuals, as markers of sepsis. However, few, such studies have 
evaluated their diagnostic and prognostic significance in the African setting.  
 
  In patients with cancer, many non-infective factors may mimic severe infection. These are 
the administration of drugs and blood products, a high-cell turnover e.g. T-cell ALL and Stage 
4 Burkitt’s lymphoma, and spontaneous tumour lysis syndrome may lead to systemic 
inflammation and mimic severe infection. 
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  The relationship between malnutrition and acute phase reactants remains uncertain. Some 
authors maintain that CRP production, in response to infections, is unaffected in the patient 
with malnutrition (Malave et al., 1998). Children with kwashiorkor have reduced rates of 
protein breakdown and synthesis, but their CRP levels were similar to those without 
kwashiorkor (Manary et al., 1998). On the other hand, Page et al reported that CRP and PCT 
were not sufficiently accurate for diagnosing invasive BSIs in patients with severe acute 
malnutrition (Page et al., 2014).  
 
2.5.1. C-REACTIVE PROTEIN  
 
  Interleukin 6, a sepsis-related cytokine, stimulates CRP production by the liver (Verboon-
Maciolek et al., 2006, Hengartner et al., 2004). CRP then binds to polysaccharides in 
pathogens, which activates the classical complement pathway. Plasma concentrations are 
elevated in patients with bacterial and fungal infections (Du Clos et al 2000). CRP has a low 
specificity therefore is not a very reliable marker for sepsis (Petrola, Toikka et al 2007), has 
limited power to discriminate between infectious and sterile inflammations (Schuttrumpf et 
al., 2006) and has a prolonged time to reach peak levels. CRP secretion starts within four to 
six hours after stimulation, peaking only after 36 hours and has a half-life of six hours 
(Gendrel D, Raymond J et al 1999).  
 
  High levels of CRP at admission were predictors of sepsis in a Chilean cohort of children 
with cancer (Santolaya et al., 2008). A Greek study documented that CRP levels were slightly 
lower in patients with non-bacterial infections, but CRP was elevated in all conditions related 
with febrile neutropenia, including non-bacterial episodes (Hatzistilianou et al., 2010).  
 
2.5.2. PROCALCITONIN 
 
  Procalcitonin was described as a new marker of infection in 1993 (Gendrel et al., 1999). 
PCT  production is induced in all tissues by bacterial infection (Muller et al., 2001). Under 
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normal conditions, negligible serum PCT is detected but can reach up to levels of 1000 ng/ml 
in severe infections (Bernard, Ferriere et al 1998). The concentration changes of the PCT 
molecule is stable and easy to determine, making it a useful marker (Hatzistilianou et al., 
2002).  
 
  PCT is produced by the liver and peripheral blood mononuclear cells in response to 
infection. PCT rises in response to bacterial or fungal infections is related to the severity of 
the infection. PCT levels rise within four hours, peak at six hours and then plateau at eight to 
24 hours after endotoxin injection (Dandona 1994). PCT has an elimination half-life of 
approximately 25 to 30 hours (Meissner et al., 2000). In non-neutropenic patients, PCT 
secretion increases three to eight hours from the beginning of the infection with a plateau at 
twelve to 24 hours (Tang et al., 2007). 
 
  In the paediatric population, several publications reported on the role of high PCT levels in 
systemic bacterial and parasitic infections (Simon et al., 2008). PCT is thought to be able to 
discriminate between bacterial and respiratory viral infections (Gendrel et al., 1999). In both 
neutropenic adult and paediatric patients, high levels of PCT have been documented in 
bacterial and fungal infections (Ruokonen et al., 1999). PCT serum concentration also has 
been demonstrated to better predict the presence of bacterial infection compared to CRP 
(Simon et al., 2008). In children with febrile neutropenia, PCT was more sensitive and 
specific than CRP for the diagnosis of Gram-negative bacteraemia (Fleischhack et al., 2000). 
 
  In a review of the literature, PCT was discriminative in distinguishing fever due to systemic 
forms of infection from non- infectious aetiologies. Patients with IFIs may have a delayed 
increase in PCT levels. PCT has a minimal role, if any, in discriminating Gram-negative from 
Gram-positive infections. and is not superior to CRP (Sakr et al., 2008). 
 
  PCT concentrations are lower in neutropenic than in non-neutropenic patients with bacterial 
infections (Hatzistilianou et al., 2010). Possible reasons for this include that neutrophils are 
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one of the sources of PCT production (Hitoglou et al., 2001) and that liver cells which also 
produce PCT may be damaged by chemotherapy (Christ-Crain et al., 2004). 
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2.6. HIV LYMPHOMAS 
2.6.1. THE EPIDEMIOLOGY OF HIV LYMPHOMAS 
 
  Despite medical, social, and political interventions, the number of people living with HIV 
continues to increase. In 2014, the number of people newly infected with HIV was 2 million 
(220 000 in children < 15 years) and, 1.2 million (150 000 in children < 15 years) deaths were 
due to AIDS (WHO, 2013). 
 
  Approximately five to ten percent of HIV-infected individuals develop NHL, which is an 
AIDS-defining illness in approximately three percent of HIV-infected individuals (Remick, 
1995). The risk of developing NHL increases with the duration of HIV-infection and the 
depth of immunosuppression. Increased survival is due to the introduction of anti-retroviral 
therapy (ARV), but long-term survivors of HIV-infection may remain at increased risk for 
NHL (Engels et al., 2008).  
 
  The incidence of NHL in sub-Saharan Africa did not increase at the rate it did in the North 
American HIV-infected population and this was attributed to mortality from infectious 
complications in LMIC, which prevented the development of malignancies (Parkin et al., 
1999). It may also be due to under-reporting as the most common clinical diagnosis of 
persistent lymphadenopathy is TB and not NHL (Naresh et al., 2011). 
 
  Individuals diagnosed with AIDS during childhood remain at an elevated risk for 
malignancy into adult-hood, despite treatment with ARVs. HIV-associated lymphomas often 
present with a more aggressive histology and advanced stage. Impaired bone marrow reserve 
and underlying immune-deficiency contribute to higher rates of infectious complications 
compared with immunocompetent patients with NHLs (Mounier et al., 2007). The baseline 
CD4+ lymphocyte count at the time of NHL diagnosis was significantly associated with 
subsequent death in adults, being strongest for those with baseline CD4+ counts < 50 cells/µL 
(Barta et al., 2013). 
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  In Africa, overall survival of NHL in HIV-infected children is poor. The median survival in 
Uganda was 11.8 months (Orem et al., 2009). In another study, the overall survival at 2 years 
from diagnosis was 59% for HIV-uninfected NHL and 30% for HIV-infected patients with 
NHL (Chao et al., 2010). In South Africa, the overall disease-free survival for all HIV-
infected children with cancer is 33.7%., 10.2% died of treatment toxicity including infectious 
complications (Davidson et al., 2014). Early in the HIV epidemic, treatment of HIV-infected 
patients diagnosed with NHL was mainly palliative, with median survival measured in 
months (Straus et al., 1998). The introduction of ARVs in 1996 resulted in reduced morbidity 
and mortality from HIV-infection, thus allowing more aggressive NHL therapy(Levine, 
2008). 
 
2.6.2. DRUG INTERACTIONS BETWEEN ANTIRETROVIRAL THERAPY AND 
CHEMOTHERAPY 
 
  Many chemotherapeutic drugs and ARVs are metabolized in the liver through the 
cytochrome p 450 enzyme system. ARVs can increase or decrease the clearance of 
chemotherapeutic drugs by alterations of the cytochrome p 450 system, resulting in  increased 
chemotherapy-associated toxicity or a decrease in the efficacy of ARVs (Floyd et al., 2006). 
 
  Many of the chemotherapeutic drugs and ARVs have similar toxicities. Zidovudine causes 
myelo-suppression in 8% of individuals. Didanosine and Stavudine cause peripheral 
neuropathy, which can add to the same effect caused by the Vinca alkaloids. HIV protease 
inhibitors cause nausea and vomiting which is the most common adverse effect of 
chemotherapy. Nucleoside analogues cause nephrotoxicity; protease inhibitors and non-
nucleoside reverse transcriptase inhibitors cause liver toxicity. Ritonavir is an inhibitor of 
Vinca alkaloids and alkylating agents. CD4+ counts decline by > 50% in patients treated with 
chemotherapy and ARVs (Powles et al., 2002). The combination of ARV therapy and 
chemotherapy augment each other’s toxicities and add to the complexities of treatment of 
children with NHL and HIV disease. 
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2.6.3. BACTERIAL INFECTIONS IN HIV-INFECTED CHILDREN 
 
  A progressive impairment of the cell-mediated and humoral immunity is seen in patients 
with HIV-infection. T-cell defects predispose to many opportunistic infections, and HIV 
causes B-cell dysfunctions, which lead to impaired humoral responses and increased risk of 
bacterial infections. Children with advanced HIV disease cannot mount an adequate humoral 
immune response to bacterial pathogens, especially encapsulated bacteria. HIV-infected 
children have increased rates of sino-pulmonary and other serious bacterial infections 
commonly caused by Streptococcus pneumoniae and other bacteria. Bacterial infections are a 
major source of morbidity and mortality in HIV-infected children (Jaspan et al., 2008). HIV-
infected children have a greater risk of bacterial infections than their HIV-uninfected 
counterparts, and these infections are more aggressive and invasive, and more likely to have 
poorer outcomes. In addition, infections in HIV-infected children are complicated by 
polymicrobial infections (McNally et al., 2007).  
 
  Pneumonia, urinary tract infection, cellulitis, abscess, chronic otitis media, and skin 
infections are more common in HIV-infected individuals. Streptococcus pneumoniae, 
Salmonella species, Haemophilus influenzae type b, and non-typhoid Salmonella are the most 
frequently cultured bacteria in HIV-infected individuals. The mortality of bacteraemia in 
HIV-infected patients is between seven to 46% (Huson et al., 2014). Pneumonia is the 
commonest cause of death in HIV-infected children, both with and without cotrimoxazole 
prophylaxis. 
 
  Multi-drug resistant bacteria are a global problem, in both HIV-infected and HIV-uninfected 
children. The resistance of both Streptococcus pneumoniae and Staphylococcus aureus to 
cotrimoxazole is significantly higher in the HIV-infected group’s isolates in Soweto (Madhi et 
al., 2000a). There is a high burden of bacterial resistance in both Gram-positive and Gram-
negative bacterial isolates from HIV-infected children (Madhi et al., 2000b, Cotton et al., 
2008, Jaspan et al., 2008, Groome et al., 2012).  
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2.6.4. PNEUMONIA IN CHILDREN WITH HIV 
 
  Pulmonary complications occur in up to 70% of HIV-infected patients , mainly of infectious 
aetiology (Benito et al., 2012). HIV-infected children with pneumonia have advanced disease, 
bacteraemia, infections with Pneumocystis jirovecii, high rates of treatment failure, and death 
compared with HIV-uninfected children (Gray and Zar, 2010). Bacteria are the leading cause 
of severe pneumonia in HIV-infected children. Streptococcus pneumoniae, Staphylococcus 
aureus, Haemophilus influenzae, Escherichia coli, and Salmonella species are the leading 
bacteria causing infections. The incidence of bacterial pneumonia is indirectly proportional to 
the decline in CD4+ count. Eighty percent of cases of bacterial pneumonia occur with a CD4+ 
count < 400 cells/µL and recurrent pneumonia with a CD4+ counts < 300 cells/µL (Hirschtick 
et al., 1995). 
 
  Pneumocystis jirovecii is a frequent cause of pulmonary infections in HIV-infected children 
hospitalized with severe pneumonia (Morrow et al., 2014). Pneumocystis jirovecii and other 
fungal pneumonias often develop in patients whose CD4+ count is < 200 cells/µL (Lee et al., 
2015). At least one third of HIV-infected persons are infected with MTB, and HIV-infection 
is the largest risk factor for developing TB (Swaminathan et al., 2010). Patients with advanced 
immunosuppression present with advanced TB and extra-pulmonary disease (Martinson et al., 
2011). TB is the commonest cause of morbidity and the leading cause of death in HIV-
infected adults in sub-Saharan Africa (Corbett et al., 2006). 
 
  There have been many changes in the Paediatric Oncology Unit at Chris Hani Baragwanath 
Academic Hospital since the 1990s. The number of children being treated for cancer has more 
than doubled, Porto-catheters have replaced Hickman lines, many treatment protocols for HM 
and ST were intensified, autologous stem cell transplants are routine treatment, the number of 
HIV-infected patients has increased, and there have been structural changes to the Oncology 
unit, including a new in-patient and outpatient treatment facility. Furthermore, as is the case 
globally, the antibiotic sensitivity pattern has likely changed over the last two decades in 
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South Africa, although this has not been recently documented in our paediatric oncology 
setting. 
 
  The aim of this research program reported in this thesis was to investigate the infectious 
related morbidity and mortality in predominantly black-African children treated for cancer at 
one of the largest hospital in the Southern Hemisphere (Johannesburg, South Africa) and in a 
setting with a high prevalence of HIV-infection.  
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3. METHODOLOGY 
3.2. AIM OF THE STUDY 
 
  The overall aim of the study was to prospectively delineate the epidemiology of infectious 
morbidity and mortality in African child with cancer. Additionally, we aimed to evaluate the 
usefulness of indirect markers and risk factors for sepsis in these children. 
 
3.3.  OBJECTIVES OF THE STUDY 
 
1. To investigate the burden of bacterial sepsis in HIV-infected and HIV-uninfected 
children treated for cancer (Chapter 4); 
2. To investigate the role of respiratory viral infections as possible etiologic agents in 
sepsis cases among children treated for cancer (Chapter 6); 
3. To compare the tuberculin skin test to the quantiferon γ release assay (T- SPOT.TB) 
for diagnosing Mycobacterium tuberculosis infection in children with cancer on 
chemotherapy (Chapter 5); 
4. To evaluate the role of nutritional status in predisposing to sepsis in African children 
with cancer (Chapters 4, 5, 6); 
5. To compare the infectious disease morbidity in HIV-infected and HIV-uninfected 
children treated for NHL with the same chemotherapy protocol (Chapter 7); 
6. To evaluate the usefulness of C-reactive protein and procalcitonin as markers of 
bacterial sepsis in children with cancer (Chapters 4, 5, 6) 
 
3.4. SETTING OF THE STUDY 
 
  The study was carried out in the Paediatric Oncology Unit at Chris Hani Baragwanath 
Academic Hospital (CHBAH). The hospital has a wide referral area, including Soweto, 
southern Gauteng, Mpumalanga, and North West province. It is a secondary-tertiary level care 
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hospital and a teaching hospital for the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, South Africa.  
 
  The Paediatric Oncology unit consists of two in-patient wards, one for children age 0 to 7 
years, and the other for those aged 8-19 years. The unit also has an outpatient clinic and a 
residence facility in Soweto, where children who do not need to be hospitalised can be housed 
with a parent. The home-facility offers accommodation, meals, and transport to the hospital 
for emergencies and treatment. 
 
3.5. STUDY DESIGN 
 
  This prospective single centre study enrolled all patients from (one year of age to 19) 
admitted with cancer to the Paediatric Oncology Unit, Chris Hani Baragwanath Academic 
Hospital from April 2009 to March 2011. The children were followed-up until the completion 
of their treatment or up until the end April 2014, when the study ended. The events studied 
were all febrile episodes in children who received treatment (including chemotherapy, 
irradiation, and or surgery) for HM or ST. The standard care for these patients included a 
detailed history and physical examination, blood investigations (full blood count with a 
differential and a blood culture for a suspected septic episode). In addition, patients enrolled 
into the study had anthropometric measures undertaken on admission (Appendix 2), a TST by 
the Mantoux method and blood was drawn to undertake the T-SPOT.TB test. For each septic 
episode, a detailed history (Appendix 3) was taken, a standardized physical examination 
performed (Appendix 4), blood was obtained for culture, full blood count, CRP and PCT 
(Appendix 5), a nasopharyngeal aspirate was performed (Appendix 6), and empiric antibiotic 
treatment was initiated (Appendix 7), which was tailored, if necessary, based on the blood, 
urine or other culture results. 
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3.6. ETHICS 
 
  All individuals older than eight years were assented and their parents or legal guardians 
provided written informed consent for participation in this study (Appendices 8, 9, 10). Ethics 
clearance was obtained (Appendix 14) from the Human Research Ethics Committee, 
University of the Witwatersrand (Ethics clearance number: M080304). 
 
3.7. STATISTICAL METHODS 
3.7.1. BINARY OUTCOMES 
 
  For binary outcomes, proportion and percentages were reported. The chi-square tests or 
Fisher’s exact tests were used to determine if significant differences existed between two 
proportions for un-clustered data. For clustered data, a generalized mixed effect logistic 
regression model was used to compare a single explanatory variable with a dependent binary 
outcome. Multiple logistic regression were used to calculate an adjusted odds-ratio, which 
adjusted for the effects of confounding factors that were statistically significant (p-value ≤ 
0.05) from the simple regression analysis. 
 
3.7.2. QUANTITATIVE OUTCOMES 
 
  The mean and standard deviation was reported for variables assumed to be normally 
distributed. Students t-tests were used to determine effects on normally distributed outcomes 
for un-clustered data. For clustered data, a linear mixed effects regression model was used to 
determine significant association between an explanatory variable with a normally distributed 
outcome. Log-transformations were used when appropriate.  
 
  For non-normal data, medians were reported and the Wilcoxon rank sum test (for un-
clustered data or clustered data) was used to determine significant associations.  
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  For count data, the incidence and 95% Confidence Intervals (95% CI) were reported. 
Follow-up time was calculated as the number of months from date of presentation of disease 
to the last follow-up visit, which was either loss to follow-up, refusal of further treatment, end 
of treatment or death. A Poisson regression or mixed effect Poisson regression was used to 
determine significant association for un-clustered and clustered data, respectively. A p-value 
≤ 0.05 was considered statistically significant.  
 
3.8. STUDY DEFINITIONS 
3.8.1. FEVER  
 
  Fever was defined as a temperature of ≥ 38.5°C as a single reading or ≥ 38 °C twice within 
one hour (Link et al., 2003, Freifeld et al., 2011). 
 
3.8.2. BACTERAEMIA AND FUNGAEMIA 
 
  Bacteraemia or fungaemia was defined as bacteria or fungi cultured from blood under sterile 
conditions. If CONS was cultured on a single blood sample, it was presumed to be a 
contaminant. However, if cultured twice from blood within 48 hours it was considered a 
significant pathogen (Link et al., 2003, Freifeld et al., 2011). We only report on those CONS 
cases that were considered significant pathogens. 
 
3.8.3. NEUTROPENIA, LYMPHOPENIA AND MONOCYTOPENIA 
 
  An absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and absolute 
monocyte count (AMC) of < 1000 cells/µL was defined as moderate bone marrow 
suppression, < 500 cells/µL as severe suppression and < 100 cells/µL as profound 
suppression. Prolonged neutropenia, lymphopenia, and monocytopenia were defined as an 
ANC, ALC or AMC of < 1000 cells/µL for ≥ 7 days (Freifeld et al., 2011). 
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3.8.4. PNEUMONIA 
 
  Children who have evidence of crackles in the absence of wheezing, or the presence of any 
airspace consolidation on radiograph were categorized as having pneumonia. 
 
3.8.5. TREATMENT INTENSITY 
 
  Treatment intensity 1 (Standard intensity) was protocols used to treat localised solid 
tumours, treatment intensity 2 (Medium intensity) was for metastatic solid tumours and 
medium-risk ALL, and treatment intensity 3 (High intensity) was used for AML, high-risk 
ALL and stem-cell transplantation. 
 
3.9. INVESTIGATIONS ON ADMISSION 
3.9.1. NUTRITIONAL STATUS AT PRESENTATION 
3.9.1.1. ANTHROPOMETRY 
 
  Anthropometry was assessed by measuring: 
 Height in centimetres 
 Weight in kilograms 
 Mid-upper arm circumference in millimetres 
 Triceps skin fold thickness in millimetres 
 WHO-Anthro and WHO-Anthro plus calculators were used to calculate WFA, WFH 
and HFA scores, BMI and Z-scores.  
 
3.9.1.2. MID-UPPER ARM CIRCUMFERENCE 
 
  Mid-upper arm circumference was measured to the nearest 1 mm. The mid-point of the 
dependant right upper arm was determined, between the olecranon process of the ulna and the 
acromial process of the scapula with the forearm held at a right angle and a mark made at this 
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point. A paper measuring tape was passed around the arm at the mark. The measurement was 
repeated twice and the mean of the three measurements was used for analysis. The results 
were compared with age and gender matched norms. 
 
3.9.1.3. TRICEPS SKIN FOLD THICKNESS 
 
  A Harpenden calliper (John Bull British Indicators, LTD., made in England) was used to 
measure the TSFT to the nearest 0.2 mm at the same level of the site used for the MUAC. The 
skin and fat was lifted away from underlying muscle tissue and the calliper blades were 
applied to either side of the fold of skin. The measurements were repeated twice within 1mm 
of the previous measurement and the mean of the three measurements was used for analysis. 
The results were referenced to age and gender matched norms (Frisancho, 1981). 
 
  Mid upper arm circumference and TSFT are surrogate measures of lean muscle and fat. The 
WFH may be misleading in children with malignancy, especially in children with large STs, 
and particularly in children with abdominal tumours, which often weigh more than ten percent 
of the total body weight, and in patients on steroid therapy who may have excessive weight 
gain. MUAC and TSFT are valuable tools in such patients, they are independent of tumour 
mass (Sala et al., 2004).We used the TSFT, MUAC and AMA to assess nutritional status in 
our study. 
 
3.9.2. SCREENING FOR TUBERCULOSIS 
3.9.2.1. TUBERCULIN SKIN TESTING 
 
  All patients enrolled on the study were screened for MTB infection using the Mantoux 
method, where 0.1ml of purified protein derivative (23TS), TUBERSOL®, Sanofi Pasteur, 
Canada) was intradermally injected on the volar aspect of the left forearm. The reactivity to 
the TST was measured within 48-72 hours. A transverse diameter of ≥ 5 millimetres 
induration was considered to indicate underlying MTB infection, as all the patients were 
considered immunocompromised. 
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3.9.2.2. ELLISPOT INTERFERON GAMMA RELEASE ASSAY TEST 
 
  Five millilitres of blood was obtained in a heparinised tube from all children at the time of 
enrolment for the IGRA test. ELISPOT was performed using a commercial kit (T-SPOT.TB; 
Oxford Immunotec Ltd, Oxford, UK) (Lalvani et al., 2001) at the Respiratory and Meningeal 
Pathogens Research Unit, Chris Hani Baragwanath Academic Hospital. The peripheral blood 
mononuclear cells were separated using Ficoll-Plaque centrifugation. The cells were washed, 
suspended, and counted. The wells of polyvinylidene fluoride–backed plates (MAIPS4510; 
Millipore, Billerica, MA, USA) were coated with 15 μg/mL of monoclonal antibody 1-D1K 
against IFN-γ (Mabtech, Nacka Strand, Sweden). The separated cells (250 000/well) were 
added to duplicate wells containing antigen (ESAT-6 or CFP-10) or mitogen. The antigen was 
not added to the background control wells. After an incubation period of 18 hours, the plates 
were washed, and one μg/mL of biotinylated monoclonal antibody 7-B6-1-biotin against IFN-
γ (Mabtech) was added. The plates were incubated for two hours, and then rewashed. 
Streptavidin-alkaline phosphatase toxoid (Mabtech) was added and incubated for 1.5 hours. 
The plates were once again rewashed, and 100 μL of chromogenic alkaline phosphatase 
substrate (Bio-Rad Laboratories, Hercules, CA, USA) was added. After 10–15 min, the plates 
were once again washed and spots were enumerated with a stereomicroscope. Mean values 
were determined and both duplicate wells were used in all calculations. The total numbers of 
spots (background control wells) were subtracted from the number in the test wells, and a 
response was positive if the number of spots per test well was ≥ 10 and at least twice the value 
found in the background control wells. 
 
3.9.3. HUMAN IMMUNODEFICIENCY VIRUS 
 
  The HIV-1 ELISA assays for HIV serology were performed using the HIV Architect (Abbot, 
Germany, 2006) or HIV Elecys-Cobas (Roche, Sweden, 2008). The HIV Ag/Ab Combo 
Architect (Abbot, Germany, 2006) used for confirmatory testing of HIV ELISA positivity. 
Both the assays detect HIV-1 antigen p 24 and total antibodies to HIV-1 and HIV-2. For 
children younger than eighteen months of age, the HIV-PCR test was done using the HIV 
PCR/Cobas Ampiclor (Roche, Sweden, 2010). 
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3.10. INVESTIGATIONS FOR A SEPTIC EPISODE 
  
  Patients on treatment for cancer who presented with a pyrexial episode, i.e. a single 
temperature of ≥ 38.5°C or two temperature recordings of ≥ 38.0 C within a 24-hour period 
were enrolled into the sepsis component of the study. Each patient had a thorough septic 
work-up done as per Appendices 3, 6 and 7. 
 
3.11.  DESCRIPTION OF TESTS 
3.11.1. FULL BLOOD COUNT AND DIFFERENTIAL  
 
  The full blood count was run on the Sysmex XE-5000 Analyser (Sysmex, Kobe, Japan, 
2009). The Sysmex XE-5000 reports the white blood cell, red blood cell, haemoglobin, 
haematocrit, mean cell volume, mean cell haemoglobin, mean cell haemoglobin 
concentration, red cell distribution width, platelet, mean platelet volume, and plateletcrit. The 
five-part differential includes percent and absolute number of neutrophils, lymphoid cells, 
monocytes, eosinophils, and basophils.  
 
3.11.2. UREA, ELECTROLYTES AND ALBUMIN 
 
  The test was performed using the colorimetric method using bromocresol green (BCG), 
Roche Modular P and Cobas 8000 (Roche Diagnostics GmbH, Mannheim, Germany, 2006). 
 
3.11.3.  C-REACTIVE PROTEIN 
 
  The test was performed using particle enhanced immune-turbidimetric method using the 
Roche Modular P and Cobas 8000 (Roche, Germany, 2006).  
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3.11.4.  PROCALCITONIN 
 
  The test was performed using electro-chemiluminescent method using the Roche Modular E 
and Cobas 8000 (Roche, Germany, 2006). 
 
3.11.5.  BLOOD CULTURE 
 
  Blood cultures were processed using the BacT/ALERT 3D, non-invasive microbial detection 
system (BioMerieux, France, 2005). The instrument is automated, capable of incubating, 
agitating, and continuously monitoring aerobic and anaerobic media inoculated with patient 
specimens suspected of having bacteraemia and fungaemia. 
 
  Carbon dioxide determines the positivity of the culture bottle and substrates in the culture 
medium. As the microorganisms metabolize the substrates in the culture medium, CO- CO2 is 
produced which causes the colour of the sensor at the bottom of the bottle, to change from 
dark to light. A light-emitting diode projects light onto the sensor and a photodetector 
measures the reflected light. The amount of CO2 produced determines the positivity of the 
culture bottle. 
 
3.11.6.  ANTIBIOTIC SUSCEPTIBILITY TESTING 
 
  Isolates from blood culture, urine and other sterile sites (if applicable) investigated for 
antibiotic susceptibility to pre-defined antibiotic compounds either manually or using the 
automated instrument following the Kirby-Bauer method, and interpretation of susceptibility 
was based on the CLSI standards M100-S19-24 (Microscan, USA, 2006). 
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3.12. INVESTIGATION FOR TB DISEASE 
3.12.1. MICROSCOPY AND CULTURE 
 
 Sputum specimens were collected for microscopy and culture in patients suspected of having 
TB disease. In those patients who were unable to expectorate a sputum specimen, a gastric 
lavage specimen was obtained. The gastric lavage was performed by placing an appropriate-
sized nasogastric tube trans-oesophageally in the stomach of a fasting patient early in the 
morning, before arising. The stomach was washed with normal saline, followed by aspiration 
of the gastric contents. The sample was collected in a sterile bottle and delivered to the 
laboratory. Samples were collected on three consecutive mornings. Trained nursing personnel 
collected the sputum. The mouth was first rinsed to avoid contamination with food particles 
and mouth flora. The patient was instructed to inhale deeply and cough deeply from the chest. 
We targeted obtaining a minimum of 2 ml of sputum.  
 
3.13. RESPIRATORY VIRUS TESTING 
 
  Nasopharyngeal aspirates (NPAs) were collected on all patients suspected of having a septic 
episode, except for cases diagnosed from Friday evening to Sunday (due to logistical issues) 
and in patients with epistaxis. Nasal secretion samples were obtained using a nasogastric tube 
(FG 8 x 10 cm in length, Given Medical Products, South Africa), attached to a 5 ml syringe 
containing 3 ml of normal saline. The nasopharynx was injected with saline and one to two 
millilitres was immediately aspirated. The NPA was placed in a universal transport medium 
and stored at 4°C. As soon as possible, this was then transported to the Respiratory and 
Meningeal Pathogens Research Unit, Chris Hani Baragwanath Academic Hospital. 
 
  Total nucleic acids were extracted from archived NPA using a Nucli-SENS easy MAG 
platform (BioMerieux; France, 2009), and eluted in a final volume of 60 ml of elution buffer 
(Loens et al., 2007). RNA was reverse transcribed with High Capacity cDNA Reverse 
Transcriptase (Invitrogen, Life Technologies, USA) and primed with oligo-dT primers 
(Invitrogen, Life Technologies; USA). RT- PCR was done in an ABI 7500 RT-PCR system 
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(Applied Biosystems, Life Technologies; USA); reactions were performed in 20 ml using 
TaqMan Universal PCR Master Mix (Applied Biosystems, Life Technologies; USA) and the 
primers and probes listed in Appendix 7. Five duplex RT-PCR reactions, targeting eight 
respiratory viruses were developed. Internal controls (the human genes: ribonucleoprotein and 
glyceraldehyde-3-phosphate dehydrogenase; or the spiked viruses: lambda and Newcastle 
Disease Virus) were included to check the efficiency of the extraction step and to detect the 
presence of PCR inhibitors. Positive controls were included in each experiment (Nunes et al., 
2014). 
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4. BACTERIAL AND FUNGAL INFECTIONS IN CHILDREN TREATED 
FOR CANCER 
4.2. RESULTS 
4.2.1. DEMOGRAPHIC AND CLINICAL DATA OF CHILDREN WITH CANCER  
 
  We enrolled 169 patients into the study, of whom 82 (42.5%) were diagnosed with a 
haematological malignancy (HM) and 87 (51.5%) with a solid tumour (ST). The HM cases 
included 32 (38.6%) acute lymphoblastic leukaemia (ALL), 10 (12%) acute myeloid 
leukaemia (AML), 23 (27.7%) Non-Hodgkin’s lymphoma (NHL) and 18 (21.7%) Hodgkin’s 
lymphoma (HL). Among the 87 patients with ST, 29 (33.7%) had Wilm’s tumour (WT), 13 
(15.1%) rhabdomyosarcoma (RMS), nine (10.5%) each of retinoblastoma (RBL) and brain 
tumours (BT), five (5.8%) each of Kaposi’s sarcoma ( KS) and osteogenic sarcoma (OS), four 
(4.7%) each of neuroblastoma (NBL) and germ cell tumours (GCT), three (3.5%) of 
hepatoblastomas (HBL), two (2.3%) of nasopharyngeal carcinomas (NPC) and three (3.5%) 
children with rare tumours (two adrenocortical carcinomas, one hepatocellular carcinoma).  
 
  Overall, 56.8% of the children were males, including being more commonly represented 
among HM (68.3%) than ST (45.9%) cases;  
 
Table 1 (p=0.006). The median age of presentation was older for children with HM (89 
months) than those with ST (48 months); Table 1. 
 
  Twenty-five of the patients with ST had Stage 4 disseminated disease (6 RMS, 4 WT, and 1 
RBL). Of the 18 patients with HL, ten had extra-nodal disease spread to the bone marrow. 
Seventeen (73.9%) of the patients with NHL had high-risk disease. One patient with NHL 
required second-line chemo-therapy after relapse and demised prior to autologous stem cell 
transplant. One HIV-infected patient was treated with an autologous stem cell transplant post 
relapse of disease.  
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  Nine (28.1%) of the 32 patients with ALL failed induction therapy, therefore needed a 
second-line course of induction chemotherapy. Twenty-five (78.1%) of the ALL were 
stratified as high-risk patients. Ten (6.3%) patients were treated with autologous stem cell 
transplantation (two each of RMS, HL, NBL, NHL, and one each with WT and OS). Eleven 
children (6.5%) were not treated (eight abandoned treatment and three were not treated 
because of advanced disease). These children were included in the analysis until death or 
abandonment of treatment.  
 
Table 1: Demographic and Clinical Data of Children with Cancer 
Characteristic Overall            
N=169 
Haematological 
Malignancy  N=82 
Solid Tumour      
N=87 
p-
value* 
Total 169 82 (42.5%) 87 (51.5%) - 
Male 96 (56.8%) 56 (68.3%) 40 (45.9%) 0.006 
Median Age 
 ( IQR
1
)-months 
68.5 (36-121) 89 (51-23) 48 (27.5-100) 0.001 
HIV-Infected 18 (10.6%) 13 (15.9%) 5 (5.8%) 0.06 
 N= number of patients, IQR
1
 = Interquartile range,*p= Haematological Malignancy vs Solid Tumour 
 
4.1.2. AETIOLOGY OF MICROBIOLOGICALLY CONFIRMED SEPTIC EPISODES IN CHILDREN 
TREATED FOR CANCER 
 
  One hundred and thirty-one (77.5%) of the 169 patients enrolled in the study experienced at 
least one microbiological confirmed sepsis episode (MCSE) during treatment for cancer, 
which was more common among children with HM (87.8%) compared to those with ST 
(67.8%; p=0.003); Table 2. The mean number of suspected sepsis episodes (SSE) was 3.1 per 
patient, which also was more common among those with HM (4.0) than in children with ST 
(2.3; p<0.001); Table 2.  
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  The person-time of follow-up was 234 and 279 child years among the HM and ST cases, 
respectively; Table 2. There was a higher incidence (per 100 child years) of SSE among 
children with HM (140) than in those with ST (71; p<0.001); Table 3. Overall, the incidence 
(per 100 child years) of MCSE was 69.4, which too, was higher among children with HM 
(96.7) compared to those with ST (46.5; p<0.001); Table 2. Overall there were 3.1 septic 
episodes per patient, 4 in those with HM and 2.3 (p<0.001) in the cohort with ST. Similarly, 
the incidence of Gram-positive bacteraemia (77.0 vs 43.7; p<0.001) and Gram-negative 
bacteraemia (74.5 vs 25.8; p<0.001) were greater in children with HM than ST; Table 3. In 
addition, the incidence of concurrent Gram-positive and Gram-negative bacteraemia (27.8 vs 
11.1; p<0.001) were higher in children with HM than ST. 
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Table 2: Aetiology of Microbiologically Confirmed Septic Episodes in Children Treated for Cancer 
Characteristic Overall                                         
N
1
 = 169 
Haematological Malignancy          
N = 82 
Solid Tumour                        
N = 87 
P-value* 
Person time observation (years) 513 234 279 NA 
Number of children with at least one SSE
3
 (%) 131 (77.5) 72 (87.8) 59 (67.8) 0.003 
Total number of SSE 528 330 198 NA 
Mean number of SSE per patient (SD)
4 
3.1 (3.1) 4.0 (3.44) 2.3 (2.4) <0.001 
SSE episodes per 100 child years (95% CI 
5
) 102.9 (94.1-111.7); n
2 
=528 141.2 (126-156.5); n=330 70.9 (61-80.7); n=198 <0.001 
At least one positive blood culture/patient (%) 120 (71.0) 69 (84.2) 51 (58.6) <0.001 
At least one episode of GPB
6
 (%) 109 (64.5) 63 (76.8) 46 (52.9) 0.002 
At least one episode of GNB
7
 (%) 86 (50.9) 53 (64.6) 33 (37.9) 0.001 
At least one episode of Fungaemia (%) 36 (21.3) 20 (24.4) 16 (18.4) 0.445 
Total number of GPB Septic Episodes 302 180 122 NA
10 
Total number of GNB Septic Episodes 246 174 72 NA 
Total number of Fungal Septic Episodes 47 24 23 NA 
Incidence of MCSE
7
 per 100 child year (95% CI) 69.4 (62.2-76.6); n=356 96.7 (84.1-109.3); n=226 46.5 (38.5-54.5); n=130 <0.001 
Incidence of Gram-positive bacteraemia per 100 child 
years (95% CI) 
58.9 (52.2-65.5); n=302 77 (65.8-88.3); n=180 43.7 (35.9-51.4); n=122 <0.001 
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Incidence of Gram-negative bacteraemia per 100 child 
years (95% CI) 
47.9 (42-53.9); n=246 74.5 (63.4-85.5); n=174 25.8 (19.8-31.7); n=72 <0.001 
Incidence of Fungaemia per 100 child years (95% CI) 9.2 (6.5-11.8); n=47 10.3 (6.2-14.4); n=24 8.2 (4.9-11.6); n=23 0.473 
Incidence
9
 of Gram-positive and Gram-negative 
bacteraemia per 100 child years (95% CI) 
18.7 (15-22.5); n=96 27.8 (21.1-34.6); n=65 11.1 (7.2-15); n=31 <0.001 
Incidence of Gram-positive bacteraemia + Fungaemia per 
100 child years (95% CI) 
4.5 (2.7-6.3); n=23 3.9 (1.3-6.4); n=9 5 (2.4-7.6); n=14 0.541 
Incidence of Gram-negative bacteraemia +Fungaemia per 
100 child years (95% CI) 
9 (6.4-11.6); n=46 9.8 (5.8-13.9); n=23 8.2 (4.9-11.6); n=23 4 
N
1
=number of patients, n
2
=number of events,
 
SSE
3
 = Suspected Septic Episode, SD
4
 = Standard deviation, CI 
5
 = Confidence interval, GPB
6
 = Gram-positive Bacteria, GNB
7
 = 
Gram-negative Bacteria, MCSE
8
 =Microbiologically-Confirmed Septic Episodes, Incidence
9
 included in the incidence of Gram-positive and negative bacteraemia and fungaemia, 
*p= Haematological Malignancy vs Solid Tumour, NA
10 = 
not applicable 
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4.2.2. CLINICAL AND LABORATORY PARAMETERS OF SUSPECTED AND 
MICROBIOLOGICALLY CONFIRMED SEPSIS IN CHILDREN TREATED FOR CANCER 
 
  The mean CRP (p=0.011) and PCT (p=0.001) were higher in children with HM among those 
with MCSE compared to those with culture-negative sepsis episodes (CNSE); Table 3. The 
maximum recorded temperature, duration of fever, mean white cell count, neutrophil count, 
lymphocyte count, and monocyte count showed no significant difference between MCSE 
compared to CNSE; Table 3. Using MUAC, 76.9% of the children were severely 
malnourished, whereas by AMA 56.8% were categorized as being severely malnourished. 
There was, however, no significant relationship between nutritional status on admission for 
those with HM and those with ST (data not shown).  
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Table 3: Clinical and Laboratory Parameters of Suspected and Microbiologically Confirmed Sepsis in Children Treated for Cancer 
Parameter Overall                                                                                  
N = 169 
Haematological Malignancy 
N = 82 
Solid Tumour                                                                                  
N = 87 
 CNSE1 MCSE2 *p-value CNSE MCSE **p-value CNSE MCSE ***p-value 
Mean maximum temperature °C 
(SD3) 
38.9 (0.5) 39.1 (0.6) 0.24 38.9 (0.5) 39.1 (0.6) 0.13 38.9 (0.5) 38.9 (0.5) 0.97 
Median duration of fever (days) 
(IQR4) 
3.0 (2.0-5.0) 3.0 (2.0-5.0) 0.12 3.0 (2.0-5.0) 4.0 (3.0-6.0) 0.20 3.0 (2.0-4.0) 3.0 (2.0-4.0) 0.47 
Median CRP5 mg/L (IQR) 99.0 (34.0-193) 112 (47.5-216) 0.18 117 (61.3-225) 129 (72.8-230) 0.011 40.0 (20.5-124) 79.5 (35.3-134) 0.08 
Median PCT6 µ/L (IQR) 1.4 (0.5- 6.8) 2.2 (0.7-11.6) 0.06 1.8 (0.5- 7.0) 2.7 (0.7-12.3) <0.001 1.2 (0.5-2.9) 2.0 (0.6-8.9) 0.27 
Median WCC7 x 109 /L (IQR) 1.4 (0.5-4.6) 1.3 (0.4-5.8) 0.43 0.8 (0.2-1.9) 0.6 (0.3-2.4) 0.38 4.7 (2.2-8.5) 4.5 (1.1-9.0) 0.95 
Median neutrophil 
count(cells/µL) (IQR) 
155 (70.0-1898) 220 (70.0-2345) 0.29 90.0 (60.0-378) 90.0 (60.0-878) 0.13 2158 (421-4815) 1410 (120.0-4800) 0.82 
Median lymphocyte 
count(cells/µL) (IQR) 
330 (90.0-1380) 295 (80.0-1170) 0.77 110 (72.5-552)  90.0 (70.0-603) 0.77 1500 (7195-2520) 960 (160-1780) 0.36 
Median monocyte 
count(cells/µL) (IQR) 
80.0 (30.0-410) 80.0 (30.0-490) 0.70 55.0 (27.5-151) 50.0 (20.0-140) 0.98 410 (75.0-1060) 291 (40.0- 805) 0.42 
N = number of patients, CNSE
1
 = Culture-negative septic episode, MSCE
2
 = Microbiologically-confirmed Septic Episode, SD
3
 = Standard deviation, IQR
4
 = interquartile ratio, CRP
5
 
= C-reactive protein, PCT
6 
= Procalcitonin, WCC
7
 = White cell count, *p = CNSE vs MCSE in the overall group, **p = CNSE vs MCSE for HM, ***p = CNSE vs MCSE for ST
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4.2.3. ADMISSION PARAMETERS ASSOCIATED WITH MICROBIOLOGICALLY CONFIRMED 
SEPSIS 
 
  Children with HM had a 2.03 (p<0.001) fold greater incidence (80 per 100 child years) of 
micro-biologically confirmed sepsis (MSCE) compared to those with ST (40); Table 4. The 
incidence of MCSE in children categorised as having high-risk HM ((109) was 4.01 fold 
greater compared to those with medium-risk HM (27; p<0.001); Table 4. Similarly, treatment 
intensity categories 2 and 3 were associated with 2.03 and 8-fold greater incidence of MSCE 
compared to children with treatment intensity 1 (p<0.001 for both; Table 4). In children with 
ST, those with metastatic disease had a higher incidence (71) of MSCE than those with only 
localized ST (29; aOR: 2.49; p<0.001); Table 4. There was no association observed for age 
group, gender, nutritional status or HIV-infection status and incidence of MCSE; Table 4. 
 
4.2.4.  FACTORS ASSOCIATIONS WITH MICROBIOLOGICALLY CONFIRMED SEPSIS IN 
CHILDREN WITH CANCER 
 
  The presence of an indwelling catheter was 2.98 fold (p<0.0001) more likely to be associated 
with MCSE in children with SSE compared to those without an indwelling catheter; Table 5. 
No such associations of a greater proportion of SSE cases having MCSE were evident in the 
presence of mucositis, herpes stomatitis, use of high-dose corticosteroids and prolonged or 
profound bone marrow suppression; Table 5. 
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Table 4: Admission Parameters Associated with Microbiologically Confirmed Sepsis 
Parameter Incidence Rate                               
(95% CI) 
Adjusted Incidence Rate Ratio                                                           
(95% CI; p-value) 
Age (years) 
  
1-5 61.5 (52.2-70.8) 1.14 (0.88-1.48); p= 0.31 
>5-10 51.1 (40.8-61.4) 0.83 (0.62-1.11); p= 0.20 
>10 61.6 (48.9-74.4) referent group 
Female 57.6 (48.7-66.6) referent group 
Male 59.2 (50.9-67.4) 0.8 (0.64-1); p= 0.048 
MUAC1>5th percentile 56.6 (44-69.3) referent group 
MUAC<5th percentile 59.4 (52.4-66.3) 1.07 (0.83-1.38); p= 0.59 
AMA2>5th percentile 55.5 (46.5-64.4) referent group 
AMA<5th percentile 61.3 (53-69.6) 1.03 (0.83-1.27); p= 0.79 
TSFT3>5th percentile 61.8 (53.9-69.7) referent group 
TSFT<5th percentile 53.6 (44-63.2) 0.9 (0.73-1.13); p= 0.37 
HIV-uninfected 59.2 (52.8-65.7) referent group 
HIV-infected 50.9 (32.4-69.4) 0.73 (0.5-1.07); p= 0.10 
Solid Tumour 39.6 (32.8-46.4) referent group 
 Solid Tumour (localized) 28.7 (22-35.4) referent group 
Solid Tumour (metastatic) 71.4 (53.4-89.5) 2.49 (1.76-3.51); p<0.001 
Haematological 
malignancy 80.4 (69.9-90.9) 2.03 (1.64-2.52); p<0.001 
Medium risk 27.3 (17-37.6) referent group 
High risk 109.3 (94.1-124.5) 4.01 (2.68-5.99); p<0.001 
Treatment intensity4 1 26.1 (20-32.2) referent group 
Treatment intensity 2 47.5 (37.4-57.6) 2.03 (1.47-2.79); p<0.001 
Treatment intensity 3 124.1 (106.9-141.2) 8 (5.24-12.2); p<0.001 
MUAC 
1
 = Mid-upper arm circumference, AMA 
2
 = Arm muscle area, TSFT 
3
 = Triceps skin-fold thickness, 
Treatment Intensity 
4
 = Treatment Intensity 1 = standard intensity, 2 = medium intensity, 3= high intensity, CI 
5
 
= Confidence interval 
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Table 5: Association between Suspected and Microbiologically Confirmed Sepsis in Children Treated for Cancer 
Parameter Proportion with MCSE4                                            
(95% CI5) 
Adjusted Odds Ratio                       
(95% CI; p-value) 
No Indwelling Catheters 46.7 (36.4-57.4) referent group 
Indwelling Catheters 71.7 (67.2-75.9) 2.9 (1.9-4.8); p<0.001 
No high-dose Corticosteroids 64.4 (58.8-69.7) referent group 
High-dose Corticosteroids 71.7 (65.0-77.6) 1.5 (0.9-2.4); p= 0.13 
No Mucositis 67.1 (62.2-71.6) referent group 
Mucositis 68.5 (59.6-76.3) 1.03 (0.7-1.6); p= 0.89 
No Herpes stomatitis 66.6 (61.8-71.1) referent group 
Herpes stomatitis 70.3 (61.1-78.2) 1.2 (0.8-1.9); p= 0.44 
No Profound neutropenia at onset of SSE1  67.1 (61.4-72.4) referent group 
Profound 2 Neutropenia at onset of SSE 67.8 (61.4-73.6) 0.9 (0.6-1.5); p= 0.86 
No Prolonged Neutropenia during SSE 68 (62.1-73.4) referent group 
Prolonged 3 Neutropenia during SSE 66.8  60.6-72.5) 0.9 (0.6-1.3); p= 0.60 
No Profound Lymphopenia at onset of SSE 66.8 (61.3-71.8) referent group 
Profound Lymphopenia at onset of SSE 68.8 (61.9-74.9) 1.04 (0.7-1.6); p= 0.84 
No Prolonged Lymphopenia during SSE 66.3 (59.9-72.1) referent group 
Prolonged Lymphopenia during SSE 68.4 (62.6-73.7) 1.05 (0.7-1.6); p= 0.79 
No Profound Monocytopenia at onset of SSE 67.1 (60.4-73.2) referent group 
Profound Monocytopenia at onset of SSE 67.9 (62.3-72.9) 0.9 (0.6-1.5); p= 0.86 
No Prolonged Monocytopenia during SSE 65.6 (58.1-72.4) referent group 
Prolonged Monocytopenia during SSE 68.6 (63.4-73.4) 1.1 (0.7-1.7); p= 0.8 
SSE1 = Suspected Septic Episode, Profound2 = Absolute cell count < 100 cells/µL, Prolonged3 = Absolute cell count <1000 
cells/µL for > 7 days, MCSE4 = microbiologically confirmed septic episode, CI5 = Confidence interval 
67 
 
4.2.5. GRAM-POSITIVE BACTERIAL PATHOGENS CAUSING SEPSIS IN CHILDREN WITH 
CANCER 
 
  Overall, there were 21.2 Gram-positive MCSE per 100 child years. The most frequently 
identified Gram-positive bacterial isolates were CONS (n=176; 59.1%), Streptococcus 
viridans (n=36; 12.1%), and Enterococcus faecium (n=27, 9.1%). The overall incidence (per 
100 child years) of CONS was 34.3, which was higher among children with HM (44.5) than 
with ST (25.8; p=0.002). Similarly, there was a higher incidence of Staphylococcus aureus 
(3.9 vs 1.8; p=0.026), Streptococcus pneumoniae (3.9 vs 0; p=0.002), and Micrococcus (3.9 
vs 1.1; p=0.044) sepsis episodes among children with HM than with ST; Table 6. 
 
4.2.6. GRAM-NEGATIVE BACTERIAL PATHOGENS CAUSING SEPSIS IN CHILDREN 
TREATED FOR CANCER 
 
  Overall, there were 16.8 Gram-negative MCSE per hundred child years. The most frequently 
identified Gram-negative bacterial isolates were Escherichia species (n=64; 26.9%) and 
Acinetobacter species (38; 16%), and Klebsiella species (28; 11.8%). The overall incidence 
(per 100 child years) of Escherichia species was 12.5, which was higher among children with 
HM (17.5) than ST was (8.2; p=0.005). Similarly, there was a higher incidence of 
Acinetobacter species (12.8 vs. 2.9; p<0.001), Klebsiella species (8.1 vs. 3.2; p=0.022), 
Pseudomonas species (8.1 vs. 2.9; p=0.012), and Bacillus species (6.4 vs 1.1; p=0.002), and 
Stenotrophomonas maltophilia (4.3 vs 0.7; p=0.01) sepsis episodes among children with HM 
than ST; Table 7. 
 
4.2.7.  FUNGAL PATHOGENS CAUSING SEPSIS IN CHILDREN WITH CANCER 
 
  Overall, there were 16.8 fungal MCSE per hundred child years. The most frequently 
identified fungal isolates were Candida albicans (n= 28; 62.2%) and Candida parapsilosis 
(n=12; 26.7%). The overall incidence (per 100 child years) of Candida albicans was six and 
three for Candida parapsilosis, which did not differ between cases with HM and ST; Table 8.  
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Table 6: Incidence (per 100 child years) of Gram-Positive Bacterial Pathogens Causing Sepsis in Children with Cancer 
Incidence  Overall                           
N=514 
Haematological Malignancy      
N=234 
Solid Tumour                        
N=280 
p-value* 
Total number of Septic episodes with Gram-positive bacteraemia  302 180 122 NA 
Incidence** of at least one Gram-positive bacterium (95% CI) 21.2 (17.3-25.2); n=109 27 (20.3-33.6); n=63 16.5 (11.7-21.2); n=46 0.021 
Incidence of CONS¹ (95% CI) 34.3 (29.2-39.4); n=176 44.5 (36-53.1); n=104 25.8 (19.8-31.7); n=72 0.002 
Incidence of S. aureus² (95% CI) 3.5 (1.9-5.1); n=18 5.6 (2.5-8.6); n=13 1.8 (0.2-3.4); n=5 0.026 
Incidence of S. pneumoniae (95% CI) 1.8 (0.6-2.9); n=9 3.9 (1.3-6.4); n=9 0 (0-0); n=0 0.002 
Incidence of Streptococcus species³ (95% CI) 1.9 (0.7-3.2); n=10 3 (0.8-5.2); n=7 1.1 (0-2.3); n=3 0.13 
Incidence of Streptococcus viridans (95% CI) 7 (4.7-9.3); n=36 7.3 (3.8-10.7); n=17 6.8 (3.7-9.9); n=19 0.85 
Incidence of Enterococcus faecium
7 
(95% CI) 5.3 (3.3-7.2); n=27 5.6 (2.5-8.6); n=13 5 (2.4-7.6); n=14 0.79 
Incidence of Enterococcus faecalis (95% CI) 1.9 (0.7-3.2); n=10 2.6 (0.5-4.6); n=6 1.4 (0-2.8); n=4 0.37 
Incidence of Micrococcus (95% CI) 2.3 (1-3.7); n=12 3.9 (1.3-6.4); n=9 1.1 (0-2.3); n=3 0.044 
CI
1
 = Confidence interval, CONS
2
 includes Coagulase-negative Staphylococcus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis, S aureus 
3
  
includes Methicillin-resistant Staphylococcus aureus, Streptococcus species
4
 includes Streptococcus milleri, Streptococcus mitis, and Streptococcus salivarius, Enterococcus 
faecium
5
 includes Vancomycin-resistant  Enterococci, N
6
 =Total person years, n
7
 = Number of events, NA
8
=Not Applicable, *p value = Haematological Malignancy vs Solid 
Tumour, Incidence** per 100 child years 
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Table 7: Incidence (per 100 child years) of Gram-Negative Bacterial Pathogens Causing Sepsis in Children with Cancer 
Incidence Overall                        
N=514 
Haematological 
Malignancy N=234 
Solid Tumour          
N=280 
p-value* 
Total number of SE with Gram-negative bacteraemia 246 174 72 NA 
Incidence** of at least one GNB (95% CI) 16.8 (13.2-20.3); n=86 22.7 (16.6-28.8); n=53 11.8 (7.8-15.8); n=33 0.006 
Incidence of Escherichia coli
1
 (95% CI) 12.5 (9.4-15.5); n=64 17.5 (12.2-22.9); n=41 8.2 (4.9-11.6); n=23 0.005 
Incidence of Acinetobacter baumanni
2
 (95% CI) 7.4 (51-9.8); n=38 12.8 (8.2-17.4); n=30 2.9 (0.9-4.8); n=8 <0.001 
Incidence of Klebsiella species
4
 (95% CI) 5.5 (3.4-7.5); n=28 8.1 (4.5-11.8); n=19 3.2 (1.1-5.3); n=9 0.022 
Incidence of Pseudomonas species
3
 (95% CI) 5.3 (3.3-7.2); n=27 8.1 (4.5-11.8); n=19 2.9 (0.9-4.8); n=8 0.012 
Incidence of Bacillus species (95% CI) 3.5 (1.9-5.1); n=18 6.4 (3.2-9.7); n=15 1.1 (0-2.3); n=3 0.002 
Incidence of Enterobacter species
5 
(95% CI) 2.7 (1.3-4.2); n=14 3.9 (1.3-6.4); n=9 1.8 (0.2-3.4); n=5 0.17 
Incidence of Corynebacterium species (95% CI) 2.5 (1.2-3.9); n=13 3.9 (1.3-6.4); n=9 1.4 (0-2.8); n=4 0.09 
Incidence of Stenotrophomonas maltophilia (95% CI) 2.3 (1-3.7); n=12 4.3 (1.6-6.9); n=10 0.7 (0-1.7); n=2 0.01 
Incidence of Neisseria species (95% CI) 0.8 (0-1.5); n=4 0.9 (0-2); n=2 0.7 (0-1.7); n=2 0.86 
Incidence of Aeromonas caviae (95% CI) 0.6 (0-1.2); n=3 0.9 (0-2); n=2 0.4 (0-1.1); n=1 0.47 
Incidence of Haemophilus influenza (95% CI) 0.4 (0-0.9); n=2 0.9 (0-2); n=2 0 (0-0); n=0 0.19 
Incidence of Brevudimonas species (95% CI) 0.4 (0-0.9); n=2 0.9 (0-2); n=2 0 (0-0); n=0 0.19 
Incidence of Proteus mirabilis (95% CI) 0.6 (0-1.2); n=3 0.9 (0-2); n=2 0.4 (0-1.1); n=1 0.47 
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Incidence of Salmonella species (95% CI) 0.4 (0-0.9); n=2 0 (0-0); n=0 0.7 (0-1.7); n=2 0.32 
Incidence of Empedobacter species (95% CI) 0.2 (0-0.6); n=1 0.4 (0-1.3); n=1 0 (0-0); n=0 0.41 
Incidence of Moraxella catarrhalis (95% CI) 0.2 (0-0.6); n=1 0 (0-0); n=0 0.4 (0-1.1); n=1 0.56 
Incidence of Orchobacter anthropi (95% CI) 0.2 (0-0.6); n=1 0.4 (0-1.3); n=1 0 (0-0); n=0 0.41 
Incidence of Pantoea species (95% CI) 0.2 (0-0.6); n=1 0.4 (0-1.3); n=1 0 (0-0); n=0 0.41 
Incidence of Serratia odifera (95% CI) 0.2 (0-0.6); n=1 0.4 (0-1.3); n=1 0 (0-0); n=0 0.41 
Incidence of Raltsonia picketii (95% CI) 0.4 (0-0.9); n=2 0.9 (0-2); n=2 0 (0-0); n=0 0.19 
Incidence of Morganella morganella (95% CI) 0.2 (0-0.6); n=1 0 (0-0); n=0 0.4 (0-1.1); n=1 0.56 
 CI 1 = Confidence interval, Escherischia coli 2 includes ESBL Escherischia coli, Acinetobacter species 3 includes baumanni, lwoffii and pan-resistant species, Klebsiella species 4 
includes baumanni, oxytoca and ESBL Klebsiella, Pseudomonas species
5
 includes aeruginosa, alcaligenes, flourescens and ESBL Pseudomonas, Enterobacter species
6
 includes 
cloacae, agglomerans and ESBL Enterobacter, N 
7
= Total person-years, n 
8
= number of events, *p= Haematological malignancy vs Solid Tumour. Incidence** per 100 child years 
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Table 8: Incidence (per 100 child years) of Fungaemia in Children with Haematological and Solid Tumour Malignancies 
Parameter Overall                                
N
2
=514 
Haematological Malignancy  
N=234 
Solid Tumour                 
N=280 
p-value* 
Total number of fungaemia episodes  246 174 72 NA 
4
 
Incidence** of at least one fungus (95% CI 
1
) 16.8 (13.2-20.3); n 
3
=86 22.7 (16.6-28.8); n=53 11.8 (7.8-15.8); n=33 0.006 
Incidence of C. albicans fungaemia (95% CI) 5.5 (3.4-7.5); n=28 6 (2.9-9.1); n=14 5 (2.4-7.6); n=14 0.65 
Incidence of C. parapsilosis fungaemia (95% CI) 2.3 (1-3.7); n=12 3 (0.8-5.2); n=7 1.8 (0.2-3.4); n=5 0.38 
Incidence of C. tropicalis fungaemia (95% CI) 0 (0-0); n=0 0 (0-0); n=0 0 (0-0); n=0 0.93 
Incidence of Prototheca fungaemia (95% CI) 0.4 (0-0.9); n=2 0.4 (0-1.3); n=1 0.4 (0-1.1); n=1 0.90 
Incidence of Fusarium fungaemia (95% CI) 0.2 (0-0.6); n=1 0.4 (0-1.3); n=1 0 (0-0); n=0 0.41 
Incidence of Aspergillus niger fungaemia (95% CI) 0.2 (0-0.6); n=1 0.4 (0-1.3); n=1 0 (0-0); n=0 0.41 
Incidence of Aspergillus flavus fungaemia (95% CI) 0.2 (0-0.6); n=1 0 (0-0); n=0 0.4 (0-1.1); n=1 0.56 
CI 
1
= Confidence interval, N 
2
= total person-years, n 
3
= number of events, NA 4=Not applicable, p*= Haematological malignancy vs Solid tumour, Incidence** per 100 chi
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4.2.8. ANTIMICROBIAL SUSCEPTIBILITY OF GRAM-POSITIVE BACTERIA ISOLATED 
DURING SEPSIS IN CHILDREN TREATED FOR CANCER 
 
  The Enterococcus isolates were generally fully sensitive to Linezolid, Teicoplanin, and 
Quinopristin-dalfopristin; Figure 1. However, 65% of Enterococcus faecium species were 
resistant to Vancomycin. Resistance of Enterococcus isolates was > 85% to penicillin and 
62% of Enterococcus faecium strains were resistant to Ampicillin. The prevalence of 
resistance of Staphylococcus aureus strains was 100% for penicillin-ampicillin, whilst 25% 
were methicillin resistant. Staphylococcus aureus was 100% sensitive to Amikacin, 75% to 
Clindamycin, 76 % to Trimethoprim-Sulfamethoxazole, 65% to Rifampicin and 68% to 
Ciprofloxacillin. Not all the GPB were tested against all the antibiotics. Streptococcus 
pneumoniae was fully sensitive to Cefotaxime.  
 
 
Figure 1: Antimicrobial Susceptibility of Gram-Positive Bacterial Pathogens Causing Sepsis in 
Children with Cancer 
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4.2.9. ANTIMICROBIAL SUSCEPTIBILITY OF GRAM-NEGATIVE BACTERIAL PATHOGENS 
CAUSING SEPSIS IN CHILDREN TREATED FOR CANCER 
 
  The antibiotic susceptibility profile of the five most common GNB causing sepsis is shown 
in Figure 2. The majority of Gram-negative pathogens were susceptible to the Carbapenems 
except for Acinetobacter baumanni (25%-30% sensitivity) and Pseudomonas aeruginosa 
(72% sensitivity). Escherichia coli were resistant to 49% - 64% of third generation 
Cephalosporins. Klebsiella pneumoniae was resistant to 65%-78% third generation 
Cephalosporins. Pseudomonas aeruginosa isolates showed less resistance to the 
antimicrobials tested than most of the other Gram-negative pathogens, 65% of the isolates 
were sensitive to Piperacillin-Tazobactam, 76% to Ceftazidime, 75% to Amikacin, and 72% 
and 71% sensitive to Meropenem and Imipenem, respectively. Acinetobacter baumanni was 
resistant to most antimicrobials tested, 27% of the isolates were sensitive to Piperacillin-
Tazobactam, 26% to Ceftazidime, 50% to Amikacin, and 26% and 30% sensitive to 
Meropenem and Imipenem, respectively. Acinetobacter baumanni and Pseudomonas 
aeruginosa were not tested against Ertapenem.  
 
 
Figure 2: Antimicrobial Susceptibility of Gram-Negative Bacterial Pathogens Causing Sepsis in 
Children Treated for Cancer 
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4.2.10. OUTCOME 
 
  Of the 169 children enrolled in the study, 53 (31.4%) died. Of these, 13 (7.6%) of the deaths 
were due to sepsis. Of the patients who died due to sepsis, eleven (84.6%) had pancytopenia 
during the septic episode. All of the sepsis-associated deaths occurred among children with 
HM (seven ALL, four NHL, one each of AML and HL). In the cohort with HM, 15.9% of 
deaths were due to sepsis. Of the thirteen children who died from sepsis, six children with 
ALL were stratified as high-risk cases and two had failed front-line induction therapy. Of the 
children with ALL, three deaths were during the induction phase, two after high-risk 
blocks,one during consolidation, and one during re-induction of the ALL-BFM 1995 protocol.  
 
  All four (100%) of the patients with NHL who died of sepsis, were stratified as high-risk, 
and were HIV-infected. Eight (15.1%) of the 53 who died were HIV-infected, four (30.8%) of 
the HIV-infected children in our cohort died because of sepsis. Aspergillus niger was isolated 
from blood culture, and an ESBL Klebsiella pneumoniae from the urine, in the patient with 
HL who died post-autologous bone marrow transplant. 
 
  Among the sepsis related deaths, 10 (76.9%) were associated with pneumonia, including 
four (30.8%) children with concurrent microbiologically confirmed TB. Four (30.8%) deaths 
had a fungal infection, including one each with confirmed Candida albicans endocarditis and 
Aspergillus pneumonia. Five (38.5%) of the children who died also had a urinary tract 
infection in which bacteria were identified. Eight (61.5%) patients had septic shock at the 
time of death and were not accepted to the Intensive Care Unit for mechanical ventilation; 
Table 9. 
75 
 
Table 9: Summary of Deaths in Children with Cancer due to Sepsis 
 
Pt Sex Age Disease HIV Blood culture Urine culture Other site Clinical Syndrome 
1 M 158 NHL
1
 Pos MRSA
5
 CONS
6
 Negative CSF
9
: MRSA Skin: 
MRSA 
Mucositis 
2 M 139 HL
2
 Neg Bacillus, Enterococcus 
faecalis,VRE
7
Aspergillus 
niger 
Ent faecalis, 
 ESBL E coli 
Nil Pneumonia, Gastroenteritis Herpes stomatitis, 
Mucositis 
3 M 137 ALL
3
 Neg CONS ESBL E coli          
C albicans 
Nil Urinary tract infection 
4 M 125 ALL Neg Bacillus, 
 Klebsiella 
 Pneumonia 
No growth Sputum: MTB
10
 Pneumonia, Herpes stomatitis, Proven TB
11
 
5 F 112 ALL Neg Acineto baumanni, Emped 
brevis 
ESBL Pseudo 
 aeruginosa 
Nil Pneumonia, Gastroenteritis, Urinary tract infection 
6 F 100 NHL Pos Negative Negative Sputum: MTB Pneumonia, Herpes stomatitis,  Mucositis, Proven 
TB 
7 F 99 ALL Neg Candida 
Albicans 
No growth Nil Mucositis 
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8 F 98 ALL Neg ESBL
8 
Klebsiella pneumonia Negative Sputum: MTB Pneumonia, Gastroenteritis, Proven TB 
9 M 50 NHL Pos CONS E coli Nil Pneumonia, Gastroenteritis, Herpes stomatitis, 
Mucositis, Urinary tract infection, Probable TB 
10 F 44 ALL Neg Negative ESBL Klebs 
 pneumonia 
Candida albicans Pneumonia, Herpes  stomatitis,  Fungal urinary 
tract infection 
11 M 23 NHL Pos ESBL E coli Nil Sputum : MTB Herpes  stomatitis, Mucositis 
12 M 21 AML
4
 Neg Ent faecalis Ent faecalis Nil Pneumonia, Gastroenteritis, Herpes  stomatitis, 
Mucositis, Probable TB 
NHL
1
 = Non-Hodgkin’s lymphoma, HL2= Hodgkin’s lymphoma, ALL3 = Acute lymphoblastic leukaemia, AML4 = Acute myeloid leukaemia, MRSA5 = Methicillin-resistant 
Staphylococci, CONS
6
 = Coagulase-negative Staphylococci, VRE
7
 = Vancomycin-resistant Enterococci, ESBL
8
 = Extended-spectrum β lactamase producer, CSF9 = Cerebrospinal 
fluid, MTB
10
 = Mycobacterium tuberculosis, TB
11
 = Tuberculosis  
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4.2.11.  BASELINE PARAMETERS ASSOCIATED WITH ALL-CAUSE MORTALITY  
 
  Compared to the mortality rate in children >10 years of age (55.6%), those aged <5 years 
(28.8%; p=0.012) or 5-10 years (34.0%, p=0.039) had lower mortality rates; Table 10. 
Overall, children with a HM had a higher case fatality ratio (CFR; 47.6%) compared to those 
with ST (27.6%; aOR 2.3; p=0.015). Furthermore, the CFR among HM cases with high-risk 
disease (59.7%) was 11.9 fold greater compared to those with medium risk disease (10%; 
p=0.02). There was no association between presence of malnutrition or HIV positivity and 
death in our cohort; Table 10.  
 
4.2.12. FACTORS ASSOCIATED WITH ALL-CAUSE MORTALITY IN CHILDREN TREATED 
FOR CANCER 
 
  The CFR among children who received at least one course of high-dose corticosteroids 
(58.6%) was 4.9 fold greater compared to those who did not receive high-dose corticosteroids 
(21.4%; p=0.007). In addition, CFR was 7.8 fold higher among children treated with high-
intensity treatment (63.8%) compared to those treated with standard and medium intensity 
treatment (p=0.004); Table 11. Additional factors independently associated with a higher CFR 
included developing pneumonia (51.5% vs 27.7%; aOR 2.4; p=0.021) and being diagnosed 
with tuberculosis (66.7% vs 33.6%; aOR 3.7; p=0.009);  
Table 11.  
 
  Neither the diagnosis of at least one SSE or MCSE were independently associated with 
mortality among our study cohort; Table 11. However, the odds of dying in those who had 
profound neutropenia at the onset of MCSE was 6.7 fold greater (p<0.001), and those with 
prolonged neutropenia 5.5 fold greater (p=0.003) compared to those sepsis episodes in which 
this was not present. Likewise, the odds of dying in those who had profound lymphopenia at 
the onset of MCSE was 5.4 (p=0.001) greater, and those with prolonged lymphopenia were 
2.8 fold more likely to die (p=0.048) compared to MCSE cases in which this was not evident. 
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Table 10: Baseline Parameters Associated with All-cause Mortality 
 
Parameter Percentage of death (95% CI) Adjusted Odds Ratio (95% CI; p-value) 
Age (years)   
<5 28.8 (19.1-40.7) 0.4 (0.2-0.8); p= 0.012 
>5-10 34 (21.6-48.9) 0.4 (0.2-0.9); p= 0.039 
>10 55.6 (40.1-70.1) referent group 
Female 31.5 (21.4-43.6) referent group 
Male 41.7 (31.8-52.2) 1.3 (0.7-2.6); p= 0.41 
MUAC1>5th percentile 36.1 (21.3-53.8) referent group 
MUAC<5th percentile 36.9 (28.8-45.9) 1.1 (0.5-2.3); p= 0.9 
AMA2>5th percentile 31.4 (21.2-43.8) referent group 
AMA<5th percentile 40.6 (30.9-51.2) 1.4 (0.7-2.7); p= 0.34 
TSFT3>5th percentile 33.7 (24.8-43.8) referent group 
TSFT<5th 41.5 (29.7-54.4) 1.5 (0.8-2.9); p= 0.25 
HIV-uninfected 36.4 (28.9-44.7) referent group 
HIV-infected 44.4 (22.4-68.7) 1.1 (0.4-3.2); p= 0.79 
Solid Tumour 27.6 (18.8-38.4) referent group 
ST4 localized 27.4 (17.2-40.4) referent group 
ST metastatic disease 28 (12.9-49.6) Not Applicable 
Haematological 
malignancy 
47.6 (36.5-58.8) 2.3 (1.2-4.5); p= 0.015 
HM5 medium risk 10 (1.8-33.1) referent group 
HM high-risk 59.7 (46.5-71.7) 11.9 (2.5-56.9); p= 0.002 
MUAC
1
 = Mid-upper arm circumference, AMA
2
 = Arm muscle are, TSFT
3
 = Triceps skinfold thickness, ST
4
 = 
Solid tumour, HM
5
 = Haematological malignancy  
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Table 11: Factors Associated with All-Cause Mortality in Children Treated for Cancer 
 
Parameter Percentage of Death  
(95% CI) 
Adjusted Odds Ratio                                    
(95% CI; p-value) 
No Indwelling Catheters 44.4 (22.4-68.7) referent group 
Indwelling Catheters 38.4 (29.5-48.1) 0.8 (0.3-2.4); p= 0.69 
No High-dose Corticosteroids 21.4 (12.9-33.2) referent group 
High-dose Corticosteroids 58.6 (44.9-71.1) 4.9 (1.6-15.9); p= 0.007 
Treatment intensity
1
 1 23108 (13.9-35.5) referent group 
Treatment intensity 2 23.9 (13.1-39.1) Not Applicable 
Treatment intensity 3 63.8 (50.1-75.7) 7.8 (1.9-31.1); p= 0.004 comparing 3 to 2 
No MCSE
2
 30.6 (18.7-45.6) referent group 
At least one MCSE 40 (31.3-49.4) 1.2 (0.6-2.5); p= 0.67 
No SSE
3
 28.9 (15.9-46.1) referent group 
At least one SSE 39.7 (31.448.6) 1.3 (0.6-2.9); p= 0.55 
No Gram-positive bacteraemia 33.3 (22.0-46.8) referent group 
Gram-positive bacteraemia 39.5 (30.4-49.3) 0.8 (0.2-2.7); p= 0.66 
No Gram-negative bacteraemia 32.5 (22.9-43.8) referent group 
Gram-negative bacteraemia 41.9 (31.5-52.9) 1.2 (0.5-2.8); p= 0.69 
No Fungaemia 37.3 (29.2-46.1) referent group 
Fungaemia 37.1 (21.9-55.1) 0.9 (0.4-1.9); p= 0.74 
No Pneumonia 27.7 (17.7-40.4) referent group 
Pneumonia 51.5 (38.9-63.9) 2.4 (1.1-5.2); p= 0.021 
No Tuberculosis 33.6 (24.9-43.5) referent group 
Tuberculosis 66.7 (44.7-83.6) 3.7 (1.4-9.8); p= 0.009 
No Urinary tract infection 35.1 (24.87-46.9) referent group 
Urinary tract infection 47.2 (33.5-61.2) 1.5 (0.7-3.2); p= 0.29 
No Gastroenteritis 37.43 (27.6-48.2) referent group 
Gastroenteritis 46.2 (30.4-62.6) 1.1 (0.5-2.5); p= 0.86 
No Mucositis 32.8 (21.9-45.8) referent group 
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Mucositis 46.3 (34.2-58.8) 1.2 (0.5-2.6); p= 0.70 
No Herpes stomatitis 34.8 (23.9-47.3) referent group 
Herpes stomatitis 45.2 (32.7-58.2) 1.1 (0.5-2.4); p= 0.80 
No Profound
4
 Neutropenia at 
onset of SE
5
 
12.8 (5.3-26.4) referent group 
Profound Neutropenia at onset of  
SE 
54.8 (43.6-65.5) 6.7 (2.3-19.5); p<0.001 
No Prolonged
6
 Neutropenia 
during SE 
13.2 (4.9-28.9) referent group 
Prolonged Neutropenia during SE 50.5 (40.0-60.9) 5.5 (1.8-16.9); p= 0.003 
No Profound Lymphopenia at 
onset of SE 
14.3 (6.4-27.9) referent group 
Profound Lymphopenia at onset 
of SE 
54.3 (42.9-65.3) 5.4 (1.9-14.7); p= 0.001 
No Prolonged Lymphopenia 
during SE 
18.4 (8.3-34.9) referent group 
Prolonged Lymphopenia during 
SE 
48.4 (37.9-58.9) 2.8 (1.0-7.7); p= 0.048 
No Profound Monocytopenia at 
onset of SE 
14.8 (4.9-34.6) referent group 
Profound  Monocytopenia at onset 
of SE 
45.6 (35.9-55.7) Not Applicable 
No Prolonged Monocytopenia 
during SE 
10.3 (2.7-28.5) referent group 
Prolonged Monocytopenia during 
SE 
48.5 (38.5-58.6) Not Applicable 
Treatment intensity
1
 = Standard intensity =1, Medium intensity = 2, High intensity = 3, MCSE
2
 = 
microbiologically confirmed septic episode, SSE
3
 = Suspected septic episode, Profound pancytopaenia
4
 = 
absolute cell count < 100 cells/µL, SE
5
 = Septic episode Prolonged
6
 pancytopenia = absolute cell count < 1000 
cells/µL for > 7 days 
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4.3. DISCUSSION 
 
  Many of our patients presented with advanced and aggressive disease, including 25% of 
children with ST presenting with Stage 4 disease, 61% of those with NHL had Stage 4 disease 
and 78% of children with ALL had high-risk disease. The presentation with such advanced 
disease, as well as the related high-intensity treatment regimen required to manage such 
children were independently associated with sepsis in our study. Our study was associated 
with high incidence (per 100 child years) of clinically suspected sepsis (overall = 103), which 
was higher among children with HM (141) than in those with ST (71). Similarly, the 
incidence of MCSE was also higher among children with HM (101) than in those with ST 
(46). In our study, 71% of all febrile illnesses were associated with a positive blood culture, 
which is higher than observed in other studies which ranged from 25% in paediatric studies 
(Hakim et al., 2009) to 52% in adult studies (Jagarlamudi et al., 2000).  
 
  In our study, children with HM were more likely to develop suspected sepsis and 
microbiologically confirmed sepsis. All 13 patients who died because of sepsis had HM. Age 
younger than ten years; metastatic ST, HM, and high intensity treatment were associated with 
an increased risk of MCSE in our cohort. Many studies from HICs (Sung et al., 2007, 
O'Connor et al., 2014) and LMICs (Bakhshi et al., 2008, Gupta et al., 2011a, Gavidia et al., 
2012, Ghosh et al., 2012) have documented the frequency, aetiology, and outcome of sepsis in 
children with HM. However, very few have documented the same in children treated for ST 
(Kocak et al., 2002).  
 
  It is presumed that the cancer treatment for children with ST is less intensive than that for 
HM. Nevertheless, our study documented complicated septic episodes in children with ST 
associated with GPB, GNB, fungal and polymicrobial septic episodes. The reasons for this 
may be that 25% of the cohort with STs presented with Stage 4 disease and were treated with 
aggressive chemotherapy, advanced and complex surgery, and wide-field radiotherapy. The 
aggressive multi-modal therapy adds to the prolonged and profound myelosuppression and is 
associated with increased predisposition for infectious complications (Barson and Brady, 
1987). 
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  Over the past decades, the epidemiological spectrum of BSIs from febrile infections in 
patients treated for cancer has changed. During the 1960s, Gram-positive pathogens 
predominated. In the 1970s, 70% of bacterial isolates from cancer patients were Gram-
negative pathogens, while in the 1980s and 1990s, probably due to the increased use of 
intravascular devices, fluoroquinolone prophylaxis, cotrimoxazole prophylaxis, and high-dose 
chemotherapy-induced mucositis, 70% of bacterial isolates from cancer patients with febrile 
illnesses are GPB (Zinner, 1999). 
 
  A report on 2142 adult cancer patients with febrile infections described 499 (23%) had 
bacteraemia (Klastersky et al., 2007). The relative frequencies of GPB, GNB, and 
polymicrobial bacteraemia were 57%, 34% and 10%, respectively. An Italian study described 
the frequency of GPB in paediatric cancer patients with febrile episodes which ranged from 
57% to 80% (Castagnola et al., 2007). These findings were in contrast with other studies that 
showed that GNB remain the predominant pathogens, 61.8% in a Turkish study (Yilmaz et 
al., 2008), and 71% in an Indian study (Bothra et al., 2013) during febrile illnesses in children 
with cancer. Our study documented 51.1% of all microbiologically confirmed sepsis was due 
to GPB, 40.4% to GNB, and 8.5% to fungal pathogens. 
 
  Mikulska et al, in a literature review on bacteraemias in adult (29 studies) and paediatric 
cancer patients (16 studies), demonstrated the median GPB: GNB ratio was 58: 42, ranging 
from 86: 14 to 32: 68 in individual studies. The main pathogens were CONS (23%, range: 9-
49%), Enterobacteriaceae (23%, range: 7-40%), Streptococcus viridans (13% range: 0-35%) 
and Pseudomonas aeruginosa (9%, range: 0-18 %) (Mikulska et al., 2014). Studies from El 
Salvador on febrile illnesses in children with cancer, documented 43% of all 
microbiologically confirmed infections were polymicrobial (Gupta et al., 2011a). In contrast, 
polymicrobial infections in patients treated for cancer in HICs are uncommon (Duncan et al., 
2007). The presence of a polymicrobial infection has important implications for mana-gement 
as it could affect the selection of antimicrobial therapy. Many reports have focused attention 
only on BSIs caused by a single organism (monomicrobial BSIs) and have not included 
detailed information on polymicrobial BSIs or infections at other sites. Consequently, these 
data may provide an incomplete picture, because the overall spectrum of infection in patients 
83 
 
with cancer may differ considerably from that associated with monomicrobial BSIs 
alone(Rolston et al., 2007).  
 
  Our study documented multiple SSE (overall 3.05 per patient), which was higher among 
children with HM (4.02 per child) than in ST cases (2.28 per child). The incidence of SSE 
among children with HM in our study was higher than reported from Morocco, where the rate 
of febrile illnesses (both microbiologically confirmed and culture negative) in patients with 
AML was a median of three episodes per patient, which was similar to that of HIC (Depasse 
et al., 2013). In one multicentre study in the United Kingdom (Dommett et al., 2009), children 
with AML developed an average of 3.03 FN per patient. In this same study, children with 
ALL developed on average 2.04 episodes per patient, which is lower than documented in our 
study. 
  We also reported a high frequency of fungaemia in both children with ST (18.4%) and HM 
(21.3%). In children treated for ST, a very low incidence of 0.4% has been documented 
between 1988 and 2000 by Ridola et al. (Ridola et al., 2004). Other studies have documented 
fungal infections ranging from 3.5% (El-Mahallawy et al., 2002) to 14.2% (Bothra et al., 
2013).The reasons for the high incidence in our study may be multifactorial and could include 
that all children are treated with empiric broad-spectrum antibiotics at the onset of a septic 
episode, and prolonged and profound bone marrow suppression. Furthermore, high 
percentages of our subjects (35% of those with suspected sepsis, 41.9% of those with 
microbiologically confirmed sepsis were on corticosteroids, which are an essential part of 
treatment for all HM and brain tumours, and is an established risk factor for invasive fungal 
infections. 
 
  Although Candida albicans remains the most common pathogen in invasive fungal 
infections, non-albicans species are increasingly associated with invasive candidiasis (Tang et 
al., 2014). However, non-albicans species was uncommon in our patients. The increased 
frequency of Candida non-albicans in other settings could be attributable to the increased use 
of anti-fungal prophylaxis (Tang et al., 2014), which is not used routinely in our setting. This 
could also contribute to the high incidence of Candida albicans sepsis in our setting. There 
were only two cases of Aspergillus species associated fungaemia, which is not surprising as 
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infection from this has been mainly identified in patients who undergo allogeneic stem cell 
transplantation (Thirumala et al., 2010). None of the patients in our study cohort had 
allogeneic stem cell transplantation. 
 
  There is a significant increase in the proportion of infections caused by multidrug-resistant 
bacteria, especially Gram-negative rods with extended-spectrum spectrum beta-lactamases 
(ESBLs), methicillin-resistant Staphylococci (MRSA), and vancomycin-resistant Enterococci 
(VRE). In our study cohort, 89.3% of Klebsiella species, 69.2% of Escherichia coli, 40% of 
Enterobacter species, 10.3% of Acinetobacter species and 7.7% of Pseudomonas species 
were multi-resistant-negative pathogens. Thirteen percent of Staphylococci were MRSA, 
65.5% of Enterococcus faecalis were VRE. 
 
  Enterobacter cloacae were resistant to 64% of fourth generation Cephalosporins, which is 
indicative of ampC β-lactamase hyper-production in combination with porin loss, which may 
confer resistance to Cephalosporins (Jacoby, 2009). Escherichia coli were resistant to 49-64% 
of the third generation Cephalosporins, which again indicates the presence of ESBL. 
Klebsiella pneumoniae was 100% sensitive to the Carbapenems. Pseudomonas aeruginosa 
isolates displayed greater susceptibility to the antimicrobial agents tested. None of the isolates 
in the study cohort was Carbapenemase-producing Enterobacteriaceae. In our study, 
Acinetobacter baumanni had a decreased sensitivity to most of the antimicrobials. The 
organism harbours multiple mechanisms of resistance such as loss of outer membrane porins, 
which reduces the permeability, efflux pump systems, and ampC β-lactamases (Bonomo and 
Szabo, 2006).  
 
  Our current policy on the empiric use of antimicrobials is outlined in Appendix 7. We 
identified a trend for increasing multi-drug GNB therefore changed our first-line empiric 
therapy to Carbapenems. Shortly after the study period, we experienced an outbreak of 
Carbapenemase-resistant Enterobacteriaceae in our unit with 80% mortality (unpublished 
data). We have now implemented stricter measures for the use of the Carbapenems. 
Epidemiological shifts occur periodically and have an effect on antimicrobial prophylaxis and 
empirical therapy. The global problem of increasing antimicrobial resistance is beginning to 
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limit therapeutic options for the treatment of multi-resistant bacterial infections in patients 
with neutropenia as well. Unfortunately, the development of new drugs is not keeping pace 
with the development of resistance. 
 
  In our cohort of patients, age less than ten years, high-risk HM, high intensity treatment, 
high-dose corticosteroids, profound neutropenia and lymphopenia at the onset of sepsis, 
prolonged neutropenia and lymphopenia during a septic episode, and the presence of 
pneumonia and tuberculosis were associated with an increased risk of death. 
 
  We had a high percentage of patients with septic episodes presenting with pneumonia 
(24.5% HM, 17.1% ST). There are conflicting reports on the prevalence of pneumonia in 
children with FN. A Canadian study reports 5% of all febrile episodes in children with cancer 
were complicated by pneumonia (Renoult et al., 2004) and a study from El Salvador 
documented 12% of septic episodes had a clinical pneumonia and 29% had a radiological 
pneumonia. In a review of adult patients with FN a total of 15–30% of documented infections 
in FN are classified as pneumonia (Rolston et al., 2007).  
 
  There are many obstacles to the diagnosis of pneumonia in patients with FN. The patients 
are neutropenic, unable to produce adequate sputum specimens and because of neutropenia, 
chest radiological changes may be subtle. In addition, since many of these patients are 
critically ill, they are unable to tolerate diagnostic procedures such as broncho-alveolar 
lavage. In LMIC settings, radiology services, especially bedside services for critically ill 
patients, are limited. Both cancer and its treatment induce derangements of innate and 
adaptive immune function. Leucocyte depletion, dysregulated inflammation, and, impaired 
pathogen recognition contribute to cancer patients’ susceptibility to LRTIs (Thirumala et al., 
2010). Furthermore, recurrent healthcare encounters that are typical among cancer patients 
promote exposure to nosocomial pathogens. The impact of pneumonia on cancer populations 
is uniquely severe, accounting for more morbidity and mortality than any other infectious 
complication (Bakhshi et al., 2008, Thirumala et al., 2010, Ghosh et al., 2012). In our cohort, 
presentation with pneumonia was associated with an increased risk of death. Pneumonia has 
been described as a predictor of death in children with HM in both HIC (Lehrnbecher et al., 
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2004) and LIC settings (Bakhshi et al., 2008, Gupta et al., 2011b, Ghosh et al., 2012). In our 
study, the diagnosis of pneumonia was made on clinical examination. The prevalence of 
pneumonia may be perhaps under-estimated by the lack of adequate radiology services. Early 
radiological detection of pneumonia may result in a change of antibiotic treatment and further 
optimization of therapy. Patients who develop acute respiratory failure may benefit from 
ventilator support in an ICU setting. None of the eight patients with pneumonia who required 
mechanical ventilation at the time of clinical deterioration in our study, were admitted to the 
ICU due to resource constrains. All eight patients subsequently demised. With earlier referral 
to ICU and improved management, the outcome may have been different in these subjects. In 
our study, pneumonia was an independent risk factor for mortality in the cohort who died of 
sepsis and in the overall cohort.  
 
  The majority of children in our cohort had severe malnutrition (76.9% MUAC < 5
th
 
percentile and 56.8% AMA < 5
th
 percentile). However, there were no significant associations 
identified between malnutrition on admission and risk for infection or mortality in our study 
cohort. The prevalence of malnutrition in children diagnosed with WT at a South African 
institute was recorded at 31% (Wessels et al., 1999). In Malawi, paediatric oncology patients 
with acute malnutrition at diagnosis had a higher rate of neutropenia, prolonged neutropenia, 
profound neutropenia, febrile neutropenia, delays in treatment and death during treatment than 
those who were not malnourished (Israels et al., 2008). In a study from Guatemala, it was 
documented that > 50% of the children with cancer had some degree of malnutrition at 
diagnosis, reflecting both a possible delay in diagnosis and the general condition of the 
population living in Guatemala (Sala et al., 2008). Malnutrition was documented at 52% of 
children with ALL (kumar et al., 2000) and 56.8% of all cancers (Jain et al., 2003) in newly 
diagnosed Indian children. In Bangladesh, 53% of children are malnourished at diagnosis. 
These children had two to three times more culture and clinically proven infection, required a 
longer duration of induction and prolonged hospital stay (Hafiz and Mannan, 2008). In those 
children who had severe malnutrition after six months of treatment, the hazard of death was 
2.4 fold compared to children with an adequate nutritional status or moderate malnutrition 
(Sala et al., 2012, Antillon et al., 2013). Malnourished children more often abandoned therapy 
and their event free survival was inferior to that of other children (Sala et al., 2012). In our 
study cohort, malnutrition had no significant relationship with infectious complications or 
death. The reasons for this are unclear. 
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  The current study emphasises the importance of frequent assessment and analysis of type, 
frequency, severity, and outcome of infectious complications to detect changing 
epidemiological patterns. There is a need for improved diagnostic tests to detect infections 
early. It also stresses the need to treat fungal infections and TB early, as they were a major 
cause of sepsis in our patients. These findings emphasise the need to aggressively investigate 
and treat children with cancer for TB, pneumonia and other septic complications. 
 
  Unquantified factors, which could have contributed to the infectious complications in our 
study, include overcrowding, lack of adequate medical, nursing and cleaning staff, lack of 
isolation facilities hence patients are constantly in an environment with a high microbial load. 
Additionally, patients are not discharged home frequently, as transport is expensive and if 
these patients were to be discharged home, transport back to the hospital may not be timeous, 
and chemotherapy-induced febrile illnesses are an oncological emergency with a high 
mortality. These may be some of the multitude of reasons for the high number of suspected 
and microbiologically confirmed septic episodes.  
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5. TUBERCULOSIS IN CHILDREN WITH CANCER 
5.2. CLINICAL CHARACTERISTICS OF TUBERCULOSIS IN CHILDREN 
TREATED FOR CANCER 
 
  Mycobacterium tuberculosis infection, as measured by a positive response to the TST was 
documented in five of 169 (2.99%) children, all of whom were empirically treated with the 
full course of anti-TB treatment. None of these five children was subsequently diagnosed with 
active TB disease during the course of their treatment. The T-SPOT.TB test yielded non-
reactive results in the first 100 children enrolled in the study, and none of the tests had an 
indeterminate result. Consequently, further testing of subsequent children enrolled into the 
study using the T-SPOT.TB test was terminated.  
 
  Twenty-four (14.2%) of the 169 children enrolled into the study were diagnosed with TB 
during the course of their cancer treatment, 7.5% for HM compared with ST (3.1%; 
p=0.0.36). The incidence ratio of developing TB for HM compared to ST was 2.39 fold (95% 
CI: 0.96-6.45); Table 12. The diagnosis of TB was microbiologically confirmed among 45.8% 
(11/24) of the TB cases, all of which were based on a positive culture for Mycobacterium 
tuberculosis, whereas the remaining 13 (54.2%) of cases were diagnosed based on clinical 
suspicion. Seven (43.8%) of 16 TB cases among children with HM and 4 (50%) of the eight 
TB cases in children with ST were based on culture-confirmed disease; Table 12.  
 
  The incidence (per 100 child years) of TB was higher among children with HM (6.8) than 
those with ST, (2.9; p=0.043). Overall, the proportion of HIV-infected children with a 
malignancy who developed TB was (4/18; 22.2%) and was (20/151; 13.2%) among HIV-
uninfected children. Among children with HM, 23.1% (3/13) of the HIV-infected children 
were diagnosed with TB compared to 20% (1/5) of HIV-uninfected children; Table 13.  
 
  Children who developed TB had a higher number of high-dose corticosteroids courses 
(397.4 per 100 child years) compared to those who did not develop TB (40.7 courses per 100 
child-years; p<0.001; Table 14). In addition, children who developed TB were more likely to 
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have septic episodes (rate per 100 child years) associated with profound neutropenia (319.5. 
vs 46.6; p<0.001), profound lympho-penia (264.9 vs 41; p<0.001) and profound 
monocytopenia (389.6 vs 63.7; p<0.001) prior to the diagnosis of TB than those who did not 
develop TB; Table 14. Similarly, children who developed TB had more septic episodes with 
prolonged neutropenia (350.6 vs 51.1; p<0.001) and prolonged lymphopenia (335.1 vs 59.2; 
p<0.001), and prolonged monocytopenia (444.2 vs 70.7; p<0.001) prior to developing TB 
than children who did not develop TB. 
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Table 12: Malignant Diseases Associated with Proven and Probable Tuberculosis 
 
Parameter Overall 
N=24 
Proven TB 
N=11 
Probable TB 
N=13 
*p-value 
Haematological 
Malignancy 
16/24 (66.7%) 7(63.6%) 9(69.2%) >0.99 
ALL
2
 9/16 (56.3%) 4(57.1%) 5(55.6%) >0.99 
AML
3
 3/16 (18.8%) 1(14.3%) 2(22.2%) >0.99 
NHL
4
 4/16 (25.0%) 2(28.6%) 2(22.2%) >0.99 
Solid Tumours 8/24 (33.3%) 4(36.4%) 4(30.8%) >0.99 
WT
5
 4/8 (50.0%) 1(25.0%) 3(75.0%) 0.49 
RMS
6
 1/8 (12.5%) 1(25.0%) 0(0.0%) >0.99 
BT
7
 1/8 (12.5%) 1(25.0%) 0(0.0%) >0.99 
ACC
8
 1/8 (12.5%) 0(0.0%) 1(25.0%) >0.99 
KS
9
 1/8 (12.5%) 1(25.0%) 0(0.0%) >0.99 
N= number of patients, TB
1 
=
 
Tuberculosis, ALL
2
 = Acute Lymphoblastic Leukaemia, AML
3
 = Acute Myeloid 
Leukaemia, NHL
4
 = Non-Hodgkin’s Lymphoma, WT5 = Wilm’s Tumour, RMS6 = Rhabdomyosarcoma, BT7 = 
Brain tumour, ACC
8
 = Adrenocorticoid carcinoma, KS
9=Kaposi’s sarcoma. NA=Non-applicable, *p= proven vs 
probable TB 
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Table 13: Clinical Characteristics of Tuberculosis in Children Treated for Cancer 
 
Parameter Overall               
N=169 
Haematological 
Malignancy N=82 
Solid Tumour                   
N=87 
p-value* 
Number of patients with 
Tuberculosis 
24 (14.2%) 16 (19.5%) 8 (9.2%)  
Person time (years) 475 231 262  
Incidence of Tuberculosis 
per 100 child years (95% 
Confidence Interval) 
4.7 (2.8-6.5) 6.8 (3.5-10.2) 2.9 (0.9-4.8) 0.043 
Mean age at presentation of 
cancer in months in children 
with TB (SD
1
) 
76.7 (46.9) 71.3 (47.19) 71.5 (49.5) 0.72 
HIV-infection prevalence in 
TB cases 
4 (16.7%) 3 (18.8%) 1 (12.5%) 0.45 
Median age at TB
2
 
presentation in months 
(IQR
3
)  
75.5         
(43.8-122.5) 
84.5                 
(48.3-122.5) 
65.0             
(42.3-101.3) 
0.83 
Mean time from presentation 
to TB diagnosis- months 
(SD) 
5.4 (6.9) 4.0 (6.0) 8.3 (8.1) 0.22 
N= number of patients, SD
1
 = Standard deviation, TB
2
 = Tuberculosis, IQR
3
 =interquartile range, *p = 
Haematological Malignancy vs Solid Tumour 
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5.3. PREDICTORS OF TUBERCULOSIS IN CHILDREN TREATED FOR CANCER 
 
  There was no identifiable association between age group, HIV status, tumour type, stage of 
tumour, treatment intensity or nutritional status at enrolment and the risk of being diagnosed 
with TB; Table 15.  
 
5.4. DEATH ASSOCIATED WITH TUBERCULOSIS IN CHILDREN WITH CANCER 
 
  There were four (16.7%) deaths among the 24 children who were diagnosed with TB, 
including two each with ALL and NHL; Table 16. Two of those who died were HIV-infected 
(both had NHL). All four had microbiologically confirmed TB. Furthermore, three of the four 
children who died had concurrent bacteraemia (two had multi-drug resistant Gram-negative 
bacteraemia) and all four had concurrent respiratory viral coinfections. 
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Table 14: White Cell Differential and High-dose Corticosteroid Exposure Prior to the Diagnosis of Tuberculosis 
 
Parameter Tuberculosis N
6
=13 No Tuberculosis N=357 p-value* 
 
Number** of cycles of high-dose Corticosteroids prior to TB diagnosis (95% CI 
1
) 397.4 (288.3-506.5); n
7
=51 40.7 (34.1-47.3); n=145 <0.001 
Number of SE
2
 with prolonged neutropenia prior to TB
3
 diagnosis (95%CI) 350.6 (248.2-453.1); n=45 51.1 (43.6-58.5); n=182 <0.001 
Number of SE with profound
4
 neutropenia prior to TB diagnosis (95%CI) 319.5 (221.7-417.3); n=41 46.6 (39.5-53.7); n=166 <0.001 
Number of SE prolonged
5
 lymphopenia prior to TB diagnosis (95%CI) 335.1 (234.9-435.2); n=43 59.2 (51.2-67.2); n=211 <0.001 
Number of SE with profound lymphopenia prior to TB diagnosis (95%CI)I 264.9 (175.9-354); n=34 41 (34.3-47.6); n=146 <0.001 
Number of SE with prolonged monocytopenia prior to TB diagnosis (95%CI) 444.2 (328.8-559.5); n=57 70.7 (62-79.4); n=252 <0.001 
Number of SE with profound monocytopenia prior to TB diagnosis (95%CI) 389.6 (281.6-497.6); n=50 63.7 (55.4-72); n=227 <0.001 
CI
1
 = Confidence interval, SE
2
 = Standard deviation, TB
3 
=Tuberculosis, Profound
4
 = Absolute cell count < 100 cells/µL, Prolonged
5
 = Absolute cell count < 1000 cells/µL for > 7 
days, N
6
 = Number of patients, n
7
 = number of events, **per 100 child years 
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Table 15: Predictors of Tuberculosis in Children Treated for Cancer 
Parameter Percentage of Tuberculosis                   
(95% CI) 
Adjusted Odds Ratio                                   
(95% CI); p-value 
Age (years)   
1-5 15.17 (8.1-25.8) 1.3  0.4-3.9); p= 0.64 
>5-10 14 (6.3-27.4) 1.2 (0.4-4.1); p= 0.74 
>10 13.3 (5.5-27.5) referent group 
Female 16.4 (9.1-27.45) referent group 
Male 12.5 (6.9-21.2) 0.6 (0.2-1.5); p= 0.29 
MUAC1>5th percentile 11.1 (3.6-27) referent group 
MUAC<5th percentile 15.4 (9.9-23) 1.5 (0.5-4.8); p= 0.51 
AMA2>5th percentile 12.9 (6.4-23.5) referent group 
AMA<5th percentile 15.6 (9.3-24.8) 1.2 (0.5-2.9); p= 0.71 
TSFT3>5th percentile 15.8 (9.6-24.8) referent group 
TSFT<5th percentile 12.3 (5.8-23.4) 0.7 (0.3-1.9); p= 0.53 
HIV-uninfected 13.3 (8.5-19.9) referent group 
HIV-infected 22.2 (7.4-48.1) 1.7 (0.5-6.2); p= 0.42 
Solid Tumour 9.2 (4.4-17.8) referent group 
ST4 local disease 9.7 (4-2-5.4) referent group 
ST metastatic disease 8 (1.4-27.5) 0.7 (0.1-3.7); p= 0.65 
Haematological malignancy 19.5 (11.9-30.0) 1.8 (0.7-4.7); p= 0.2 
HM5 medium risk 5 (0.3-26.9) referent group 
HM high-risk 24.2 (14.6-37.0) 5.4 (0.7-44.2); p= 0.12 
Treatment intensity6 1 7.7 (2.9-17.8) referent group 
Treatment intensity 2 8.7 (2.8-21.7) 1.1 (0.3-4.7); p= 0.85 
Treatment intensity  3 25.9 (15.7-39.3) 5.2 (0.8-32.9); p= 0.08 
No MCSE7 4.1 (0.71-15.1) referent group 
At least one MCSE 18. (12.1-26.7) 4.4 (0.9-20); p= 0.055 
No SSE8 0 (0-11.4) referent group 
At least one SSE 18.3 (12.3-26.2) Not Applicable 
MUAC1 = Mid-upper arm circumference, AMA2 = Arm muscle area, TSFT3 = triceps skinfold thickness, ST4 = solid tumour, 
HM5 = haematological malignancy, treatment intensity6 1= Standard intensity, 2 = medium intensity, 3 = high intensity, 
MCSE7 = microbiologically confirmed septic episode, SSE8 = Suspected septic episode 
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Table 16: Death Associated with Tuberculosis in Children with Cancer 
 
Pt Sex Age 
(months) 
Disease Time from 
TB 
diagnosis to 
Death 
HIV Blood culture Sputum Virus Clinical Syndrome 
1 M 125 ALL
1
 6 weeks Neg Bacillus, 
 Klebsiella 
 pneumoniae 
MTB
3
 CV
5
OC43, 
 CVHUK1 
Pneumonia, Herpes stomatitis, Proven TB 
2 F 100 NHL
2
 4 weeks Pos Nil MTB FluA
6
, HRV
7
, 
CVOC43, 
CVNL63 
Pneumonia, Herpes stomatitis,  Mucositis, Proven TB  
3 F 98 ALL 5 weeks Neg ESBL
4
 K. 
pneumoniae 
 MTB CVNL63,                              
KIPyV
8
 
Pneumonia, Gastroenteritis, Proven TB 
4 M 23 NHL 3 weeks Pos ESBL E coli  MTB HRV,                          
CVNL63 
Pneumonia, Herpes stomatitis,  Proven TB, Mucositis 
ALL
1
 = Acute lymphoblastic leukaemia, NHL
2
 = Non=Hodgkin’s lymphoma, MTB3 = Mycobacterium tuberculosis, ESBL4 = Extended-spectrum β-lactamase inhibitor, CV5= 
human Coronavirus,
, 
FluA 
6
 = Influenza A, HRV
7
= human Rhinovirus, PyV
8 
= human Polyomavirus 
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5.5. DISCUSSION 
 
  The incidence for TB in our study cohort was 4.7 per 100 child years (95% CI: 2.8-6.5), 6.8 
(95% CI; 3.5-10.2) in children with HM, and 2.9 (95% CI: 0.9-4.8) in children with ST. 
However, almost 50% of the patients in our study were culture positive, which is very high 
for children. Stefan et al reported an incidence of 9.14 per 100 child years among children 
with cancer, in the Western Cape, South Africa (1999 to 2005). Only children with a positive 
culture for MTB, positive sputum smear or clinical and radiological signs of active TB were 
included in the study. Stefan et al estimated at that time, the risk of developing TB in children 
with cancer was 22.4 times higher than in the general population which was estimated at 0.47 
per 100 child years, for the study period 1999 to 2005 (Marais et al., 2006a, Stefan et al., 
2008b). The lower incidence in our study may be due to a general decline in the incidence of 
TB since the mid-2000, including among children <15 years of age (Nanoo et al., 2015). 
 
  The study by Stefan et al. documented 53% of TB occurred in children with HM, 10.5% 
were HIV-infected 63.2% were males and the time from diagnosis of cancer to diagnosing TB 
was 7.6 months (Stefan et al., 2008a) . In our study, 66.7% of the cohort with TB had a HM, 
16.7% were HIV-infected, and the time from diagnosis of cancer to TB was shorter at 5.5 
months (4.19 months for HM, and 8.12 months for children with ST). 
 
  The diagnosis of TB is often delayed among children, especially those who are immune-
compromised, due to both a low index of suspicion and unavailability of diagnostic tests 
(Narasimhan et al., 2013). In addition, young children and immunocompromised patients are 
more likely to have a negative TST, and less likely to have positive sputum staining for AFB 
(Klossek et al., 2004). Broncho-alveolar lavage is reported to be an effective and well-
tolerated technique for the microbiological diagnosis of pneumonia, including TB, in adult 
patients with HM (Cordani et al., 2008), but in settings such as ours this technique is not 
readily available. In addition, many children with cancer may have an increased risk for 
bleeding, due to complications of the disease or treatment, hence are not suitable candidates 
for invasive procedures such as broncho-alveolar lavage. In our study cohort, all children had 
a T-SPOT.TB test on enrolment into the study, however, the first 100 patients yielded a 
negative result, and the T-SPOT.TB test was abandoned. Very low sensitivity and specificity 
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were found on analysis of IGRA tests in studies in immunocompromised children. The meta-
analysis estimate for sensitivity was only 0.54 for T-SPOT.TB test, and 0.47 for QFT-G-IT, 
confirming that IGRA results should be used with caution in immunocompromised children. 
In LMICs and in immunocompromised children, IGRAs’ performance is equivalent or 
inferior to TST (Sollai et al., 2014). TST is a suboptimal test for screening for TB. The 
population infection rate is 3% year-on-year; therefore, in our study cohort who presented 
with a median age of 6.4 years, the expected TST positivity rate would have been 19.2% 
instead of our result of 2.9%. We have to be cautious when TB is excluded based on a 
negative TST result. 
 
  The balance between the tubercle bacillus and the immune system influences the 
development of active TB from latent TB infection. Patients with HM have an underlying 
immunological deficiency that increases the risk for infections (Pagano et al., 2012). 
Alteration in the immune response of patients with cancer, leads to an impaired immune 
response that promotes the progression from latent TB infection to active TB (Al-Anazi et al., 
2007).  
 
  In low-burden TB areas, the risk of active TB disease is also increased. In the USA, it was 
documented that adult patients with HM who had been treated with haemopoietic stem cell 
transplantation had 40 times the risk of developing active TB disease than the general 
population (Kamboj and Sepkowitz, 2006). Adults Indian patients with leukaemia, especially 
AML have a 23 times increased risk of developing active TB disease(Mishra et al., 2006). 
 
There was no identifiable association between age group, HIV status, and tumour type, stage 
of tumour, treatment intensity, or nutritional status at enrolment and the risk of being 
diagnosed with TB. The most likely explanation for this is the small number of patients with 
cancer who developed TB  
 
  In our children diagnosed with TB, we documented all patients had septic episodes with 
prolonged and profound pancytopenia prior to the diagnosis of TB. Other studies did not 
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document the haematological parameters in patients with cancer and TB except for one study 
from Taiwan. Chen et al reported that tuberculosis in adult AML patients was associated with 
significant febrile neutropenia compared to non-AML patients. The risk of acquiring TB 
disease correlated partly with the patient's absolute neutrophil count (Chen et al., 2012).  
 
  Recent research on neutrophil peptides has documented that neutrophils are bactericidal 
against TB, which suggests that neutrophils play an important role in the defence against 
tuberculosis via the innate immune system. In an adult non-cancer TB cohort, the risk of TB 
disease was inversely and independently associated with peripheral blood neutrophil counts 
on enrolment into the study, in patients diagnosed with pulmonary TB (Martineau et al., 
2007). This result was consistent with our study supporting the important role of neutrophils 
in the defence against TB infection.  
 
  In our cohort of children with TB, malnutrition was highly prevalent on enrolment into the 
study; however, the presence of malnutrition did not predict an increased risk for TB in our 
cohort. We did, however, by using a logistic regression model establish that children who 
developed TB were treated with more courses of high-dose corticosteroids than those who did 
not develop TB (109 vs 10 courses per 100 child years), indicating this to be risk factor for 
developing TB. This was similar to a report by Silva et al, who too reported that pre-treatment 
with corticosteroids was a risk factor for the development of TB disease in cancer patients 
(Silva et al., 2005). In addition, a Saudi Arabian study documented that 61% of adult patients 
with cancer and TB had received corticosteroids prior to the diagnosis of TB (Al-Anazi et al., 
2007). The increased risk of TB in patients receiving high-dose corticosteroids could be due 
to its immunosuppressive effects on cell-mediated immunity. High-dose corticosteroid 
treatment has also been linked to increased disease severity of TB at presentation, increased 
risk for miliary TB, and higher case fatality rates from TB (Lancioni et al., 2009) .  
 
  Thirteen patients in our study patients died because of sepsis, including four (36.4 %) of 11 
children who had microbiologically confirmed TB. Furthermore, three of the four children 
who died had concurrent bacteraemia (two had multi-drug resistant Gram-negative 
bacteraemia) and all four had concurrent respiratory viral co-infections. The cohort of 
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patients, who died, in addition to MTB, had co-infections with bacteria and respiratory 
viruses. This suggests a complex disease process at the time of death. Post-mortem studies 
were not conducted in these patients; hence, it is difficult to delineate the role of the 
pathogens identified as the cause of death. Some of the viruses may have been co-incidentally 
detected in the airway at the time of death. Other studies, in adult cancer patients with TB, 
have recorded even higher mortality figures, including that by Silva et al (62%) (Silva et al., 
2005). Also, a study from the USA in adult cancer patients with TB, documented a 48% 
mortality in the 1970s (Kaplan et al., 1974). There are no recent studies documenting 
mortality from TB in children with cancer, and none of the children with cancer and TB in the 
study from the Western Cape, died (Stefan et al., 2008b). 
 
  The five cases that had a positive TST on admission were treated with a full course of 
empirical TB treatment, and none subsequently developed TB. This indicates that despite the 
low yield positivity (3%), it remains imperative to try to establish a diagnosis of latent TB 
infection and consider preventive therapy that could avoid the progression from a latent state 
to active TB. The TST was not a useful test in our study population. High rates of false 
negative results have been reported in HIV-infected children. In a study in Cape Town, 
among almost 300 children with TB, those with HIV-infection were less likely to have a 
positive TST than those who were HIV negative (36% versus 59%) (Moyo et al., 2010). In a 
further study in South Africa among HIV-infected children with culture-confirmed TB, only 
56% had a positive TST (Hesseling et al., 2005). 
 
  In our study, we did not utilize any of the nucleic acid amplification tests that are available 
for the rapid diagnosis of TB. In 2011, World Health Organization (WHO) endorsed the Gene 
Xpert (Gen Xpert MTB/RIF®) test for the diagnosis of TB but there were no specific 
recommendations for its use in children because of limited data. In October 2013, the WHO 
recommended that Gene Xpert should be used instead of the conventional microscopy, for the 
initial diagnosis in children suspected of having MDR TB or HIV-associated TB. It was also 
recommended that Gene Xpert be used rather than conventional microscopy and culture as the 
initial test in all children suspected of having TB. The test is simple to use, has a high 
sensitivity and it provides rapid diagnosis of TB. Additionally, this method, detects an 
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eventual resistance to rifampicin in less than two hours after obtaining the sample (WHO, 
2013). 
 
  Subsequently, a study from Vietnam confirmed that Gene Xpert is a suitable, rapid and 
specific method for the diagnosis of childhood TB with approximately twice the sensitivity of 
smear microscopy (Giang et al., 2015). In future, Gene Xpert is a test that should be utilized 
together with TST and IGRA to increase the yield in children with cancer and TB. 
 
   The diagnosis of TB is often challenging, because it is not easy to obtain microbiological 
confirmation in such cases. However, in children it is recommended starting empirical anti-
tuberculosis treatment, if TB is suspected. The children in the study cohort did not receive 
Isoniazid prophylaxis. In a study from Kenya it is documented that Isoniazid prophylaxis 
reduced the risk of developing tuberculosis by 59% among children aged 15 years or younger 
(Ayieko et al., 2014). 
 
  In a high-burden setting for TB, it is an important disease in children with cancer. Extreme 
care has to be taken to exclude latent TB and a high suspicion has to be maintained for active 
TB. In our cohort, 2.9% of TST was positive, none of the IGRA tests was positive but 50% of 
the cohort with TB had microbiologically confirmed TB. In addition, four children who died 
had microbiologically confirmed TB and co-infections with multiple bacteria (including 
multi-drug resistant bacterial pathogens) and respiratory viruses. However, the significance of 
the pathogens in relation to death is unknown. It may suggest a complex disease pathogenesis. 
The recommendation for children with cancer in a high-burden disease setting, especially 
those with HM, stem cell transplant and those with dual pathologies of cancer and HIV-
infection, would be active exclusion of latent TB, high clinical suspicion for TB and that all 
patients be initiated on Isoniazid prophylaxis 
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6. RESPIRATORY VIRAL INFECTIONS IN CHILDREN TREATED FOR 
CANCER  
6.2. RESULTS 
6.2.1. DEMOGRAPHICS OF RESPIRATORY VIRAL ASSOCIATED INFECTIONS AND CO-
INFECTIONS WITH BACTERIA AND FUNGI IN CHILDREN TREATED FOR CANCER 
 
  Of the 528 suspected septic episodes (SSE), 211 (37.3%) were associated with the 
identification of a respiratory virus. The identification of at least one respiratory virus per SSE 
episode was more common among children with haematological malignancies (HM; 44.5%) 
compared to those with solid tumours (ST; 32.3%; p=0.007); Table 17. One hundred and 
forty-two (68.3%) of respiratory virus associated septic episodes (SE) had one virus 
identified, including 98 (66.7%) of the episodes among HM and 44 (68.8%) in children with 
ST (p=0.77). Of the remainder, respiratory virus associated SEs, 22.2% had two respiratory 
viruses identified and 10.43% had > two viruses identified concurrently; data not shown. 
There was no association between the number of viruses detected and tumour type (p=0.77; 
data not shown). Human rhinovirus was the most frequent virus identified in combination 
with other viruses, including eight cases with concurrent Adenovirus, seven with CV NL63 
and six each with RSV and KIPyV; Table 18. 
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Table 17: Demographics of Respiratory Viral Associated Infections and Co-infections with Bacteria 
and Fungi in Children treated for Cancer 
 
Characteristic Overall    
N=169 
Haematological 
Malignancy N=82 
Solid Tumour 
N=87 
p-
value*   
Total number of SSE
1
 528 330 198  
Number of SSE associated with 
respiratory virus 
211 (37.3%) 147(44.5%) 64(32.3%) 0.007 
Number of SSE cases with 
respiratory virus identified and 
concurrent bacteraemia/fungaemia 
157 (27.4%) 112 (33.9%) 45 (22.7%) 0.013 
Number of SSE with 1 respiratory 
virus 
142/211 
(67.30%) 
98/147       
(66.67%) 
44/64 
(68.75%) 0.77 
Number of SSE with 2 respiratory 
viruses 
47/211 
(22.27%) 
37/147       
(25.17%) 
10/64 
(15.62%) 0.12 
Number of SSE with > 2 
respiratory viruses 
22/211 
(10.43%) 
12/147          
(8.16%) 
10/64 
(15.62%) 0.28 
Number of SSE with > 3 
respiratory viruses 
69/211 
(32.70%) 
49/14                 
(33.33%) 
20/64 
(31.25%) 0.77 
Number of SE with GPB
4
 and 
respiratory virus 
86 (54.8%) 47 (15.6%) 39 (22.9%) 0.13 
Number of SE with GNB
5
 and 
respiratory virus 
71 (45.2%) 46 (15.2%) 25 (13.6%) 0.53 
Number of SE with Fungus and 
respiratory virus 
26 (16.6%) 15(4.6%) 11 (5.7%) 0.56 
N= number of patients, SSE
1
 = Suspected Septic Episode, BC
2
 = Blood Culture positive for bacteria or 
fungi, SE
3
 = Septic Episode, GPB
4
 = Gram-positive Bacteria, GNB
5
 = Gram-negative Bacteria, *p-
value: comparing Haematological Malignancy to Solid Tumour cases 
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Table 18: Contribution of Respiratory Viruses in Children with Cancer as Single (diagonal) or Coinfection (matrix) Infection  
 
 
ADV  
n=21 
(6.9%) 
FluA 
n=17 
(5.3%) 
FluB       
n=7 
(2.2%) 
RSV  
n=21 
(6.6%) 
HMPV 
n=11 
(3.5%) 
HRV 
n=9  
(30.2%) 
PIV1 
n=11 
(3.5%) 
PIV2 
n=7 
(2.2%) 
PIV3 
n=6 
(1.9%) 
HBoV  
n=11 
(3.5%) 
CV22E     
n=1 
(0.3%) 
CVO43    
n=20 
(6.3%) 
CVNL63 
n=22 
(6.9%) 
CVHUK1   
n=26 
(8.2%) 
WUPV 
n=1 
(3.8%) 
KIPyV 
n=29 
(9.1%) 
ADV1 7                
Flu2 A 0 6               
Flu B 0 1 3              
RSV3 1 0 1 10             
HMPV4 0 3 4 1 4            
HRV5 8 3 1 6 2 55           
PIV6 1 0 0 1 1 1 4 3          
PIV 2 0 0 1 1 1 2 5 1         
PIV 3 0 1 0 0 0 2 2 2 2        
HBoV7 2 0 0 1 0 3 0 0 1 5       
CV8 229E 1 0 0 0 0 0 0 0 0 0 0      
CV OC43 2 2 0 0 0 6 0 0 0 1 0 9     
CV NL63 0 2 0 3 0 7 0 0 0 1 0 3 10    
CV 
HUK1 0 3 2 3 3 5 0 0 0 1 0 3 3 12   
WUPyV9 3 0 1 1 1 4 1 1 0 1 0 0 0 0 3  
KIPyV10 1 2 0 0 0 6 0 1 1 2 0 0 3 0 2 13 
ADV
1
= Adenovirus, Flu
2
 = Influenza, RSV
3
 = Respiratory syncytial virus, HMPV
4
 = human Metapneumovirus, HRV
5
 = human Rhinovirus, PIV
6
 = Parainfluenza virus, HBoV
7
 = 
human Bocavirus, CV
8
 = Coronavirus, WUPyV
9
 =WU human Polyomavirus, KIPyV
10
=KI human Polyomavirus
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Table 19: Respiratory Virus Associated Infections in Children Treated for Cancer 
 
Incidence of viral associated Suspected Septic 
Episodes 
Overall                                    
N =169 
Haematological 
Malignancy N=82 
Solid Tumour               
N=87 
p-value* 
Mean number of viral infection per patient 
(SD
1
) 
1.9 2.6(3.5) 1.1(2.1) 0.09 
Person time of follow-up- years 514 234 280  
Viral associated SSE** (95%CI) 61.2 (54.4-68); n=314 92.4 (80.1-104.8); n=216 35.1 (28.1-42); n=98 <0.001 
Human Rhinovirus (95% CI) 18.7 (15-22.5); n=96 29.1 (22.2-36); n=68 10 (6.3-13.7); n=28 <0.001 
Coronavirus (95% CI
2
) 13.4 (10.3-16.6); n=69 19.3 (13.6-24.9); n=45 8.6 (5.2-12); n=24 0.002 
             CV
3
 229E (95% CI) 0.2 (-0.2-0.6); n=1 0.4 (-0.4-1.3); n=1 0 (0-0); n=0 0.41 
             CV OC43 (95% CI) 3.9 (2.2-5.6); n=20 4.3 (1.6-6.9); n=10 3.6 (1.4-5.8); n=10 0.69 
             CV NL63 (95% CI)  4.3 (2.5-6.1); n=22 5.6 (2.5-8.6); n=13 3.2 (1.1-5.3); n=9 0.21 
             CV HUK1 (95% CI) 5.1 (3.1-7); n=26 9 (5.1-12.8); n=21 1.8 (0.2-3.4); n=5 <0.001 
Polyomavirus (95% CI)  7.2 (4.9-9.5); n=37 12 (7.5-16.4); n=28 3.2 (1.1-5.3); n=9 <0.001 
             WUPyV
4
 (95% CI) 2.3 (1-3.7); n=12 3.9 (1.3-6.4); n=9 1.1 (-0.1-2.3); n=3 0.044 
             KIPyV (95% CI) 4.9 (3-6.8); n=25 8.1 (4.5-11.8); n=19 2.1 (0.4-3.9); n=6 0.003 
Parainfluenza virus (95% CI) 4.7 (2.8-6.5); n=24 6.8 (3.5-10.2); n=16 2.9 (0.9-4.8); n=8 0.043 
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PIV1
5
 (95% CI) 2.1 (0.9-3.4); n=11 2.6 (0.5-4.6); n=6 1.8 (0.2-3.4); n=5 0.56 
PIV2 (95% CI) 1.4 (0.4-2.4); n=7 2.6 (0.5-4.6); n=6 0.4 (-0.3-1.1); n=1 0.035 
PIV3 (95% CI) 1.2 (0.2-2.1); n=6 1.7 (0-3.4); n=4 0.7 (-0.3-1.7); n=2 0.30 
Respiratory Syncytial virus (95% CI) 4.1 (2.3-5.8); n=21 5.1 (2.2-8); n=12 3.2 (1.1-5.3); n=9 0.29 
Adenovirus (95% CI) 4.1 (2.3-5.8); n=21 5.6 (2.5-8.6); n=13 2.9 (0.9-4.8); n=8 0.14 
Influenza A virus (95% CI) 3.3 (1.7-4.9); n=17 6 (2.9-9.1); n=14 1.1 (-0.1-2.3); n=3 0.003 
Influenza B virus (95% CI) 1.4 (0.4-2.4); n=7 1.7 (0-3.4); n=4 1.1 (-0.1-2.3); n=3 0.54 
Human Metapneumovirus (95% CI) 2.1 (0.9-3.4); n=11 3.9 (1.3-6.4); n=9 0.7 (-0.3-1.7); n=2 0.017 
 Bocavirus per 100 child years (95% CI) 2.1 (0.9-3.4); n=11 3 (0.8-5.2); n=7 1.4 (0-2.8); n=4 0.24 
N=number of patients, SD
1
 = Standard deviation, CI
2
 = Confidence interval, CV
3
 = Coronavirus, PyV
4
 = Polyomavirus, PIV
5
 = Parainfluenza virus, *p = Haematological 
Malignancy vs Solid Tumour, Incidence**per 100 child years 
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6.2.2. RESPIRATORY VIRUS ASSOCIATED SEPTIC EPISODES IN CHILDREN WITH CANCER 
 
  The overall incidence (per 100 child years) of respiratory virus associated SSEs was 61.2, 
which was higher in children with HM (92.4) than those with ST were (35.1; p<0.001); Table 
19. The most frequently identified viruses were human Rhinovirus (n=96; 30.6%), human 
Coronavirus (n=69; 22%) and human Polyomavirus (n=37; 11.8%). In addition, 6.7% of SSE 
episodes were associated with RSV and Adenovirus each, and 5.4% with Influenza A virus. 
 
  The overall incidence (per 100 child years) of human Rhinovirus was 18.7, (29.1 HM vs 10 
ST; p<0.001). Similarly there was higher incidence of human Coronavirus (19.3 vs 8.6; 
p=0.002), human Polyomavirus (12 vs 3.2 p<0.001), Influenza A virus (six vs 1.1; p=0.003), 
and human Metapneumovirus (3.9 vs 0.7; p=0.017) associated SSE episodes among children 
with HM than those with ST; Table 19. 
 
6.2.3. SEPTIC EPISODES WITH RESPIRATORY VIRUS AND BACTERIAL/FUNGAL CO-
INFECTIONS IN CHILDREN TREATED FOR CANCER 
 
  Overall, 157(27.4%) septic episodes had co-infections with respiratory viruses and 
bacteria/fungi, 112(33.9%) in those with HM, and 45 (22.7%) in those with ST (p=0.013). 
The most frequently associated viruses with bacterial/fungal co-infections were human 
Rhinovirus (32.9%, n=64), human Coronavirus (23.2%, n=45), and human Polyomavirus 
(11.9%, n=23); Table 19. 
 
  The overall incidence (per 100 child years) of HRV with bacterial/fungal co-infections was 
12.5, 20.1 in those with HM, and 6.1 in those with ST (p<0.001). Similarly, human 
Coronavirus (13.3 vs 5; p=0.003), human Polyomavirus (7.7 vs 1.8; p=0.002), Influenza A 
virus (3.9 vs 0.7; p=0.017), human Metapneumovirus was more frequently associated with 
bacterial/ fungal co-infections in children. 
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  Human Rhinovirus was identified as a sole virus in 32 (52.5%) of SEs and as part of a 
bacterial/fungal co-infection in 64 (42.7%) of SEs. KIPyV was a sole virus in 10 (16.4%) and 
as part of a co-infection in 15 (10%) SEs, CV HUK1 was a sole virus in eight (13.1%) and 18 
(12%) of SEs with bacterial/fungal co-infections, and RSV was a sole virus in nine (14.8%) 
and 12 (8%) of coinfections. The overall incidence (per 100 child years) of human Rhinovirus 
co-infection with bacteraemia/fungaemia was 13, which was greater in children with HM (21) 
that those with ST (7; p<0.001); Table 20. Similarly there was a higher incidence of 
respiratory virus associated SSE with concurrent bacteraemia/fungaemia with human 
Coronavirus (14 vs 5; p=0.002), human Polyomavirus (8 vs 2; p=0.002), Influenza A (4 vs 1; 
p=0.017), and human Metapneumovirus (3 vs 0; p=0.035) among those with HM than ST; 
Table 20. The most frequently associated respiratory viruses with bacteraemia/fungaemia co-
infections were human Rhinovirus (n=69; 30.8%), human Coronavirus (n=48; 21.4%), and 
human Polyomavirus (n=23; 10.3%). 
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Table 20: Mixed Bacterial and or Fungal and Respiratory Viral Co-infections in Children Treated for Cancer 
 
Parameter Overall            
N=169 
Haematological 
Malignancy N=82 
Solid Tumour  
N=87 
P*-
value 
Number of SSE cases with respiratory virus identified and concurrent 
bacteraemia/ fungaemia 
157 (27.4%) 112 (33.9%) 45 (22.7%) 0.013 
Bacterial/Fungal Co-infection with human Rhinovirus** (95% CI
1
) 12.5 (9.4-15.5); n=64 20.1 (14.4-25.9); n=47 6.1 (3.2-9); n=17 <0.001 
Bacterial/Fungal Co-infection with human Coronavirus (95% CI) 8.8 (6.2-11.3); n=45 13.3 (8.6-17.9); n=31 5 (2.4-7.6); n=14 0.003 
Bacterial/Fungal Co-infection with CV
2
 229 E (95% CI) 0 (0-0); n=0 0 (0-0); n=0 0 (0-0); n=0 0.93 
Bacterial/Fungal Co-infection with CV OC 43 (95% CI)  3.1 (1.6-4.6); n=16 3 (0.8-5.2); n=7 3.2 (1.1-5.3); n=9 0.83 
Bacterial/Fungal Co-infection with CV NL 63 (95% CI)  3.3 (1.7-4.9); n=17 4.7 (1.9-7.5); n=11 2.1 (0.4-3.9); n=6 0.12 
Bacterial/Fungal Co-infection with CV HUK1 (95% CI)  3.5 (1.9-5.1); n=18 7.3 (3.8-10.7); n=17 0.4 (-0.3-1.1); n=1 <0.001 
Bacterial/Fungal Co-infection with human Polyomavirus (95% CI) 4.5 (2.7-6.3); n=23 7.7 (4.1-11.3); n=18 1.8 (0.2-3.4); n=5 0.002 
Bacterial Co-infection with WUPyV
3
 (95% CI) 1.8 (0.6-2.9); n=9 3 (0.8-5.2); n=7 0.7 (-0.3-1.7); n=2 0.05 
Bacterial/Fungal Co-infection with KIPyV (95% CI) 2.9 (1.4-4.4); n=15 5.1 (2.2-8); n=12 1.1 (-0.1-2.3); n=3 0.008 
Bacterial/Fungal Co-infection with Parainfluenza virus (95% CI) 2.3 (1-3.7); n=12 3.4 (1.1-5.8); n=8 1.4 (0-2.8); n=4 0.15 
Bacterial/Fungal Co-infection with PIV
4
1 (95% CI)  1.4 (0.4-2.4); n=7 1.7 (0-3.4); n=4 1.1 (-0.1-2.3); n=3 0.54 
Bacterial/Fungal Co-infection with PIV2 (95% CI) 1.2 (0.2-2.1); n=6 2.6 (0.5-4.6); n=6 0 (0-0); n=0 0.013 
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Bacterial/Fungal Co infection with PIV3 (95% CI) 1 (0.1-1.8); n=5 1.7 (0-3.4); n=4 0.4 (-0.3-1.1); n=1 0.13 
Bacterial/Fungal Co-infection with RSV (95% CI) 2.3 (1-3.7); n=12 2.6 (0.5-4.6); n=6 2.1 (0.4-3.9); n=6 0.76 
Bacterial/Fungal Co-infection with Influenza A (95% CI) 2.1 (0.9-3.4); n=11 3.9 (1.3-6.4); n=9 0.7 (-0.3-1.7); n=2 0.017 
Bacterial/Fungal Co-infection with Influenza B (95% CI) 1.2 (0.2-2.1); n=6 1.7 (0-3.4); n=4 0.7 (-0.3-1.7); n=2 0.30 
Bacterial/Fungal Co-infection with human Bocavirus (95% CI) 1.6 (0.5-2.6); n=8 2.6 (0.5-4.6); n=6 0.7 (-0.3-1.7); n=2 0.09 
Bacterial/Fungal Co-infection with HMPV(95% CI) 1.4 (0.4-2.4); n=7 2.6 (0.5-4.6); n=6 0.4 (-0.3-1.1); n=1 0.04 
Bacterial/Fungal Co-infection with Adenovirus (95% CI) 1 (0-2); n=6 2 (0-3); n=4 1 (0-2); n=2 0.30 
N=number of patients, CI
1
 = Confidence interval, CV
2
 = Coronavirus, PyV
3
 = Polyomavirus, PIV
4
 = Parainfluenza virus*p = Haematological malignancy vs Solid Tumour. 
Incidence** per 100 child years 
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6.2.4. CLINICAL AND LABORATORY PARAMETERS FOR MIXED BACTERIAL AND OR 
FUNGAL COINFECTIONS WITH RESPIRATORY VIRUSES IN CHILDREN TREATED 
FOR CANCER 
 
  There were no significant differences in the maximum temperature,  duration of fever,  
median CRP and PCT, median white cell count, and absolute neutrophil, lymphocyte and 
monocyte counts between the overall group and cohorts with HM and ST for sole respiratory 
viral infection and coinfections with bacteria/fungi and respiratory viruses; data not shown. 
 
6.2.5. PNEUMONIA IN CHILDREN WITH ACUTE RESPIRATORY VIRAL INFECTIONS 
TREATED FOR CANCER 
 
  Of the 528 SSE episodes, 116 (21.97%) were diagnosed as having pneumonia (82 and 34 
with HM and ST respectively). Respiratory viruses were more commonly identified in sepsis 
cases associated with pneumonia (66.3%; 61/116) compared to those without pneumonia 
(49.2%; 150/412; p=0.012). The respiratory viruses most frequently associated with 
pneumonia were HRV (24.1%), CV HUK1 (6.5%), KIPyV (6.3%), and Adenovirus and RSV 
(5.3% each). Influenza A which was identified in 9.8% pneumonia SEs cases 2.6% of non-
pneumonia SEs (p=0.005); Figure 3. 
 
6.2.6. TIME TO RECOVERY OF INFECTION BY TYPE OF PATHOGEN 
 
 There were no differences in time to recovery of the septic episode for infections by sole 
bacterial/fungal infection(p=0.14), sole respiratory viruses (p=0.163), and, respiratory viral 
and bacterial/fungal co-infections (p=0.376) for the cohort with HM and ST, (data not 
shown).  
 
6.2.7. FACTORS ASSOCIATED WITH RESPIRATORY VIRAL AND BACTERIAL 
COINFECTIONS 
 
  Among children with a respiratory virus associated SSE, those who were HIV-infected 
(61.5%) to have concurrent bacteraemia/fungaemia compared to HIV-uninfected children 
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(87.9%; p=0.015); Table 21). Tumour type, nutritional status, age, gender, and treatment 
intensity had no association with greater percentage of children with a respiratory virus 
associated SSE having concurrent bacteraemia/fungaemia; Table 21. 
 
 
Figure 3: Respiratory Virus in Pneumonia and non-Pneumonia Septic Episodes in Children with 
Cancer 
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Table 21: Factors Associated with Sole Respiratory Viral and Respiratory Viral Bacterial/Fungal Co-
infections 
 
Parameter Percentage of Respiratory Viral and 
Bacterial/Fungal Co-infections 
compared with Sole Respiratory Viral 
Infections    (95% CI) 
Adjusted Odds Ratio 
(95% CI; p-value) 
Age (years)   
1-5 91.3 (78.3-97.2) 3.8 (0.8-17.6); p= 0.09 
>5-10 76.9 (55.9-90.3) 1.0 (0.3-4.2); p= 0.95 
>10 78.3 (55.8-91.7) referent group 
Female 92.1 (77.5-97.9) referent group 
Male 79.3 (66.3-88.4) 0.3 (0.07-1.2); p= 0.08 
MUAC1>5th percentile 94.4 (70.6-99.7) referent group 
MUAC<5th percentile 82.1 (71.4-89.5) 0.3 (0.03-2.2); p= 0.22 
AMA2>5th percentile 92.1 (77.5-97.9) referent group 
AMA<5th percentile 79.3 (66.3-88.4) 0.3 (0.1-1.2); p= 0.09 
TSFT3>5th 85.0 (72.9-92.5) referent group 
TSFT<5th percentile 83.3 (66.5-93.0) 0.9 (0.3-2.8); p= 0.84 
HIV-uninfected 87.9 (78.5-93.8) referent group 
HIV-infected 61.5 (32.3-84.9) 0.2 (0.04-0.7); p= 0.015 
Solid Tumour 82.9 (65.7-92.8) referent group 
ST4 local 80.0 (58.7-92.4) referent group 
ST metastatic 90.0 (54.1-99.5) 2.3 (0.2-22.1); p= 0.49 
Haematological malignancy 85.3 (73.3-92.62) 1.2 (0.4-3.7); p= 0.76 
HM5 Medium risk 100 (65.6-100) referent group 
HM High-risk 82.4 (68.6-91.1) 0 (0-Inf); p= 0.99 
Treatment intensity6 1 80.0 (58.7-92.4) referent group 
Treatment intensity 2 90.9 (69.4-98.4) 2.2 (0.4-14.2); p= 0.39 
Treatment intensity 3 83.7 (69.8-92.2) 0.9 (0.1-8.2); p= 0.96 
MUAC
1
 = mid-upper arm circumference, AMA
2
 = Arm muscle area, TSFT
3
 = Triceps skinfold thickness, ST
4
 = 
Solid tumour, HM
5
 = Haematological malignancy, Treatment intensity
6
 = Standard intensity =1, Medium 
intensity = 2, High intensity =3, MCSE
7
 = microbiologically confirmed septic episode, SSE
7
 = Suspected septic 
episode  
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6.2.8. DEATHS IN CHILDREN WITH ACUTE RESPIRATORY VIRAL INFECTIONS AND 
CANCER 
 
  Twelve (7.1%) children died because of sepsis with respiratory viral and concurrent 
bacteraemia /fungaemia. All twelve of these individuals had a HM, including (22.2%; n=4) 
who were HIV-infected. Eighteen viruses were identified in the 12 children who died. 
Additionally, at the time of death, there were multiple bacteria and fungi were isolated, 
including multi-drug resistant bacteria. Four who died, also had microbiologically confirmed 
TB. Human Coronaviruses (44.4% of 18) was the most common virus in the children who 
died (one CV HUK1 1, three CV OC43, and four CV NL63), followed by HRV (27.8%; n=5). 
Additional viruses identified among the fatal cases were HMPV (5.6%; n=1), Influenza A 
(11.1%; n=2), HPyV (11.1%; n=2); Table 22. 
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Table 22: Summary of Deaths from Respiratory Viral and Bacterial and/or Fungal Coinfections Causing Sepsis in Children Treated for Cancer 
 
Pt Sex Age Disease HIV Blood culture Urine culture Other site Virus Clinical Syndrome 
1 M 158 NHL
1
 Pos MRSA
5,
 CONS
6
 No growth CSF
9
: MRSA 
Skin: MRSA 
HMPV
11
 Mucositis 
2 M 139 HL
2
 Neg Bacillus, Enterococcus 
faecalis, VRE
7
 
Aspergillus niger 
Enterococcus 
faecalis, ESBL 
Escherichia coli 
Nil HRV
12
 Pneumonia, Gastroenteritis, Herpes 
stomatitis, Mucositis 
3 M 137 ALL
3
 Neg CONS ESBL 
Escherichia  coli          
Candida albicans 
Nil HRV Urinary tract infection 
4 M 125 ALL Neg Bacillus, Klebsiella 
pneumonia 
Not done Sputum MTB
10
 CV
13
OC43, 
 CVHUK1 
Pneumonia, Herpes stomatitis, Proven TB 
5 F 112 ALL Neg Acinetobacter baumanni, 
Empedobacter brevis 
ESBL 
Pseudomonas 
aeruginosa 
Nil CVNL63 Pneumonia, Gastroenteritis, Urinary tract 
infection 
6 F 100 NHL Pos No growth Not done Sputum: MTB Flu
14
A, HRV, 
CVOC43, 
CVNL63 
Pneumonia, Herpes stomatitis,  Mucositis, 
Proven TB 
7 F 99 ALL Neg Candida albicans No growth Nil WUPyV
15
 Mucositis 
8 F 98 ALL Neg ESBL
8 
Klebsiella 
pneumonia 
No growth Sputum: MTB CVNL63, Pneumonia, Gastroenteritis, Proven TB 
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KIPyV 
9 M 50 NHL Pos CONS Escherichia coli Nil HRV Pneumonia, Gastroenteritis, Herpes 
stomatitis, Mucositis, Urinary tract 
infection, Probable TB 
10 F 44 ALL Neg No growth ESBL Klebsiella 
 pneumoniae 
Candida albicans CVOC43 Pneumonia, Herpes stomatitis, Fungal 
urinary tract infection, Probable fungal 
sepsis 
11 M 23 NHL Pos ESBL Escherichia coli No growth Sputum : MTB HRV, CVNL63 Herpes stomatitis, Mucositis, 
Probable fungal sepsis 
12 M 21 AML
4
 Neg Enterococcus faecalis Enterococcus 
faecalis 
Nil FluA Pneumonia, Gastroenteritis, Herpes 
stomatitis, Mucositis, Probable TB, 
Probable fungal sepsis 
NHL
1
 = Non-Hodgkin’s lymphoma, HL2= Hodgkin’s lymphoma, ALL3 = Acute lymphoblastic leukaemia, AML4 =Acute myeloid leukaemia, MRSA5 =Methicillin-resistant 
Staphylococci, CONS
6
 =Coagulase-negative Staphylococci, VRE
7
 =Vancomycin-resistant Enterococci, ESBL
8
 =extended spectrum β-lactamase producer, CSF9 =cerebrospinal fluid, 
MTB10 =Mycobacterium tuberculosis, HMPV
11
 =human Metapneumovirus, HRV
12
 =human Rhinovirus, CV
13
 =human Coronavirus, FluA
14
 =Influenza A virus, PyV
15
=human 
Polyoma virus 
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6.3. DISCUSSION 
 
 Our study documented that a high percentage (53.1%) of suspected septic episodes were 
associated with identification of a respiratory virus, both in children with HM (57.1%) and ST 
(47.2%). These findings are similar to other studies in children with cancer, but the panel of 
respiratory viruses did not include all the viruses we investigated for, where respiratory 
viruses have been identified from 44% to 57% of children with febrile neutropenia (Benites et 
al., 2014, Koskenvuo et al., 2008, Torres et al., 2012b). Sixty-four (47.2%) of SSEs in 
children with ST were associated with at least one respiratory virus. We identified very few 
previously published studies that investigated the role of respiratory viral infections in 
children with ST, independently of inclusion with HM cases. A recent study reported that 
patients with ST had significantly more respiratory viral infections (53%) but seemed to 
tolerate them better and required shorter hospitalisation than children with HM (Christensen 
et al., 2005). A study of influenza in a paediatric oncology subpopulation, reported that 5.3% 
influenza-documented illnesses occurred in children with cancer and more than a third of 
these had been diagnosed with ST (Tasian et al., 2008). 
 
  In our study the most frequently identified respiratory viruses were HRV (26%), HCoV 
(18%) and, HPyV (11%). Other studies also documented a high frequency of HRV ranging 
from 31% (Benites et al., 2014) to 59% (Suryadevara et al., 2012b). In a cohort of South 
African children without cancer, HRV was the most prevalent in HIV-infected (31.7%) and 
HIV-uninfected children (32.0%), followed by CV OC43 (12.2%) and HBoV (9.5%) in HIV-
I; and by HBoV (13.3%) and WUPyV (11.9%) in HIV-uninfected children (Nunes et al., 
2014). A prospective case-control study from the Netherlands, to investigate the prevalence of 
respiratory viruses in asymptomatic and symptomatic young non-cancer children study 
showed that the prevalence of respiratory viruses is high in asymptomatic children (27%), 
particularly in infants (44%). Studies using a large panel of respiratory viruses (Kusel et al., 
2006) have reported a prevalence of 25% in prospectively followed infants during periods 
without symptoms, and Jartti et al.(Jartti et al., 2008) found at least one virus in 45% of 
asymptomatic infants younger than 1 year old. 
 
117 
 
   There is conflicting data about the significance of HRV as an aetiological agent for sepsis, 
in children with or without cancer. An Italian study was undertaken in young children to 
evaluate HRV infection and factors involved in disease severity. The study documented that 
HRV was a common pathogen (71%) in mild disease and was involved in 29% of cases with 
severe LRTI. Co-infection with RSV was the main contributor to disease severity (Costa et 
al., 2014). A study to investigate the impact of human Rhinovirus on morbidity and mortality 
outcomes in children with severe viral respiratory infection documented 32% of children with 
HRV infection required mechanical ventilation with a mortality of 2.1%. An immune-
compromised state and bacterial co-infections were associated with mortality in this cohort. 
The study concluded substantial morbidity associated with severe respiratory infection due to 
HRV in children (Spaeder et al., 2015).  
 
  Previous studies in children with cancer have shown that HCoVs are relatively rare, 
accounting for less than five to eight percent of all detected respiratory viruses (Torres et al., 
2012a, Benites et al., 2014). Our study, however, documented HCoVs to be the second most 
frequent respiratory virus. In South African children without cancer, HCoV was the second 
most commonly detected respiratory virus in HIV-infected children (12.2%) (Nunes et al., 
2014). In a report from Brazil in children with cancer, HCoV was the most commonly 
identified respiratory virus, although HCoV was most commonly identified in children with 
multiple virus infections (Alvares et al., 2014). A study from the USA to documented a 7.6% 
prevalence of HCoV species among non-cancer children hospitalized for acute respiratory 
illness and/or fever and a prevalence of 7.1% in asymptomatic controls. The study concluded 
that in children hospitalized for acute respiratory illness and/or fever, HCoV infection was not 
associated with hospitalization or with increased severity of illness (Prill et al., 2012). 
 
  In our study, PIV accounted for six percent of the respiratory viruses. This finding is in 
contrast to other studies in which PIV3 was the most prevalent virus in children with cancer. 
Maeng et al documented 6.4% of children with cancer had a respiratory viruses isolated 
during a febrile illness; of these 54% were PIV, with PIV3 the predominant virus. The overall 
mortality from PIV infection was 23% (Maeng et al., 2012, Srinivasan et al., 2011). However, 
this study did not investigate for all the viruses in our study panel. 
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  Globally, RSV is the most common cause of childhood acute LRTI and a major cause of 
admission to hospital because of severe acute LRTI in predominantly otherwise healthy 
children. Mortality data suggest that RSV is an important cause of death in childhood from 
acute LRTI (Nair et al., 2010). In our study cohort, 5.6% of all SSE episodes were associated 
with RSV infection, 8.4% of bacteraemic /fungaemic episodes were co-infected with RSV, 
and RSV was identified together with HRV in six SEs. None of the patients in our cohort who 
had RSV identified, died. This finding is similar to that reported from Brazil in which the 
prevalence of RSV was 8.7%, although none of the children with RSV identified, died 
(Benites et al., 2014). In contrast, another study followed 59 high-risk paediatric cancer 
patients identified with RSV infection. One third had pneumonia with a mortality rate of 5%. 
Lymphopenic and male children progressed from a URTI to a LRTI (Chemaly et al., 2014). In 
contrast to HRV, RSV is seldom encountered in control patients, which suggests that a 
positive RSV test result is usually of clinical significance (Jansen et al., 2011) . 
 
  None of the patients in our cohort received Influenza A immunization. It has been 
documented that cancer increases the risk of influenza complications and mortality can reach 
up to 9% in cancer patients undergoing active therapy (Loulergue et al., 2008). Cancer 
patients are a high-risk group who are prone to post-influenza complications, therefore should 
be immunized against influenza before every seasonal epidemic (Shehata and Karim, 2014). 
 
  However, it is currently unclear whether patients undergoing systemic chemotherapy can 
achieve adequate serologic responses to vaccines. Patients undergoing treatment for cancer 
are at increased risk of infection, for which the influenza vaccine may offer additional 
protection and significant benefit.
 
A Cochrane review in paediatric oncology patients 
receiving chemotherapy concluded that children are able to generate an immune response to 
the influenza vaccine, but it remains unclear whether this immune response protects them 
from influenza infection or its complications (Goossen et al., 2013). The Infectious Disease 
Society of North America recommends that children with cancer should be treated with the 
antiviral agent, Tamiflu (Harper et al., 2009), though none of the children in our cohort were 
treated prophylactically or therapeutically with Tamiflu. Additionally, protective measures 
e.g. adequate infection control, hand washing, immunization of close contacts, medical, 
119 
 
nursing and hospital staff, early investigation, and treatment with Tamiflu for suspected cases 
of Influenza must be considered. 
 
  Overall, 17.5% of SEs in our study cohort had viral co-infections, which is similar to that 
reported by others (17%-19.7%) (Koskenvuo et al., 2008, Benites et al., 2014), with HRV 
(23.1%) and RSV (8.7%%) having the highest rates of co-infection. Similar rates for viral-
viral co-infections are also observed in children without immunosuppression (14% to 44%), 
with HRV being the second or third most frequent virus (Sly and Jones, 2011). Co-detection 
of multiple viruses alone was, however, not associated with severity of the illness or death. 
This, as well as identification of some of respiratory viruses in general, could be due to 
identification of these viruses either being co-incidental to the clinical illness, or self-limiting 
in their clinical course even among immunocompromised children with underlying cancer. It 
may also reflect prolonged excretion of these viruses (Jansen et al., 2011). The relationship 
between immunosuppression in children with cancer and viral shedding is not clear. Detection 
of CV HUK1 and CV 229E in respiratory specimens of transplanted children were reported 
for at least 38 days and 11 weeks, respectively, possibly suggesting that immunocompromised 
children may have a prolonged duration of shedding of these respiratory viruses (Song et al., 
2010). Such prolonged shedding in immunocompromised individuals may result in a greater 
frequency of identification of these respiratory viruses when investigated for respiratory 
illness. This may influence greater nosocomial transmission of these respiratory viruses 
because of children with cancer and febrile illnesses are hospitalized for treatment and 
monitoring. Nosocomial respiratory viruses add to the burden in children's hospitals and 
increase the risk of transmission, especially to immune-compromised children. Early 
identification of respiratory viruses in asymptomatic children will enable effective isolation in 
hospital with adequate isolation facilities, especially for immunocompromised children. 
 
  There are conflicting reports on the significance of viral-viral co-infections in children. A 
study from Italy, in children without immunosuppression documented those with viral-viral 
co-infections more frequently required hospital admission than those with single respiratory 
viruses (Cilla et al., 2008), although specific viral combinations may impact on the clinical 
relevance of the viral-viral co-infections. 
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  HRV was the most frequent respiratory virus in combination with other respiratory viruses, 
(23 SEs with HCoV, 10 with HPyV, 8 each PIV with ADV, 7 with CV NL63, 6 each with 
RSV and KIPyV). Human Rhinovirus (17.3%) was the most frequent virus in co-infections, 
followed by HCoV (11%), and HPyV (5.3%). In our study, there were no statistically 
significant differences for HRV as a sole respiratory virus or as part of a co-infection. 
However, CV 229E and CV OC43 (20 SEs with co-infection) did not occur as sole respiratory 
virus and only occurred in SEs with co-infections. CV NL63 was detected twice as a sole 
respiratory virus and in 20 SEs with co-infection, and, CV HUK1 was identified four times as 
a sole respiratory virus and in 22 SEs as part of a co-infection. HPyV was isolated in 35 SEs, 
29.41% as a sole respiratory virus and in 14.04% of co-infections. Additionally, KIPyV was 
isolated in 25 SEs as a sole viral pathogen. Certain respiratory viruses such as PIV, HBoV, 
HMPV, and RSV, have been reported to be more significantly associated with the presence of 
co-infections (Diaz et al., 2015). RSV, HMPV, and HBoV have been reported to have a 
higher frequency of infections with more than one virus (da Silva et al., 2013). In a study 
from Chile in paediatric oncology patients, RSV (31.17%), HRV (24.68%) and HBoV 
(12.99%) were most frequently iden-tified in co-infections, while RSV(35.58%), HRV 
(24.04%) and Influenza A(14.42%) were the most common respiratory viruses detected as 
sole respiratory virus (Torres et al., 2012b).  
 
  Thirty five percent of the respiratory virus associated SSEs had concurrent bacteraemia-
/fungaemia in our study, which was more common in children with HM (33.9%) than in 
children with ST (22.7%). Children with concurrent respiratory virus infection and 
bacteraemia/fungaemia in our study had a greater depth of pancytopenia with SEs than those 
with culture negative and respiratory virus negative sepsis. Severe lymphopenia has been 
documented as a risk from for progression to LRTIs and death in children with RSV infection 
(El Saleeby et al., 2008b). In adult patients who were transplanted for leukaemia, the risk 
factors for respiratory viral infections were neutropenia and lymphopenia, and fatality was 
documented in those with absolute lymphocyte count of < 200 cells/µL in those patients who 
had influenza, but the study did not document if these individuals had concurrent bacteraemia 
/fungaemia (Chemaly et al., 2006). A study from Brazil in children with cancer (Benites et al., 
2014) documented 23.5% with leukopenia, 20.5% with neutropenia, 16.7% with severe 
neutropenia and 41% of patients with lymphopenia had respiratory viruses identified during a 
febrile illness. None of the febrile episodes in this study had respiratory viral and 
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bacterial/fungal co-infections. Not many studies have documented respiratory viral and 
bacterial/fungal co-infections in children undergoing cancer therapy. A study from Chile 
reported 33% of respiratory viral infections had co-infections with bacteraemia (Torres et al., 
2012b).  
 
  We documented bacterial/fungal and respiratory viral co-infections were associated with a 
greater depth of neutropenia, lymphopenia, and monocytopenia than those with culture 
negative and respiratory viral negative sepsis. The Chilean study found no differences 
between neutropenia, lymph-openia and monocytopenia between sole viral or co-infections 
with bacteria/fungi and respiratory viruses (Torres et al., 2012b). However, this study did not 
explore the relationship between depth and duration of pancytopenia and association to co-
infections with respiratory viruses and bacteraemia /fungaemia. 
 
  In our study, biomarkers were not useful to discriminate between SSEs with respiratory viral 
and bacterial co-infections and those without. Biomarkers provide information about the host 
response to pathogens (bacteria, virus or fungi) causing infection. There is rising evidence that 
different microorganisms may promote different inflammatory responses, and levels of some 
biomarkers such as CRP and PCT are associated with distinct aetiological pattern. CRP and 
PCT show higher levels in bacterial pneumonia than pneumonia caused by respiratory viruses 
(Cillóniz et al., 2015). However, this was not the case in our study. 
 
  In our study, respiratory viruses were frequently associated with pneumonia. The respiratory 
viruses most frequently associated with pneumonia were human Rhinovirus (28.26%), human 
Coronavirus (20.88%), human Polyomavirus (9.9%), and Influenza A virus (9.78%). In our 
study, none of the respiratory viruses showed a significant relationship as aetiological agents 
for pneumonia as they were also detected in non-pneumonia cases, except for Influenza A 
which was identified as a possible aetiological agent for pneumonia in 10% of the episodes of 
pneumonia (p=0.005). 
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  Twelve patients of the overall thirteen in the cohort who died because of sepsis had 
bacteraemia/ fungaemia (seven multi-drug resistant bacterial pathogens) and respiratory viral 
co-infections. Eighteen different viruses were identified in the twelve patients, including two 
with Influenza A and four patients had microbiologically confirmed TB. The presence of a 
respiratory virus and its clinical significance and relationship with outcome is uncertain as 
none of the patients who died had post-mortems, which would have helped to delineate the 
microbiological cause of death. Some studies reported less severe infections and no fatal 
outcomes in children with cancer diagnosed with respiratory viruses (Suryadevara et al., 
2012b, Benites et al., 2014). Others have reported severe infections with fatal outcomes 
(Christensen et al., 2005, Srinivasan et al., 2013). Among the respiratory viruses, RSV is of 
particular concern for resultant mortality in high-risk patients. In immunocompetent patients, 
RSV is often a self-limiting URTI; however, in patients with AML and haemopoietic stem 
cell recipients, RSV can progress to a LRTI. In this setting RSV is associated with a 14% case 
fatality rate in patients with AML and a 50% case fatality rate in paediatric recipients of 
haemopoietic stem cell transplantation (Sung et al., 2007, El Saleeby et al., 2008b).  
 
  Multiple potential pathogens, including viruses, bacteria, fungi, and MTB were identified 
from the children who died of sepsis in our study. The deaths in patients with multiple co-
infections suggest a more severe clinical context and a may be explained by the prolonged and 
profound pancytopenia documented in this cohort of patients. In future, post-mortem studies 
may benefit in identifying the exact microbiological cause of death. 
 
  The result of our study indicate that further studies are essential with asymptomatic children 
with cancer controls, to help us understand the significance of respiratory viral infections 
either as sole agents or as part of viral-viral co-infections or viral bacterial/fungal co-
infections and its role in sepsis among children with cancer. We also need to study 
interactions between specific respiratory viruses, and to identify whether the severe acute 
infection is related to the underlying immunological status, type of cancer or the respiratory 
virus. Accurate and timely diagnosis of respiratory viral infections in children has potential 
benefits by reducing excessive antibiotic use.  
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  All children in the study cohort received antimicrobials; therefore, we could not investigate 
the clinical course of respiratory viral infection in the absence of antibiotic use. Although 
detection of a respiratory virus in a child with a febrile illness cannot influence empirical 
antimicrobial therapy, studies are necessary to understand the relationship between respiratory 
viral infections and the aetiology of the febrile illness episode.  
 
  Limitations of our study, and others, with regard to the identification of respiratory viruses 
include that detection of respiratory virus in nasopharynx by molecular techniques does not 
necessarily indicate respiratory disease. Future studies may consider determining viral load in 
sequential samples and correlating findings with clinical signs and symptoms. 
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7. INFECTIOUS COMPLICATION IN HIV-INFECTED AND HIV-
UNINFECTED CHILDREN TREATED FOR B-CELL NON-HODGKIN’S 
LYMPHOMA  
7.2. INTRODUCTION  
 
  Since the implementation of the antiretroviral (ARV) roll out programme in South Africa, 
HIV-infected children with NHL, are treated with ARVs and, treated similarly to HIV-
uninfected children. There are, however, a number of challenges to chemotherapy treatment in 
HIV-infected children, including that cancer therapy compounds an already immune-
suppressed state in these children. There are no established treatment guidelines in both adult 
and paediatric populations for the treatment of HIV-related NHL. A number of issues remain 
to be addressed; including whether treatment should be palliative or curative, the effect of 
ARVs and cancer drug interactions and the effect of the underlying HIV on the susceptibility 
to severe and fatal infections. There are currently no published studies, to our knowledge, that 
have compared the treatment-associated morbidity in HIV-infected compared to HIV-
uninfected children with NHL. Because of the underlying organ dysfunction including that of 
the bone marrow, impaired immune system and the need for multiple drugs to treat HIV 
infection, it is assumed that HIV-infected children are less likely to tolerate standard 
chemotherapy (Mueller, 1999). 
 
7.3. AIM OF THE STUDY 
 
  This retrospective study aimed to establish the infectious complications in HIV-infected and 
HIV-uninfected children treated for NHL with the same chemotherapy treatment regimen: 
Appendix 11. We also compared the stage of disease (Ann Arbor system), the degree and 
depth of bone marrow suppression and its association with infectious complications. 
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7.4. METHODS 
 
  Hospital records for HIV-infected and HIV-uninfected children with NHL were 
retrospectively reviewed for the period 2000 to 2009. The following variables: age at 
diagnosis, HIV status, stage of cancer, sex, and, anthropometric measures at presentation. In 
addition, the CD4+ lymphocyte number and percentage, and HIV-1 viral load was 
documented for HIV-infected children. All HIV-infected children were initiated on ARVs; 
Appendix 13. The statistical methods employed are described in Chapter 3. 
 
  Data on septic events noted in the patient records were abstracted onto a standardised form, 
including maximum temperature, duration of fever, white cell count, absolute neutrophil, 
lymphocyte and monocyte counts, CRP, blood culture results, urine culture results and 
associated clinical syndromes such as pneumonia and tuberculosis at the time of the sepsis 
episode.  
 
7.5. RESULTS 
7.5.1. DEMOGRAPHICS OF HIV-INFECTED AND HIV-UNINFECTED CHILDREN WITH 
NON-HODGKIN’S LYMPHOMA 
 
  Fifty-eight children with NHL were identified, 30 (51.7%) of whom were HIV-infected. The 
majority of children (80.7%) were males and the median age at diagnosis was 89.5 months; 
which was not significantly different between both groups. HIV-infected children were 
generally more malnourished than HIV-uninfected children were, albeit only significant for 
the HFA Z-score (p=0.046); Table 23.  
 
7.5.2. ADMISSION PARAMETERS ASSOCIATED WITH MICROBIOLOGICALLY CONFIRMED 
SEPSIS 
 
  Children one to five years old had an incidence of 84 per 100 child years of micro-
biologically confirmed sepsis (MSCE) which was 2.4 fold greater comparted to in children 
>10 years of age (p<0.001; Table 24). The incidence of MCSE was 2.2 fold greater in HIV-
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infected (95 per 100 child years) than in HIV-uninfected children (p<0.001). Male children 
had a lower incidence (60 per 100 child years) of MCSE than females (p=0.021).  
 
7.5.3. COMPARISON OF SEPTIC EVENTS IN HIV-INFECTED AND HIV-UNINFECTED 
CHILDREN WITH NON-HODGKIN’S LYMPHOMA  
 
 The person-time of follow-up was 128.8 and 56.3 per 100 child years among the HIV-
uninfected and HIV-infected children, respectively; Table 25. During this time, there was a 
higher incidence (per 100 child years) of suspected sepsis episodes (SSE) among the HIV-
infected than HIV-uninfected cases (170 vs. 80, p<0.001). Overall, 84% of SSE were 
associated with a positive blood culture, which did not differ by HIV-status; Table 25. Among 
HIV-infected children, no significant associations were identified between HIV-1 viral load 
and frequency of fungaemia, and Gram-negative bacterial pathogens causing urinary tract 
infections.  
 
  There was a higher incidence (per 100 child years) of MCSE among HIV-infected (122.5) 
than HIV-uninfected children (48.2), including higher incidence of Gram-positive 
bacteraemia (121 vs. 35, p<0.001) and Gram-negative bacteraemia (101 vs. 31, p<0.001); 
Table 25. 
 
The incidence (per 100 child years) of polymicrobial infections with Gram-positive and 
Gram-negative bacteraemia (43 vs 19; p<0.001), and Gram-positive bacteraemia plus Gram-
negative bacteraemia plus fungaemia (7 vs. 1; p=0.018) were also more frequent in HIV-
infected than HIV-uninfected children. There were more pathogens per septic event isolated 
by blood culture in HIV-infected (1.4) than in HIV-uninfected children (0.9; p= 0.005). 
Similarly there were more GPB (0.71 vs 0.43; p=0.025) and GNB (0.59 vs 0.39; p=0.025) per 
septic event in HIV-infected than in HIV-uninfected children with sepsis. 
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Table 23: Demographics of HIV-Infected and HIV-Uninfected Children with Non-Hodgkin’s 
Lymphoma 
 
Characteristic Overall  
N=58 
HIV-Infected 
N=30 
HIV-Uninfected 
N=28 
P*value 
Male 46 (80.7%) 24(80.0%) 22(81.5%) 0.88 
Mean Age 
(months) (SD
1
) 
89.5 (53.3) 96.3 (51.2) 82.1 (55.5) 0.32 
Median LDH
2 
(µ/L) (SD) 
1044(708-2269) 875(678-1973) 1124(780-2760) 0.23 
Stage 2 2 (3.6%) 0(0%) 2(7.7%) - 
Stage 3 41 (73.2%) 20(66.7%) 21(80.8%) - 
Stage 4 13 (23.2%) 10(33.3%) 3(11.5%) 0.05 
WFH
3
 Z-score 
(SD) 
-0.78(1.46) -1.12(1.46) -0.58(1.48) 0.39 
WFA
4
 Z-score 
(SD) 
-1.46 (1.32) -1.74(1.44) -1.21(1.18) 0.21 
HFA
5
 Z-score 
(SD) 
-1.89(1.40) -2.24(1.29) -1.48(1.45) 0.05 
BMI
6
 Z-score 
(SD) 
-0.68(1.57) -0.98(1.40) -0.14(1.74) 0.09 
N= number of patients, SD
1
 = Standard deviation, LDH
2
 = Lactate dehydrogenase enzyme, WFH
3
 = Weight-for-
Height, WFA
4
 = Weight-for-Age, HFA
5
 = Height-for-Age, BMI
6
 = Body mass index, *p= HIV-infected vs HIV-
uninfected 
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Table 24: Admission Parameters Association with Sepsis Children with Non-Hodgkin’s Lymphoma 
 
Parameter Incidence Rate 
 (95% CI) 
Adjusted Incidence Rate Ratio  
(95% CI; p-value) 
Age (years)   
1-5 84 (63-105) 2.4 (1.56-3.7); p<0.001 
>5-10 58 39-76) 1.1 (0.7-1.84); p= 0.61 
>10 41 26-55) referent group 
Female 96 (57-135) referent group 
Male 60 (48-71) 0.6 (0.4-0.9); p= 0.021 
HIV-uninfected 44 (33-55) referent group 
HIV-infected 95 (72-117) 2.2 (1.5-3.1); p<0.001 
 
 
7.5.4. CLINICAL SYNDROMES ASSOCIATED WITH SEPSIS IN HIV-INFECTED AND HIV-
UNINFECTED CHILDREN TREATED FOR NHL 
 
  The overall incidence (per 100 child years) of pneumonia was 31, and was higher in HIV-
infected (75) than HIV-uninfected children were (12; p<0.001). Similarly, there was a higher 
incidence of tuberculosis (25 vs 2; p<0.001), invasive fungal infections (28 vs 7; p=0.001), 
Herpes stomatitis (137 vs 44; p<0.001), and gastroenteritis (39 vs 15; p=0.004) in HIV-
infected than HIV-uninfected children; Table 26. Clinical syndromes in HIV-infected children 
were associated with higher incidence ratio rates (IRR). The IRR in the HIV-infected cohort 
for TB was 10.8, for pneumonia 6.5, for invasive fungal infections 9.2, for Herpes stomatitis 
3.1, and for gastroenteritis, 2.7. 
 
 
 
129 
 
7.5.5. CLINICAL AND LABORATORY PARAMETERS OF SUSPECTED AND 
MICROBIOLOGICALLY CONFIRMED SEPSIS IN HIV-INFECTED AND HIV-
UNINFECTED CHILDREN WITH NON-HODGKIN’S LYMPHOMA 
 
Generally, the clinical presentation of SSE and MCSE were similar between HIV-infected and 
HIV-uninfected children, including CRP and PCT levels. The mean maximum temperature 
was, however, higher in the HIV-infected with MCSE (p=0.022; Table 26). In addition, HIV-
infected children with SSE had a longer duration of neutropenia (p<0.001) and similarly, the 
duration of lymphopenia was longer in the HIV-infected group with SSE (p<0.001) and for 
MCSE (p=0.001) than in HIV-uninfected children, Table 27. 
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Table 25: Comparison of Septic Events in HIV-Infected and HIV-Uninfected Children Treated for Non-Hodgkin’s Lymphoma  
 
Parameter 
 
Overall;                  
N=58 
HIV-Infected;           
N=30 
HIV-Uninfected;         
N=28 
p-value
4
 
Person time observation (years) 185 56. 128. NA 
Number children with SSE
1 
(%) 57 (98.3%) 30(100.0%) 27(96.4%) 0.79 
Number of SSE 199 96 103 NA 
Mean number of SSE per patient (SD) 3.43 (2.04) 3.20 (1.85) 3.68 (2.23) 0.38 
SSE episodes per 100 child year (95% CI) 107.5 (92.6-122.5); 
n=199 
170.4 (136.3-204.5);  
n=96 
80 (64.6-95.4);           
n=103 
<0.001 
At least one positive blood culture per SSE (%) 49 (84.5%) 26 (86.7%) 23 (82.1%) 0.78 
Mean number of pathogens in blood per SSE (SD) 1.14 (1.23) 1.40 (1.40) 0.90 (1.00) 0.005 
Mean number of Gram-positive bacteria in blood per SSE(SD) 0.56 (0.86) 0.71 (0.97) 0.43 (0.72) 0.025 
Mean number of Gram-negative bacteria per SSE (SD) 0.48 (0.66) 0.59 (0.69) 0.38 (0.61) 0.025 
Mean number of Fungi per SSE (SD) 0.09 (0.29) 0.09 (0.29) 0.09 (0.28) 0.86 
Total death due to sepsis (%) 12 (20.69%) 10(33.33%) 2 (7.14%) 0.022 
MCSE
2
 (95% CI) 70.8 (58.7-82.9); n=131 122.5 (93.6-151.4); n=69 48.2 (36.2-60.1); n=62 <0.001 
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Incidence Gram-positive bacteraemia (95% CI)
3 
61.1 (49.8-72.3); n=113 120.7 (92-149.4); n=68 35 (24.7-45.2); n=45 <0.001 
Incidence Gram-negative bacteraemia (95% CI) 52.4 (42-62.8); n=97 101.2 (74.9-127.5); n=57 31.1 (21.4-40.7); n=40 <0.001 
Incidence fungaemia per 100 child year (95% CI) 9.7 (5.2-14.2); n=18 16 (5.5-26.4); n=9 7 (2.4-11.6); n=9 0.09 
Incidence
3
 Mixed Gram-positive + Gram-negative bacteraemia 
(95% CI) 18.9 (12.6-25.2); n=35 42.6 (25.6-59.6); n=24 8.5 (3.5-13.6); n=11 <0.001 
Incidence Mixed Gram-positive bacteraemia + Fungaemia  
(95% CI) 4.3 (1.3-7.3); n=8 10.7 (2.1-19.2); n=6 1.6 (0-3.7); n=2 0.008 
Incidence Mixed Gram-negative Bacteraemia + Fungaemia 
(95% CI) 4.9 (1.7-8); n=9 8.9 (1.1-16.7); n=5 3.1 (0.1-6.2); n=4 0.11 
Incidence Mixed Gram-positive + gram-negative bacteraemia + 
Fungaemia (95% CI) 2.7 (0.3-5.1); n=5 7.1 (0.1-14.1); n=4 0.8 (0-2.3); n=1 0.018 
N=number of patients, SSE
1
 = Suspected Septic Episode, MCSE
2
 = Microbiologically-Confirmed Septic Episode, 
3 
Incidence per 100 child years. 
4
p = HIV-infected vs HIV-
uninfected, Incidence 
5
 number of bacteria and fungi included in individual analysis 
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Table 26: Incidence (per 100 Child Years) of Clinical Syndromes Associated with Sepsis in HIV-infected and HIV-uninfected Children Treated for Non-Hodgkin’s 
Lymphoma 
 
Parameter Overall                                    
N=185 
HIV-Infected                   
N=56 
HIV-Uninfected                        
N=128 
IRR                     
(95% CI) 
P*-value 
Incidence** of Pneumonia (95% CI) 30.8 (22.8-38.8); n=57 74.6 (52-97.1); n=42 11.7 (5.8-17.5); n=15 6.5 (3.5-12.5) <0.001 
Incidence of Tuberculosis (95% CI) 9.2 (4.8-13.6); n=17 24.9 (11.8-37.9); n=14 2.3 (0-5); n=3 10.8 (3-58.3) <0.001 
Incidence of Proven Tuberculosis (95% CI) 6.5 (2.8-10.2); n=12 17.8 (6.7-28.8); n=10 1.6 (0-3.7); n=2 11.5 (2.5-108.1) <0.001 
Incidence of Probable Tuberculosis (95% CI) 2.7 (0.3-5.1); n=5 7.1 (0.1-14.1); n=4 0.8 (0-2.3); n=1 9.2 (0.9-453.8) 0.018 
Incidence of Fungal infections (95% CI) 13.5 (8.2-18.8); n=25 28.4 (14.5-42.3); n=16 7 (2.4-11.6); n=9 4.1 (1.7-10.5) 0.001 
Incidence of Herpes stomatitis (95% CI) 72.4 (60.1-84.7); n=134 136.7 (106.2-167.2); n=77 44.3 (32.8-55.8); n=57 3.1 (2.2-4.5) <0.001 
Incidence of Gastroenteritis (95% CI) 22.2 (15.4-28.9); n=41 39.1 (22.7-55.4); n=22 14.8 (8.1-21.4); n=19 2.7(1.4-5.2) 0.004 
N=total person-years, n= number of events, *p- value compare HIV-infected vs. HIV-uninfected children, Incidence** reported per 100 child years 
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Table 27: Clinical and Laboratory Parameters of Suspected Septic Episodes and Microbiologically Confirmed Sepsis in HIV-Infected and HIV-Uninfected Children with Non-
Hodgkin’s Lymphoma 
 Overall Suspected Septic Episode Microbiologically Confirmed Septic Episode 
Parameter HIV-Infected            
N=30 
HIV-Uninfected    
N=28 
P* HIV-Infected    
N=30 
HIV-Uninfected 
N=28 
P** HIV-Infected       
N=30 
HIV-Uninfected 
N=28 
P*** 
Mean maximum Temperature °C 
(SD1) 
38.9                               
(0.44) 
38.8                          
(0.37) 
0.031 38.9                  
(0.47) 
38.8                            
(0.49) 
0.69 38.9                              
(0.44) 
38.7                       
(0.29) 
0.022 
Duration of Fever (days) (IQR2) 4.0                              
(3.0 - 6.0) 
4.0                          
(2.0 - 6.0) 
0.81 5.0                                 
(2.3 - 5.8) 
3.0                       
(2.8 - 5.0) 
0.36 4.0                                     
(3.0 - 6.0) 
4.0                
(2.0 - 7.0) 
0.29 
Median CRP3 mg/L (IQR) 67.5                          
(34.5 - 105.5) 
75.0                      
(43.5 - 110.3) 
0.30 79.0                              
(28.5 - 125) 
75.5                   
(48.8 - 113) 
>0.99 66.5                                
(37.0 - 99.8) 
75.0            
(40.5 - 109) 
0.27 
Median WCC4 x 109 cells/µL 
(IQR) 
0.6                                       
(0.3 - 1.2) 
0.9                                        
(0.2 - 5.8) 
0.40 0.7                                          
(0.4 - 1.0) 
0.8                              
(0.1 - 2.4) 
0.96 0.6                                     
(0.3 - 1.2) 
0.9                                 
(0.3 - 5.9) 
0.38 
Median neutrophil count cells/µL 
(IQR) 
90.0                          
(90.0 - 528) 
90.0                                    
(90.0 - 2977) 
0.08  90.0                  
(90.0 - 413) 
104                    
(90.0 - 570) 
0.42 90.0                               
(90.0 - 573) 
90.0                           
(90.0 - 3237) 
0.13 
Median lymphocyte count cells/µL 
(IQR) 
90.0                          
(90.0 - 467) 
90.0                         
(90.0 - 1000) 
0.18  90.0                              
(90.0 - 433) 
100                    
(90.0 - 497.0) 
0.32 90.0                                 
(90.0 - 487) 
90.0                  
(90.0 - 1000) 
0.35 
Median monocyte count cells/µL 
(IQR) 
90.0                                  
(90.0 - 1645) 
90.0                      
(90.0 - 670) 
0.12 90.0                               
(90.0 - 164) 
90.0                             
(90.0 - 659) 
0.39 90.0                                        
(90.0 - 148) 
90.0                           
(90.0 - 600) 
0.23 
Duration of neutropenia5 during a 
SE6 (days) (IQR) 
9.0                                               
(5.0 - 11.8) 
8.0                          
(6.0 - 10.8) 
0.80 9.0                                      
(8.0 - 17.5) 
8.0                                
(6.3 - 10.0) 
<0.001 9.0                                         
(4.0 - 10.0) 
8.5                            
(6.0 - 11.3) 
0.29 
Duration of lymphopenia7 during a 
SE (days) (IQR) 
10.0                                          
(7.0 - 15.0) 
8.0                                      
(9. 0 -31.0) 
<0.001 20.5                   
(12.0 - 36.8) 
10.5                                 
(6.0 - 16.5) 
<0.001 15.0                         
(8.5 - 27.0) 
10.0                          
(7.0 - 14.5) 
0.001 
N=number of patients, SD 1= Standard deviation, IQR2 =inter-quartile range, CRP3 =C-reactive protein, WCC4 = White cell count, Neutropenia 5 = Absolute neutrophil count < 1000 cells/µL, SE6 = 
Septic episode, Lymphopenia 7 = Absolute lymphocyte count < 1000 cells/µL *p = overall sepsis HIV-infected vs HIV-uninfected, **p = Suspected sepsis in HIV-infected vs HIV-uninfected, ***p = 
microbiologically confirmed sepsis for HIV-infected vs HIV-uninfected 
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7.5.6. GRAM-POSITIVE BACTERIA CAUSING SEPSIS IN HIV-INFECTED AND HIV-
UNINFECTED CHILDREN TREATED FOR NON-HODGKIN’S LYMPHOMA 
 
 Overall, there were 61 Gram-positive MCSE per 100 child years, 121 in HIV-infected and 35 
in HIV-uninfected children (p<0.001); Table 28. The most frequently identified Gram-
positive bacterial iso-lates were Streptococcus species (n=15; 25.9%), Enterococcus faecium 
(n=14; 24.1%), and Staphylo coccus aureus and Streptococcus viridans (n=13; 22.4%) each.  
 
  The overall incidence (per 100 child years) of Enterococcus faecium was eight, which was 
higher among HIV-infected (16) than HIV-uninfected children were (four; p=0.009). 
Similarly, there was a higher incidence of Vancomycin- resistant Enterococci (seven vs 1; 
p=0.018) and Staphylococcus aureus (14 vs 4; p=0.02) sepsis episodes among HIV-infected 
than HIV-uninfected children; Table 28 
 
7.5.7. GRAM-NEGATIVE BACTERIA CAUSING SEPSIS IN HIV-INFECTED AND HIV-
UNINFECTED CHILDREN TREATED FOR NON-HODGKIN’S LYMPHOMA  
 
  Overall, there were 52 Gram-negative MCSE per 100 child years, 101 in the HIV-infected 
cohort and 31 in the HIV-uninfected cases (p<0.001); Table 29. The most frequently 
identified Gram-negative bacterial isolates were Klebsiella species (n=18; 23.7%), ESBL 
Klebsiella (n=14; 18.4%), Acinetobacter baumanni (n=10, 13.2%) and Escherichia coli (n=9; 
11.8%).  
 
  The overall incidence (per 100 child years) of Acinetobacter baumanni was five, which was 
higher among HIV-infected (11) than HIV-uninfected children were (three; p=0.049). 
Similarly, there was a higher incidence of Pseudomonas aeruginosa (11 vs 2; p=0.022), 
Stenotrophomonas maltophilia (nine vs 1; p=0.006), Bacillus species (five vs 0; p=0.018), and 
Salmonella species (five vs 0; p=0.015) sepsis among HIV-infected than HIV-uninfected 
children; Table 29. 
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Table 28: Incidence (per 100 Child Years) of Gram-Positive Bacteria Causing Sepsis in HIV-Infected and HIV-Uninfected Children Treated for Non-Hodgkin’s 
Lymphoma  
 
Gram-Positive Bacteria Overall                                
N=185 
HIV-Infected                         
N=56 
HIV-Uninfected 
N=128 
P* value 
Incidence** of Streptococcus species (95% CI) 8.1 (4-12.2); n=15 14.2 (4.4-24); n=8 5.4 (1.4-9.5); n=7 0.07 
Incidence of Enterococcus faecium (including 
VRE
1
)(95% CI) 7.6 (3.6-11.5); n=14 16 (5.5-26.4); n=9 3.9 (0.5-7.3); n=5 0.009 
Incidence of VRE(95% CI) 2.7 (0.3-5.1); n=5 7.1 (0.1-14.1); n=4 0.8 (0-2.3); n=1 0.018 
Incidence of Staphylococcus aureus (including MRSA
2
) 
(95% CI) 7 (3.2-10.8); n=13 14.2 (4.4-24); n=8 3.9 (0.5-7.3); n=5 0.02 
Incidence of MRSA(95% C)I 2.7 (0.3-5.1); n=5 3.6 (0-8.5); n=2 2.3 (0-5); n=3 0.64 
Incidence of Streptococcus viridans (95% C)I 7 (3.2-10.8); n=13 12.4 (3.2-21.6); n=7 4.7 (0.9-8.4); n=6 0.08 
Incidence of CONS
3
(95% CI) 4.3 (1.3-7.3); n=8 5.3 (0-11.4); n=3 3.9 (0.5-7.3); n=5 0.66 
Incidence of Enterococcus faecalis (95% CI) 2.2 (0-4.3); n=4 3.6 (0-8.5); n=2 1.6 (0-3.7); n=2 0.39 
Incidence of Enterococcus brevis (95% CI) 0.5 (0-1.6); n=1 1.8 (0-5.3); n=1 0 (0-0); n=0 0.17 
N=total person-years, n= number of events, NA= not applicable, VRE
1
 = Vancomycin-resistant Enterococci, MRSA
2
 = Methicillin-resistant Staphylococci, CONS
3
 = Coagulase-
negative Staphylococci,*p = HIV-infected vs HIV-uninfected, **Incidence per 100 child years  
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Table 29: Incidence (per 100 child years) Gram-Negative Bacteria Causing Sepsis in HIV-Infected and HIV-Uninfected Children treated for Non-Hodgkin’s 
Lymphoma 
 
Gram-negative Pathogen Overall                            
N=185 
HIV-Infected                        
N=56 
HIV-Uninfected                      
N=128 
p-value* 
Incidence** of Klebsiella species (including ESBL
1
) (95% 
CI) 9.7 (5.2-14.2); n=18 12.4 (3.2-21.6); n=7 8.5 (3.5-13.6); n=11 0.45 
Incidence of ESBL Klebsiella species (95% CI) 7.6 (3.6-11.5); n=14 10.7 (2.1-19.2); n=6 6.2 (1.9-10.5); n=8 0.33 
Incidence of Acinetobacter baumanni (95% CI) 5.4 (2.1-8.8); n=10 10.7 (2.1-19.2); n=6 3.1 (0.1-6.2); n=4 0.049 
Incidence of Escherichia coli (including ESBL) (95% CI) 4.9 (1.7-8); n=9 8.9 (1.1-16.7); n=5 3.1 (0.1-6.2); n=4 0.11 
Incidence of ESBL Escherichia coli (95% CI) 1.1 (0-2.6); n=2 3.6 (0-8.5); n=2 0 (0-0); n=0 0.05 
Incidence of Pseudomonas aeruginosa (95% CI) 4.9 (1.7-8); n=9 10.7 (2.1-19.2); n=6 2.3 (0-5); n=3 0.022 
Incidence of Enterobacter cloacae (including ESBL) (95% 
CI) 3.8 (1-6.6); n=7 5.3 (0-11.4); n=3 3.1 (0.1-6.2); n=4 0.48 
Incidence of ESBL Enterobacter cloacae (95% CI) 3.8 (1-6.6); n=7 5.3 (0-11.4); n=3 3.1 (0.1-6.2); n=4 0.48 
Incidence of Stenotrophomonas maltophilia (95% CI) 3.2 (0.6-5.8); n=6 8.9 (1.1-16.7); n=5 0.8 (0-2.3); n=1 0.006 
Incidence of Bacillus species (95% CI) 2.7 (0.3-5.1); n=5 7.1 (0.1-14.1); n=4 0.8 (0-2.3); n=1 0.018 
Incidence of Salmonella species (including ESBL) (95% CI) 1.6 (0-3.5); n=3 5.3 (0-11.4); n=3 0 (0-0); n=0 0.015 
Incidence of ESBL Salmonella species (95% CI) 1.6 (0-3.5); n=3 5.3 (0-11.4); n=3 0 (0-0); n=0 0.015 
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Incidence of Aeromonas hydrophilia (95% CI) 1.6 (0-3.5); n=3 1.8 (0-5.3); n=1 1.6 (0-3.7); n=2 0.91 
Incidence of Chromobacterium (95% CI) 1.1 (0-2.6); n=2 0 (0-0); n=0 1.6 (0-3.7); n=2 0.61 
Incidence of Morganella morganella (95% CI) 0.5 (0-1.6); n=1 1.8 (0-5.3); n=1 0 (0-0); n=0 0.17 
Incidence of Proteus mirabilis (95% CI) 0.5 (0-1.6); n=1 0 (0-0); n=0 0.8 (0-2.3); n=1 0.87 
Incidence of Neisseria species (95% CI) 0.5 (0-1.6); n=1 1.8 (0-5.3); n=1 0 (0-0); n=0 0.17 
Incidence of Bordetella (95% CI) 0.5 (0-1.6); n=1 1.8 (0-5.3); n=1 0 (0-0); n=0 0.17 
N=total person-years, n= number of events, NA= not applicable, ESBL
1
 = Extended Spectrum β-lactamase producer, *p= HIV-infected vs HIV-uninfected, **Incidence per 100 
child years 
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7.5.8.  FUNGI ASSOCIATED WITH SEPSIS IN HIV-INFECTED AND HIV-UNINFECTED 
CHILDREN TREATED FOR NON-HODGKIN’S LYMPHOMA 
 
Overall, there were 10 fungal MCSE per 100 child years. The most frequently identified 
fungal isolates were Candida albicans (n= 9; 52.9%), and Candida parapsilosis (n=3; 17.6%). 
The overall incidence (per 100 child years) of Candida albicans was five, and two for 
Candida parapsilosis. There were no significant differences in incidence of fungaemia 
between HIV-infected and HIV-uninfected children; Table 30.  
 
7.5.9. OUTCOME 
 
  Of the 30 HIV-infected children, ten (33.3%) died because of sepsis. Of these, 60% had 
Stage 4 disease and the rest had Stage 3 disease.in addition, 80% of those who died had a 
CD4+ < 15%, and 70% had a HIV-viral load greater than 200 000 RNA copies/ml. Multiple 
pathogens were isolated from children who died including multi-drug resistant bacteria. 
Pneumonia was documented in 90% of children at the time of death; Table 31.   
 
Table 30: Fungi Associated with Sepsis in HIV-Infected and HIV-Uninfected Children Treated for 
Non-Hodgkin’s Lymphoma 
Fungi Overall    
N=185 
HIV-Infected 
N=56 
HIV-Uninfected 
N=128 
P*-
value 
Incidence** of Candida albicans (95% CI) 4.9 (1.7-8); n=9 7.1 (0.1-14.1); 
n=4 
3.9 (0.5-7.3); n=5 0.37 
Incidence of Candida parapsilosis (95% CI) 1.6 (0-3.5); n=3 1.8 (0-5.3); n=1 1.6 (0-3.7); n=2 0.91 
Incidence of Cryptococcus (95% CI) 1.1 (0-2.6); n=2 3.6 (0-8.5); n=2 0 (0-0); n=0 0.05 
Incidence of Candida tropicalis (95% CI) 0.5 (0-1.6); n=1 1.8 (0-5.3); n=1 0 (0-0); n=0 0.17 
Incidence of Candida glabrata (95% CI) 0.5 (0-1.6); n=1 0 (0-0); n=0 0.8 (0-2.3); n=1 0.87 
Incidence of Crytosporidium (95% CI) 0.5 (0-1.6); n=1 0 (0-0); n=0 0.8 (0-2.3); n=1 0.87 
N=total person-years, n= number of events, NA=not applicable, p*= Haematological malignancy vs Solid 
tumour, Incidence** per 100 child years 
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Table 31 Summary of Sepsis-Related Deaths in Children with Non-Hodgkin’s Lymphoma  
 
Number Sex Age 
(months) 
CD4 (%) CD4+ 
count 
HIV-1 
Viral load 
Stage of 
NHL1 
Blood Culture Clinical Syndrome 
1 Male 188 14.3 413 1 200 4 CONS2, Streptococcus 
viridans, Enterococcus 
faecium, VRE3, Pseudomonas 
aeruginosa, Candida albicans  
Pneumonia, proven TB6, GE7, Herpes stomatitis, proven fungus 
2 Male 171 8.7 119 320 000 4 CONS, Bacillus species, 
Candida albicans 
Pneumonia, GE, proven fungus 
3 Male 155 4.9 42 80 000 3 CONS, MRSA4, P. 
aeruginosa 
Pneumonia, Herpes stomatitis, meningitis 
4 Female 146 3 275 224 000 4 Negative Pneumonia, Herpes stomatitis 
5 Male 132 19.4 220 300 000 4 ESBL5 Enterobacter cloacae Pneumonia, Herpes stomatitis 
6 Female 82 6.2 57 618 000 3 Negative Pneumonia, measles 
7 Male 51 3.5 130 750 000 4 Escherichia  coli Herpes stomatitis 
8 Male 50 7.9 331 15 000 4 Negative Pneumonia, Herpes stomatitis 
9 Male 40 12.3 630 3 000 000 3 ESBL Salmonella Pneumonia 
10 Male 19 26.5 613 458 000 3 ESBL Klebsiella pneumonia Pneumonia, TB, Herpes stomatitis 
NHL
1
 =Non-Hodgkin’s lymphoma, CONS2 =Coagulase-negative Staphylococci, VRE3 =Vancomycin-resistant Enterococci, MRSA4 =Methicillin-resistant Staphylococci, ESBL5 
=extended spectrum β-lactamase producer, TB6 =Tuberculosis, GE7 =Gastroenteritis 
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7.6. DISCUSSION 
 
  In our study, underlying HIV-infection, male sex and age < 5 years were identified as 
independent risk factors for SSE and MCSE. However, although MCSE was 2.2 fold greater 
among HIV-infected children, it was not identified as an independent risk factor contributing 
to mortality in our study. The higher case fatality ratio (33.3%) in HIV-infected than HIV-
uninfected children in our study was likely due to HIV-infected children more likely to 
presenting with Stage 4 NHL disease, and a high proportion of them being severely 
immunocompromised upon presentation.  
 
  Notably in our study, only one child of the thirty was known to be HIV-infected and on 
ARVs prior to the diagnosis of NHL. In the other 29, the HIV-infection was diagnosed 
concurrently with the malignant disease and was the AIDS defining presenting illness. 
 
  Diamond et al compared the survival of HIV-infected adults with NHL according to those 
who were diagnosed with HIV-infection and on ARVs prior to the diagnosis of NHL to those 
individuals whose HIV-infection was diagnosed concurrently with NHL and ARV naïve. The 
median survival in the group who were diagnosed with HIV-infection and NHL concurrently, 
was three months(Diamond et al., 2006). 
 
  There were no significant differences in the median age of presentation between HIV-
infected (6.5 years) and HIV-uninfected children (4.8 years) in our study. Our cohort was, 
however, younger than reported in other studies among HIV-uninfected children with NHL, 
which have a reported median age of 8-10 years at presentation (Ahmad et al., 2010, 
Budiongo et al., 2015).  
 
  The majority of HIV-infected children in our study were severely immunosuppressed; with 
the median CD4+ percentage markedly low, including CD4+ percentage being < 15% in 
63.3% of the children. This is similar to adults, among whom severe immunosuppression, 
defined by a low CD4+ count and percentage, was strongly associated with an increased 
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systemic NHL rate in HIV-infected adults (Bower et al., 2009). However, adult patients in 
Africa have been also documented to present with HIV-associated NHL at a higher CD4+ 
count compared to those in HICs (Ulrickson et al., 2012). 
 
  All HIV-infected children and 86% of HIV-uninfected children in our study cohort, 
presented with advanced disease (stage 3 and 4). Advanced stage of presentation of NHL has 
been documented in LMICs (Ahmad et al., 2010) and in Africa (Budiongo et al., 2015) and in 
HIV-infected individuals (Gopal et al., 2012). 
 
  There were no significant differences in anthropometry in either group, except the children 
in the HIV-infected group were stunted (p=0.033). There are conflicting reports on the 
association of HIV-infection and stunting in children. One study reports no association with 
stunting in HIV-infected children (Sunguya et al., 2011) and another reports a prevalence of 
68% (Nalwoga et al., 2010). 
 
  Both cohorts had leukopenia and pancytopenia at the time of the septic episode. The duration 
of neutropenia and lymphopenia during a septic episode was longer in the HIV-infected 
cohort. Prolonged neutropenia during a SE increased the odds of microbiologically confirmed 
sepsis. 
 
  HIV-infection is associated with haematological abnormalities, the most common 
manifestation being characterized by a reduction in, and the impaired function of all blood 
cell lines: anaemia, neutropenia, and thrombocytopenia (Kyeyune et al., 2014). However, in 
HIV-infected individuals, it is not only the virus but also the ARVs that both contribute to 
persistent hematopoietic suppression and ensuing cytopenias (Koka and Reddy, 2004). 
 
   The HIV-infected cohort had more suspected septic episodes (170 vs 80 per 100 child 
years), more microbiologically confirmed septic episodes (123 vs 48 per 100 child years), 
more episodes of Gram-positive bacteraemia (121 vs 35 per 100 child years), and more 
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episodes of Gram-negative bacteraemia (102 vs 31 per 100 child years) than those in the HIV-
uninfected cohort. We found the total number of pathogens from the blood, and the total 
number of bacteria in blood; and, the total number of pathogens and bacteria per septic 
episode was increased in the HIV-infected child. The most frequently isolated Gram-negative 
pathogens in our cohort were Klebsiella species, Escherichia coli and Acinetobacter 
baumanni, and the most common Gram-positive pathogens were Streptococcus species, 
Enterococcus faecium, and Staphylococcus aureus. None of the bacterial cultures isolated 
Streptococcus pneumonia. Gram-positive and Gram-negative bacteraemia increased the risk 
of all-cause mortality in our cohort. 
 
  Bacterial infections are a major source of morbidity and mortality in HIV-infected children 
(Jaspan et al., 2008). HIV-infected children have a greater risk of BSIs than their HIV-
uninfected counterparts, and these infections are more invasive, more likely to disseminate, 
and have worse outcomes in HIV-infected children. In Europe and the United States, as well 
as in Africa, the main pathogen isolated from HIV-infected individuals without underlying 
malignancies is Streptococcus pneumoniae (22.8–58.5%). In our study cohort, we did not 
isolate Streptococcus pneumoniae in either group. In Africa, non-typable Salmonella is the 
most prominent isolate in non-cancer HIV-infected children (Huson et al., 2014). In addition, 
HIV-infected children often have multiple diagnoses and polymicrobial infections (McNally 
et al., 2007). Reported factors associated with BSIs in HIV-infected patients are related to the 
level of immunosuppression. In contrast, Musiime et al found no difference in CD4+ counts 
between HIV-infected non-cancer children with or without BSIs (Musiime et al., 2013).  
 
  Multi-resistant bacteria are reported to be more frequent in HIV-infected children (Cotton et 
al., 2008, Groome et al., 2012). We identified more ESBL Escherichia coli (p=0.05) and more 
ESBL Salmonella (p=0.015) in our HIV-infected cohort. However, Musiime et al reported a 
low prevalence of antimicrobial resistance in bacterial isolates from HIV-infected children in 
Uganda and Zambia (Musiime et al., 2013). There are no published data on HIV-infected 
children with Non-Hodgkin’s lymphoma; therefore, we are citing studies in HIV-infected 
non-cancer children. 
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  We found a significantly increased presence of pneumonia (p<0.001) in the HIV-infected 
cohort. Pneumonia is common in HIV-uninfected children with cancer and a strong predictor 
of mortality (Bakhshi et al., 2008, Ghosh et al., 2012). There are no data published on the 
prevalence and outcome of pneumonia in HIV-infected children with cancer. 
 
  Fourteen of the 30 HIV-infected children had TB (p=0.001), and the odds of developing TB 
in the HIV-infected cohort was 19.2 times that of the HIV-uninfected cohort. HIV-infection 
may explain the frequency of TB in the HIV-infected child. HIV alters the pathogenesis of 
TB, and increases the risk of developing active TB in those with latent infection as well as in 
those newly exposed to TB. Corticosteroids are used in all cycles of chemotherapy for NHL. 
The increased immunosuppression due to corticosteroid administration could be associated 
with increased toxicity in patients with HIV due to other infectious comorbidities. The 
increased risk of re-activation or infection with MTB most likely explains the high prevalence 
in the HIV-infected cohort. In the HIV-uninfected population, only around 10% of people 
infected with TB will develop TB disease. However, in HIV-infected individuals, there is a 
20-30 fold increased relative risk of developing TB disease from latent state compared with 
that in HIV-uninfected individuals . Key factors for the increased susceptibility of HIV-
infected patients to develop TB include general as well as Mycobacterium tuberculosis 
specific CD4+ cell depletion (Zumla et al., 2013) and in the HIV-infected cohort, the use of 
high-dose corticosteroids also increases the susceptibility of TB re-activation. However, 
studies have also shown that HIV-infected individuals in high TB incidence regions have an 
increased risk of developing active TB. In addition, HIV-infected individuals on ARVs with 
high CD4+ counts continue to have an increased risk of developing TB (Gupta et al., 2012a, 
Venturini et al., 2014). This may be due to functional immune defects that may persist despite 
excellent CD4+ cell count recovery (Lawn et al., 2005). Another possibility is that individuals 
living with HIV in our community have greater exposure to TB or other common risk factors 
for the acquisition of both infections.  
 
  Ten (33.3%) of the HIV-infected cases and 3.6% of HIV-uninfected patients died due to 
sepsis in our study (p=0.0006). Other studies have also documented high case fatality ratio 
between 7-46% in non-cancer HIV-infected children with blood stream infections (Huson et 
al., 2014).  
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   In the general population, the main risk factor for death is the HIV viral load. The odds of 
dying is almost 12 times (p=0.014) for those with log (VL) ≥ 4 compared to those with log 
(VL) < 4. The HIV viral load, after adjusting for CD4+ count, increases the risk of death. For 
each log10 increase in viraemia copy-years, the risk of death is increased by 44% (Mugavero 
et al., 2011) . 
 
  Although ARVs have reduced the mortality and morbidity of HIV-infected patients and 
lowered the incidence of AIDs- related cancers, lymphomas remain a major issue in the HIV-
infected population. The main concerns regarding the use of chemotherapy in HIV-infected 
patients, compared with the general population, are subsequent immune depletion and an 
increased rate of infections, mostly because, like most NHLs, AIDS-related cancers generally 
occur when the CD4+ count is low and the patient is severely immunosuppressed. As children 
with HIV survive longer due to better antiretroviral and supportive therapies, HIV-related 
malignancies may become an increasingly common problem. 
 
  All children in the study presented with advanced stage of NHL. The factors associated with 
delay in diagnosis of cancers in children are complex. In children with HIV-infection, TB and 
cancer, the diagnosis is complicated by the similarities in clinical presentation. Current 
recommendations include greater awareness of HIV-infection, regular clinical evaluation of 
HIV-infected children paying particular attention to the warning signs of cancer (Poyiadjis et 
al., 2011). Pneumonia and TB are major complications in the HIV-infected child treated for 
NHL. In LMICs, ventilator support is minimal and this lack contributes to death in this cohort 
of children. All HIV-infected children with NHL should be screened for TB and TB treatment 
should be initiated at the earliest opportunity. It has not been the practise to treat this high-risk 
group of children with TB prophylaxis in our setting. This may be an important protocol to 
develop for the future. 
 
  HIV-infected children with NHL have a high bacterial load complicating septic episodes. 
Many studies have reported on the use of prophylactic antibiotics in the HIV-uninfected 
adults with cancer; there is a higher risk of antimicrobial resistance in adults given 
prophylactic antibiotics. In South Africa, multi-resistant bacterial isolates from children 
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infected with HIV, is a growing concern (Groome et al., 2012). The use of prophylactic 
antibiotics will add to the burden. 
 
  The overall burden of cancer is a growing problem in LMICs who are faced with the 
difficult choices of allocation of scarce financial resources for cancer awareness, screening, 
diagnosis, and treatment of the disease and supportive. Cancer is often a low public health 
priority, such that treatment approaches take precedence over prevention, early detection, and 
palliative care. As a result of these policies, most cancer patients in developing countries are 
diagnosed with late-stage disease (Jones et al., 2006). 
 
  The cost of cancer care is a barrier to increasing access in LMICs. Non-communicable 
diseases are a global health and economic threat; and “cancer now kills more people each year 
in LMICs than AIDS, tuberculosis, and malaria combined” (Jones et al., 2006). This 
highlights the ethical and financial imperative to improve the care of lymphoma globally and 
serves as a call to action for the haematology- oncology community (Ulrickson et al., 2012). 
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8. THESIS CONCLUSION 
 
  Infectious complications following treatment in the Black South African child with cancer is 
a major burden, which contributes to morbidity and mortality in this group of children. Our 
study demonstrated the incidence (per 100 child years) of suspected septic episodes was 103, 
and microbiologically confirmed sepsis 96.7, both of which were higher in children with 
haematological malignancies (HM) than in solid tumours (ST). Blood cultures were positive 
in 71% of suspected septic episodes. We also recorded that 51.1% of microbiologically 
confirmed sepsis was due to Gram-positive bacteraemia, 40.4% to Gram-negative 
bacteraemia, 8.5% to fungaemia, and all were more common in the cohort with 
haematological malignancies than solid tumours. Each patient experienced multiple septic 
episodes during the course of treatment, 4.02 in those with HM and 2.3 in those with ST. 
There were also polymicrobial septic episodes seen in both cohorts. The incidence (per 100 
child years) of Gram- positive bacteraemia, Gram-negative bacteraemia, and fungaemia was 
58.9, 47.9, and 9.2, respect-ively, all of which were also higher in children with HM. The 
most frequently isolated Gram-positive bacterial pathogens were Coagulase-negative 
Staphylococci, Streptococcus viridans, and Enterococcus faecium; Gram-negative pathogens 
were Escherichia species, Acinetobacter species, and Klebsiella species, and fungi were 
Candida albicans and Candida parapsilosis. Studies from other LMICs have documented 
MSCE ranging from 25-50%, Gram-positive bacteraemia accounting for 20-60%, and Gram-
negative bacteraemia, from 50-60% of MSCE (Gupta et al., 2011a, Bakhshi et al., 2008). 
 
  The high incidence of sepsis in our study could be due to many of the patients presenting 
with advanced and aggressive disease, including 25% of children with ST and 61% of those 
with NHL presenting with Stage 4 disease and 78% of acute lymphoblastic leukaemia patients 
categorized as having high-risk disease. The presentation with such advanced disease, as well 
as the related high intensity chemotherapy regimens, advanced and aggressive surgery, and 
wide field radiotherapy, which is required to manage such children, was independently 
associated with sepsis in our study. The cohort with high-risk HM had a 4.01 greater risk of 
microbiologically confirmed sepsis than those with medium-risk HM. Treatment intensity 
category 2 and 3 was associated with a 2.03 and 8 fold greater risk of microbiologically 
confirmed sepsis than those who received treatment intensity 1. In addition, children with 
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metastatic ST had a 2.49 fold higher risk of microbiologically confirmed sepsis than those 
with localized disease. In addition, although our study did not identify malnutrition to be an 
independent risk factor for sepsis, the majority of patients were malnourished, including 
76.9% by MUAC and 56.8% by arm muscle area.  
 
  The HIV-infected cohort had more suspected septic episodes (170 vs 80 per 100 child years), 
more microbiologically confirmed septic episodes (123 vs 48 per 100 child years), more 
episodes of Gram-positive bacteraemia (121 vs 35 per 100 child years), and more episodes of 
Gram-negative bacteraemia (102 vs 31 per 100 child years) than those in the HIV-uninfected 
cohort. 
 
   We found a significantly increased presence of pneumonia (p<0.001) in the HIV-infected 
cohort. Ten (30%) of the HIV-infected cases and 3.6% of HIV-uninfected patients died due to 
sepsis in our study Fourteen of the 30 HIV-infected children had TB (p=0.001), and the odds 
of developing TB in the HIV-infected cohort was 19.2 times that of the HIV-uninfected 
cohort.  
 
  The complexity of manging children with malignancies for sepsis in our setting, including 
the high (40.6%) of children in whom multiple pathogens were identified for an individual 
sepsis episode. In addition, we documented a high prevalence of antibiotic resistance for some 
pathogens, including 65% of Enterococcus faecium being resistant to Vancomycin, > 85% 
resistance to penicillin and 62% Enterococcus faecium strains being resistant to Ampicillin. 
Furthermore, 25% of Staphylococcus aureus strains were methicillin-resistant. The majority 
of Gram-negative pathogens were, however, susceptible to the Carbapenems except for 
Acinetobacter baumanni and Pseudomonas aeruginosa. More than 50% of Escherichia coli 
and Klebsiella pneumoniae were resistant to the third generation Cephalosporins. 
Pseudomonas aeruginosa isolates showed less resistance to the antimicrobials tested than 
most of the other Gram-negative pathogens, and Acinetobacter baumanni was resistant to 
most antimicrobials tested. 
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  All deaths related to sepsis occurred in children with HM, and more with high-risk HM than 
those with medium-risk HM. Contributing factors to death in our study included treatment 
with high-dose steroids and chemotherapy treatment intensity. Additionally, although sepsis 
itself was not identified as an independent risk factor for death, the CFR was greater in 
children who developed pneumonia and in those with microbiologically confirmed TB. In 
addition, among children who died due to sepsis, the odds of dying were greater in those who 
had profound neutropenia and lymphopenia at the onset of sepsis, and those who had 
prolonged neutropenia and lymphopenia during the course of a septic episode. Children who 
are at risk for profound and prolonged pancytopenia should, if possible, be isolated and 
carefully monitored for the earliest signs of sepsis. 
 
  The incidence of tuberculosis in our study cohort was 4.7 per 100 child years (6.8 in HM vs 
2.9 in ST), including 50% of tuberculosis cases being microbiologically confirmed among 
whom usually only 10-30% of TB cases are microbiologically confirmed. Nevertheless, we 
showed that tuberculin skin test and the IGRA assay were poorly sensitive for diagnosing 
underlying MTB infection, with only 2.9% of the children having a reactive TST. This would 
have been expected to be closer to 15-18% at 6-7 years of age (mean age group in our study), 
based on the annual risk for MTB infection in children being 3% year-on-year (Wood et al., 
2011)  
 
  There were a high percentage of respiratory viral associated septic episodes in our patients. 
The overall incidence (per 100 child years) was 92.4 in those with HM, and 33.1 in those with 
ST. The most frequently isolated viruses were human Rhinovirus, Coronavirus, and human 
Polyomavirus. 68.3% of respiratory viral associated septic episodes had one virus isolated, 
22.2% had two viruses, and 10.4% had more than two viruses per septic episode. Overall, 
22.4% of septic episodes had bacterial/fungal and respiratory viral co-infections, 33.9% in 
those with HM, and 22.7% in those with ST. The viruses most frequently associated with co-
infections were yet again human Rhinovirus, Coronavirus, and human Polyomavirus. 
 
  Respiratory viruses were associated with 66.3% of pneumonia cases, and the most 
commonly isolated were HRV, CV HUK1, and KIPyV. Influenza A virus was documented in 
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9.8% of pneumonia, and 2.6% of non-pneumonia cases. The exact causal role of respiratory 
viruses to sepsis in children is unclear.  
 
  In our study cohort, 53% of patients died. Of these, 13 (7.6%) were related to sepsis. All of 
those who died had HM, and all four Non-Hodgkin’s lymphoma patients who died, were 
HIV-infected. The cohort who died had polymicrobial infections with bacteria (including 
multi-drug resistant Gram-positive and negative bacterial pathogens), fungi, and respiratory 
viruses. Influenza A virus was identified in two patients at the time of death. It would be 
prudent to consider vaccinating children with cancer with the Influenza A vaccine seasonally. 
 
  Awareness and education of children’s cancer, improved primary health care facilities for 
cancer screening and detection, and prompt referral to specialist centres will result in earlier 
diagnosis and improved survival in children’s cancer, which reaches cure rates (with bone 
marrow transplantation) of up to 80% in HICs.  
 
  Non-communicable diseases are a global health and economic threat; and “cancer now kills 
more people each year in LMICs than AIDS, tuberculosis, and malaria combined” (Jones et 
al., 2006). It is urgent and imperative to improve the awareness, early detection, and optimize 
cancer and supportive care of lymphoma and other malignant diseases and serves as a call to 
mobilize health authorities and the haematology-oncology community to reduce the morbidity 
and mortality of this curable disease (Ulrickson et al., 2012) 
 
  The major issues that need further clarification in our cohort of children is the relationship 
between polymicrobial sepsis and disease severity and outcome, the causal role of respiratory 
viral infections in children with cancer, and their association with death. Ideally, these 
patients should have post-mortem studies to help delineate the cause of death. We also need to 
be more vigilant with the early identification of tuberculosis, and to plan a trial of Isoniazid 
prophylaxis in high-risk cancer children. Influenza A virus was identified in two children who 
died, which may have been prevented by vaccination. Influenza immunization, if possible, 
should be given seasonally to children receiving anti-cancer therapy. The paediatric-oncology 
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community should add their voice to the early detection and treatment of HIV-infected 
children. Additionally, the warning signs of cancer should be widely disseminated with the 
hope of early detection of childhood cancers (Poyiadjis et al., 2011). 
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9. APPENDICES 
9.1. APPENDIX 1: ADMISSION DATA 
Patient number Study number 
Date of birth Date of presentation 
Sex RTHC 
Diagnosis 
1=ALL, 2=AML, 3=NHL, 4=HD, 5=WT, 6=RBL, 7=NBL, 8=OS, 9=BT, 10=RMS, 
11=HBL, 12=HCC, 13=GCT, 14=KS, 15=NPC, 16=other 
PPD 1=yes, 2=no BCG scar 
Blood tests  
WCC Hb 
MCV PLT 
Na                       K Urea                  creatinine               albumin 
HIV   1=pos, 2=neg     Date of Dx IgG                    IgM                IgA 
Fe                        transferrin TB Ellispot 
CXR  
Mother: highest level of education Mother: Employment Status 
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9.2. APPENDIX 2: ANTHROPOMETRY ON ADMISSION  
 
Pt ID Study Number 
Date of Birth  
Date of Presentation  
Height in cm  
Weight in kg  
MUAC in mm  
TSFT in cm  
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9.3. APPENDIX 3: CLINICAL HISTORY FOR SEPSIS ADMISSION  
 
 Previous documented infections and colonization 
 Stage of disease and treatment  
 Remission status 
 Non-infectious cause of fever e.g. transfusion of blood products 
 Underlying co-morbid conditions e.g. recent surgery 
 Use of corticosteroids 
 Presence of indwelling catheters 
 Duration of fever 
 Site specific symptoms: myalgia, headache, cough, vomiting, diarrhoea, dysuria, 
perianal pain or bleeding, chest symptoms, ear pain, sore throat, skin lesions 
 Use of granulocyte colony stimulating agents 
 Radiotherapy (dates, dose, field) 
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9.4. APPENDIX 4: PHYSICAL EXAMINATION FOR SEPSIS ADMISSION 
 
 Mucous membranes for mucositis , bleeding, fungal infections, herpes infection 
 Dentition for periodontal abscesses 
 Sinuses 
 Oropharynx 
 Lungs 
 Abdomen for pain 
 Perineum for signs of infection 
 CNS: level of consciousness, meningism, intra- cranial bleeding. 
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9.5. APPENDIX 5: ADMISSION DATA FOR SEPSIS 
Study Number Sepsis number 
Chemo Protocol Start Date 
End Date 
Date of fever T T max  Duration of T > 38°C 
BP  
WCC  
Neutrophil count  
Lymphocyte count  
Monocyte count  
Plt                 Plt T/f  (y/n)          Number of 
units 
HB               PC T/f (y/n)           Number of 
units 
GCSF  y/n         Duration U/E 
CRP PCT 
BDG LFT 
Blood Culture Urine Culture 
Sputum for AFB Other Site Culture 
Antibiotics Antibiotic Duration 
CXR Clinical Syndromes 
Respiratory Virus y/n  
Outcome of Sepsis  
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9.6. APPENDIX 6: RESPIRATORY VIRUSES 
 
 Respiratory Syncytial Virus 
 Influenza A 
 Influenza B 
 Parainfluenza 1, 2, 3 
 Human Rhinovirus 
 Human Metapneumovirus 
 Human Bocavirus 
 Coronavirus 229E, OC43, NL 63, HUK1 
 Adenovirus 
 Human Polyomavirus WUPyV, KIPyV 
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9.7. APPENDIX 7: ANTIBIOTIC PROTOCOL 
9.7.1. INITIAL ANTIBIOTIC PROTOCOL 
 Piperacillin- Tazobactam (300 mg/ kg divided into 3 doses) i.v.i. 
 Amikacin (15 mg/ kg daily) i.v.i. 
 Vancomycin (40 mg /kg in 2 divided doses) i.v.i. will be added if the patient has an 
indwelling venous access device (central line/ or Portocatheter) or if the patient is 
hemodynamically unstable. 
9.7.1.1. Modification of Therapy in the First Week of Treatment 
9.7.1.1.1. Patient becomes afebrile in 3 – 5 days 
If an aetiologic agent is identified, therapy will be adjusted to the most appropriate 
antibiotic(s). If no aetiologic is identified, the initial antibiotics will be continued. If the blood 
cultures remain negative for gram-positive organisms, vancomycin will be discontinued (if 
already commenced). 
9.7.1.1.2. Persistent Fever throughout the First 3-5 Days 
Therapy will be reassessed on day 3. If there is no clinical worsening, the initial antibiotics 
will be continued. If there is persistent fever, the initial antibiotics will be stopped, a septic 
workup repeated and Meropenem (40 mg/ kg/ dose 8 hourly) i.v.i will be added. 
If the patient is febrile after 5 days, Amphotericin B (1 mg/ kg daily) i.v.i. will be added. 
 
9.7.2. DURATION OF ANTIBIOTICS 
9.7.2.1. Patient is Afebrile by Day 3 
If the patient’s neutrophil count is greater than or equal to 500 cells/µL for two consecutive 
days, if there is no definite site of infection and if cultures do not yield positive results, 
antibiotic therapy will be stopped when the patient is afebrile for more than or equal to 48 
hours. If the patient’s neutrophil count is < 500 cells/µL by day seven, if there are no 
subsequent complications antibiotic therapy will be stopped when the patient is afebrile for 
five-seven days. 
9.7.2.2. Persistent Fever on Day 3 of Antibiotics 
If the patient’s neutrophil count is ≥ 500 cells/µL, stop antibiotic therapy four-five days after 
the neutrophil count is greater than or equal to 500 cells/µL. If the patient’s neutrophil count 
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is < 500 cells/µL, reassess and continue antibiotic therapy until the neutrophil count is ≥ 500 
cells/µL. 
 
9.7.3. USE OF ANTIVIRAL DRUGS 
Acyclovir (15 mg / kg per dose 8 hourly) i.v.i or Acyclovir p.o. will be commenced and the 
choice of intravenous or oral will be determined by the severity of the infection 
 
9.7.4. USE OF COLONY – STIMULATING FACTORS 
Colony stimulating factors i.e. granulocyte colony stimulating factors (G-CSF) will be used as 
per chemotherapy protocol. 
 
9.7.5. ANTIBIOTIC PROPHYLAXIS 
Trimethoprim-sulfamethoxazole will be used to prevent Pneumocystis jirovecii in high–risk 
patients. 
 
9.7.6. SELECTIVE GUT DECONTAMINATION  
Patients presenting with diarrhoea will be treated with Cholestyramine, Metronidazole, and, 
Gentamycin. 
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9.8. APPENDIX 8: ASSENT FORM 
 
Good day, my name is Dr Naidu. I work in the Paediatric Department, Haematology 
Oncology unit, Chris Hani Baragwanath Academic Hospital 
You have been diagnosed with cancer. Your treatment will include 
chemotherapy/radiotherapy/ surgery. Treatment for cancer weakens the immune system, 
which predisposes the patient to different forms of infections caused by bacteria, fungi, or 
viruses. Infections in patients with cancer can be very serious and therefore have to be treated 
aggressively. 
You are invited to consider participating in a research study to determine the factors which 
predispose the patient with cancer to infections, the type of infection and how best to pick up 
the infections early and to treat them effectively. The total amount of time required for your 
participation in this study will be the duration of the cancer treatment and the follow-up 
period. 
If you do agree to participate in the study, a medical history will be obtained, followed by a 
physical examination. Twenty mls i.e. four teaspoons of blood will be withdrawn from you 
for laboratory investigations. Drawing of the blood may result in faintness, inflammation of 
the vein, pain, bruising or bleeding. Your nutritional status will be assessed by blood tests and 
a DEXA scan. 
You will not benefit directly from your participation in the study, but the medical knowledge 
acquired from the study may help other patients who have cancer in the future. 
Participation in the study is voluntary and you can decline to participate, or stop at any time 
without stating any reason. Please inform me if you decide to discontinue participating in the 
study. 
All information obtained during the course of the study, including hospital records and 
research data will be kept strictly confidential. 
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9.9. APPENDIX 9: INFORMED CONSENT 
9.9.1. INTRODUCTION 
 
Good day, my name is Dr Gita Naidu. I work in the Paediatric Department, Haematology 
Oncology Unit, Chris Hani Baragwanath Academic Hospital. Your child has been diagnosed 
with cancer and will receive chemotherapy/radiotherapy surgery and these forms of treatment 
may be complicated by infections. 
 
You are invited to consider your child to participate in a research study to investigate the 
predisposing factors for infections in patients with cancer, the type of infections and to study 
the best way to pick up these infections early This will enable us to  give the most effective 
form of treatment.  
 
Your child’s participation in this study is voluntary. Before agreeing for your child to 
participate, it is important that you read and understand the purpose of the study, the study 
procedures, risks and discomforts, and your right to refuse for your child to participate and to 
withdraw from the study at any time. 
 
This information leaflet is to help you to decide on whether your child should participate in 
the study. If there are any questions, do not hesitate to ask me. You should not agree to 
participate in the study unless you properly understand all the procedures involved in this 
study. If you agree for your child to participate in this study, this document has to be signed to 
confirm an understanding of the study. You will be given a copy to keep.I would like to 
request permission to review your child's hospital records 
 
9.9.2. PURPOSE OF THE STUDY 
 
Your child has been diagnosed with cancer and I would like you to consider your child taking 
part in the research of the infections that may be experienced during the treatment. The 
purpose of this study is to determine the predisposing factors for infectious complications for 
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children with cancer, to determine the spectrum and resistance patterns of infections and to 
determine the early markers of infections. 
 
9.9.3. DURATION OF THE STUDY AND NUMBER OF PARTICIPANTS 
 
The study will be performed at the. Chris Hani Baragwanath Academic Hospital. 
Approximately 400 participants will be enrolled in this study. The participants will be 
between the ages of 0 and 18. The total amount of time required for participation in this study 
will be the duration of the treatment of the cancer and the follow-up period. 
9.9.4. PROCEDURES 
 
If you agree to allow your child to participate in this study, information about your child’s 
health will be obtained followed by a physical examination. These are part of the standard 
routine for all patients admitted to the hospital. Before receiving treatment, blood for standard 
tests done as part of the hospital protocol for all patients with cancer plus 20 mls of blood (4 
teaspoons) for study specific tests will be taken. A DEXA scan will be performed initially to 
document the participants nutritional status and thereafter at six monthly intervals. For each 
hospital admission for sepsis (approximately six times during treatment), blood tests which 
are done as part of the hospital protocol and X-rays will be performed. In addition, nasal 
swabs and bloods for nutritional and infective markers will be done as part of the study 20 
mls i.e. 4 teaspoons). 
 
9.9.5. WILL ANY OF THESE PROCEDURES RESULT IN DISCOMFORT OR INCONVENIENCE? 
 
Drawing blood may result in faintness, inflammation of the vein, pain, bruising or bleeding at 
the puncture site. There is also a slight possibility of infection. Your protection is that 
experienced personnel perform the procedures under sterile conditions. A total of 100 ml of 
blood (i.e. half a cup) will be collected over the course of the entire study.A chest x-ray, a 
commonly used diagnostic procedure and a DEXA scan exposes the participant to a small 
amount of radiation. Although all radiation is cumulative over your lifetime, small doses 
should not create a significant risk to your health. 
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9.9.6. BENEFITS 
 
There are no benefits to your child resulting from participation in the study. Participation in 
this study will contribute to medical knowledge that may help other patients who have cancer 
in the future. Rights as a participant in this study participation in this study is voluntary and 
you can decline to participate, or stop at any time, without stating any reason. Withdrawal will 
not affect access to other medical care. Please inform me if you decide to discontinue your 
child's participation in the study. 
 
9.9.7. ETHICAL APPROVAL 
 
This clinical study protocol has been submitted to the University of the Witwatersrand, 
Human Research Ethics Committee (HREC) and written approval has been granted. The 
study has been structured in accordance with the Declaration of Helsinki (last updated: 
October 2000), which deals with the recommendations guiding doctors in biomedical research 
involving human participants. A copy may be obtained from me should you wish to review it. 
 
9.9.8. SOURCE OF ADDITIONAL INFORMATION 
 
For the duration of the study, you will be under my care. If at any time between your visits, 
you feel that any of your symptoms are causing you any problems, or you have any questions 
during the study, please do not hesitate to contact me. Other doctors from this department 
who are working on this study are: Dr L Wainwright, Dr S Poyiadjis, Dr D Mackinnon, and 
Dr B Rowe 
The 24-hour telephone number for Dr G. Naidu is 082 788 8190.  
If you want any information regarding your rights as a research participant, or complaints 
regarding this research study, you may contact Professor Cleaton-Jones, Chairperson of the 
University of the Witwatersrand, HREC, which is an independent committee established to 
help protect the rights of research participants at (011) 717 2229.10.8.  
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9.9.9. CONFIDENTIALITY 
 
All information obtained during the course of this study, including hospital records, personal 
data and research data will be kept strictly confidential. Data that may be reported in scientific 
journals will not include any information that identifies you as a participant in this study. Any 
information uncovered regarding your test results or state of health as a result of your 
participation in this study will be held in strict confidence. You will be informed of any 
findings of importance to your child’s health or continued participation in this study but this 
information will not be disclosed to any third party in addition to the ones mentioned above 
without your written permission. The only exception to this rule will be cases of 
communicable diseases where a legal duty of notification of the Department of Health exists. 
In this case, you will be informed of my intent to disclose such information to the authorised 
state agency. 
 
9.9.10. INFORMED CONSENT FOR PARENTS/LEGAL GUARDIANS 
(On behalf of minors under 18 years old) 
 
Dr Gita Naidu has provided me with a copy of the Participant Information Leaflet and 
Consent regarding the study “Infectious Complications in African Children with Cancer” and 
has fully explained to me the nature, benefits, and purpose of the study. The study doctor has 
given me the opportunity to ask any questions concerning the study. It has been explained to 
me that I will be free to withdraw my child from the study at any time, without any 
disadvantage to future care. I have understood everything that has been explained to me and I 
consent for my child to participate in this clinical study. 
PARENT/LEGAL GUARDIAN: 
Printed Name   Signature/Mark or Thumbprint  Date and Time 
 
PARTICIPANT ASSENT: * (Seven years old and above) 
Printed Name   Signature/Mark or Thumbprint  Date and Time 
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(* Minors competent to understand must participate as fully as possible in the entire 
procedure) 
STUDY DOCTOR: 
Printed Name    Signature    Date and Time 
TRANSLATOR/OTHER PERSON EXPLAINING INFORMED CONSENT ……………..…             
(DESIGNATION): 
Printed Name     Signature   Date and Time 
WITNESS (If applicable): 
Printed Name     Signature   Date and Time 
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9.10. APPENDIX 10: SUBJECT INFORMATION SHEET 
 
Infectious Complications in African Children with Cancer  
 
Hello! My name is Dr. Gita Naidu. 
 I am a Paediatric Oncologist working in the Paediatric Haematology-Oncology Unit, Chris 
Hani Baragwanath Academic Hospital, and University of the Witwatersrand. 
Patients with cancer receive chemotherapy and / or radiotherapy which weakens the blood and 
predisposes them to infections, which may be life threatening. Malnutrition during treatment 
may increase their susceptibility to infections. Bacteria, viruses, fungi, or parasites may cause 
these infections. 
 Our present treatment is uniform irrespective of the cause of the infection and some patients 
may be over treated e.g. if viral infections are treated with antibiotics.  
We want to carry out a study on the causes and predisposing factors to infections in children 
with cancer. We would also like to investigate the most reliable and earliest marker of 
infection to ensure the most effective means of treatment.  
The blood and radiological investigations are those that are done routinely.  
Nasopharyngeal aspirates will be collected to test for acute respiratory viruses. 
All information obtained will remain confidential. Allocated study numbers will protect your 
anonymity.        
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9.11. Appendix 11: Berlin Frankfurt Munster Non-Hodgkin's Lymphoma 
1995 Protocol 
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9.12. Appendix 12: Turn-It-In Document  
172 
 
9.13. APPENDIX 13: FIRST LINE ANTIRETROVIRAL THERAPY 
 
Age Group Treatment 
< 3 years <10 kg Abacavir + Lamivudine + Lopinavir/Ritonavir 
3-10 years > 10 kg Abacavir + Lamivudine = Lopinavir/Ritonavir 
10-15 years < 40 kg Abacavir + Lamivudine + Efavirenz 
≥ 15 years > 40 kg Tenofivir + Lamivudine + Efavirenz 
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9.14. APPENDIX 14: ETHICS DOCUMENT 
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